Design, synthesis characterization and application of FRET probes for the detection of channel-activating protease (CAP) activity by Rickert-Zacharias, Verena Martina
 
1 
 
 
 
 
 
 
 
 
 
 
 
Dissertation 
submitted to the 
 
Combined Faculty of Natural Sciences and Mathematics 
of the Ruperto Carola University Heidelberg, Germany 
for the degree of 
Doctor of Natural Sciences 
 
Presented by 
M.Sc. Molecular Biotechnologist 
Verena Martina Rickert-Zacharias 
born in Aschaffenburg, Germany 
 
Oral examination: 06.09.2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
 
 
 
 
 
 
 
 
 
 
 
Design, synthesis characterization and 
application of FRET probes for the detection of 
channel-activating protease (CAP) activity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Referees:  Dr. Anne-Claude Gavin 
  Prof. Dr. Ralf Bartenschlager 
  
Table of Contents 
 
3 
Table of Contents 
 
 
I Abbrevations ....................................................................................... 6 
II List of figures ....................................................................................... 8 
III List of tables ........................................................................................ 10 
IV Abstract ............................................................................................... 11 
V Zusammenfassung ............................................................................... 13 
1 Introduction .............................................................................................. 15 
1.1 Ion transport defects in cystic fibrosis …………………………………………………… 15 
1.2 
The epithelial sodium channel and its proteolytic regulation by channel-
activating proteases ……………………………………………………………………………… 
16 
1.2.1 Channel-activating protease 1: Prostasin ……..………………………………………. 17 
1.2.2 Channel-activating protease 2 .................................................................. 18 
1.2.3 Channel-activating protease 3: Matriptase …………………………………………… 18 
1.2.3 Other CF- relevant or potential ENaC-activating proteases …………………… 19 
1.3 
Interplay between CAP1 and CAP3, models of altered protease-
antiprotease balance and increased ENaC-activity in CF airways ……….…. 
21 
1.4  Basic principles of fluorescence and fluorescence energy transfer ……….. 23 
1.5 Aims of the project ……………………………………………………………………………….. 24 
2 Results …………………………………………………………………………………………………. 26 
2.1 
Representative purification and identification of peptide-based probes 
after solid-phase synthesis ……………………………………………………………………. 
26 
2.2  
Characterization of CAP probe based on autoactivation cleavage site of 
matriptase ……………………………………………………………………………………………. 
29 
2.2.1 Physical properties of soluble and lipidated probes CAPRee1-3 ……………. 39 
2.2.2 Kinetic properties and specificity towards CAPs over other proteases ….. 37 
2.2.3 Specificity of CAPRee1 on cell lines …………………………………………………….. 43 
2.2.4 Characterization of lipidated probes on murine and human cell lines …… 44 
2.3 Characterization of ENaC-based CAP probes ………………………………………… 56 
2.3.1 Physical properties of soluble and lipidated probes ……………………………… 57 
2.3.2 Kinetic properties and specificity towards CAPs over other proteases…… 59 
Table of Contents 
 
4 
2.3.3 Characterization of lipidated probes on murine and human cell lines …… 64 
2.4 
Application of CAP probes to murine models system: tracheal epithelial 
cells isolated from βENaC-transgenic show significantly decreased CAP 
activity compared to wildtype C57BL/6 mice ………………........................... 
73 
2.5 
Application of CAP probes to human samples: Increased CAP activity of 
CF cell lines and cultured human nasal epithelial cells isolated from CF 
patients compared to healthy controls …………………………………………………. 
76 
3 Discussion ……………………………………………………………………………………………. 82 
3.1 Physical and biochemical properties of FRET probes …………………………….. 82 
3.2 Specificity of soluble and lipidated probes ……………………………………………. 84 
3.3 Effects of amino acid sequence on localization …………………………………….. 85 
3.4 
Analysis of kinetic properties of the CAPRee probes and consequences 
for assay design ……………………………………………………………………………………. 
86 
3.5 Increased CAP activity in CF – cell lines and human nasal epithelial cells. 89 
4 Conclusion ……………………………………………………………………………………………. 91 
5  Outlook ………………………………………………………………………………………………… 93 
6 Material and Methods …………………………………………………………………………. 95 
6.1 Material ……………………………………………………………………………………………….. 95 
6.2 Methods ………………………………………………………………………………………………. 95 
6.2.1 Chemical synthesis and purification ……………………………………………………… 95 
6.2.2 Detailed structure and procedure of individual probes …………………………. 96 
6.2.3 In vitro characterization ………………………………………………………………………… 110 
6.2.3.1 Characterization with recombinant enzymes ………………………………………… 110 
6.2.3.2 
Characterization with broad spectrum inhibitors on M-1 and CFBE41o-
cells………………………………………………………………………………………………………. 
110 
6.2.3.3 Liposome preparation …………………………………………………………………………… 111 
6.2.4  Cell culture …………………………………………………………………………………………… 111 
6.2.4.1 Cell lines ………………………………………………………………………………………………. 112 
6.2.4.2 Primary cells …………………………………………………………………………………………. 112 
6.2.4.2.1 Murine tracheal epithelial cells …………………………………………………………….. 112 
6.2.4.2.2 Human nasal epithelial cells ………………………………………………………………….  112 
6.2.5 Microscopy …………………………………………………………………………………………… 114 
Table of Contents 
 
5 
6.2.6 Image and data analysis ……………………………………………………………………….. 115 
6.2.7 Statistical analysis …………………………………………………………………………………. 115 
7 References ……………………………………………………………………………………………. 116 
8 Appendix ………………………………………………………………………………………………. 123 
Abbreviations   
 
6 
I Abbreviations 
 
aa      amino acids 
AEC     airway epithelial cells 
a.u.     arbitrary units 
AMC      7-amino4-methyl-coumarin 
ASL      airway surface liquid 
A1AT      alpha-1-antitrypsin 
BAL     bronchoalveolar lavage 
ENaC-Tg     ENaC-overexpressing 
equi.     equivalents 
CAP     channel-activating protease 
CTSB     cathepsin B 
CTSS     cathepsin S 
CF      cystic fibrosis 
CFTR      cystic fibrosis transmembrane conductance regulator 
Cou343     Coumarin343 
COMU (1-Cyano-2-ethoxy-2-oxoethylidenaminooxy) 
dimethylamino- morpholino-carbenium-
hexafluorophosphate 
CPP     cell-permeable peptide 
DCM     dichloromethane 
DIPEA     diisopropylethylamine 
DMF     dimethylformamide 
DNA      deoxyribonucleic acid 
D/A      donor/acceptor 
ENaC      epithelial sodium channel 
ESI      electrospray ionization 
FACS      fluorescence activated cell sorting 
Fmoc      fluorenylmethoxycarbonyl 
FRET      Foerster resonance energy transfer 
Abbreviations   
 
7 
GPI     glycosylphosphatidylinositol 
HAI     Hepatocyte growth factor activator inhibitor 
HAT     human airway trypsin-like protease 
HBTU 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate 
hNEC     human nasal epitheiial cells 
IPF     idiopathic pulmonary fibrosis 
h/m     human/murine 
HL-60      neutrophil-like cell line 
mTEC     murine tracheal epithelial cells 
MetOCou    7-amino methoxy coumarin 
Mtt     4-Methyltrityl 
NE      neutrophil elastase 
HPLC      high-pressure liquid chromatography 
LPS      lipopolysaccharide 
LUT     look up table 
MeOCou     7-amino- 4-methoxy-coumarin 
MMP      matrix-metalloproteinase 
Palm     palmitic acid 
Peg      polyethylenglycol 
RNA     ribonucleic acid 
SD     standard deviation 
SEM      standard error of the mean 
ST-14     suppressor of tumorigenicity- 14 
SPLUNC    short-palate lung and nasal epithelial clone 
TAMRA     5,6-carboxytetramethylrhodamine 
TBTA     1-hydroxybenzotriazole 
TFA     trifluoroacetic acid 
TMPRSS    transmembrane protease, serine 
TRIS     tris(hydroxymethyl)-aminomethan 
WT      wild type 
List of Figures   
 
8 
II List of Figures 
 
Figure 1 Ion transport processes in healthy lung epithelium 15 
Figure 2 Proteolytic activation of ENaC 16 
Figure 3 Regulation of ASL height by activation and inactivation of ENaC in 
normal and CF epithelium 
22 
Figure 4 Principle of FRET probe design and readout 24 
Figure 5 Representative preparative HPLC trace of CAPRee1 during 
purification 
26 
Figure 6 Stability of CAPRee1 as lyophylized powder and in DMSO solution 28 
Figure 7 Common structure of all CAP3-based CAPRee probes 29 
Figure 8 Behavior of CAPRee1 in absence or presence of enzyme 30 
Figure 9 pH-sensitivity of donor fluorescence and D/A ratio change 31 
Figure 10 In vitro cleavage of CAPRee3 in buffer, on liposomes or HL-60 cells 32 
Figure 11 In vitro cleavage of CAPRee3 in presence of 5 nM mCAP3 33 
Figure 12 Modifications of CAPRee1 and their effect on initial D/A ratio 34 
Figure 13 Structures of different acceptor fluorophores tested for lipidated 
CAPRee probe 
35 
Figure 14 Effect of different acceptor fluorophores on lipidated CAPRee 
probes CAPRee2, CAPRee2_b, CAPRee2_c 
36 
Figure 15 Modification of CAPRee1 – D-arginine in P1 38 
Figure 16 Determination of CAPRee1 kinetics with mCAP3 41 
Figure 17 Behavior of donor fluorescence and D/A ratio of CAPRee3 upon 
cleavage by hCAP3, mCAP3 and HAT 
42 
Figure 18 Cleavage of CAPRee1 and CAPRee3 by different recombinant 
enzymes 
43 
Figure 19 Specificity of CAPRee1 on M-1 and CFBE cells with broad 
spectrum inhibitors 
44 
Figure 20 CAPRee2 on HEK293 cells 45 
Figure 21 CAPRee2 on M-1 cells 47 
Figure 22 Localization of CAPRee2 on CFBE41o- 48 
List of Figures   
 
9 
Figure 23 CAPRee2 and derivatives on fixed M-1 cells 50 
Figure 24 Localization of CAPRee2_b on M-1 cells after 3 h 50 
Figure 25 Localization and cleavage of CAPRee2_c on M-1 cells 52 
Figure 26 Localization of CAPRee3 on M-1 cells and CFBE41o- 53 
Figure 27 Localization of cleavage products of CAPRee3 55 
Figure 28 In vitro behaviour of CAPRee4 56 
Figure 29 Emission wavescans of the lipidated probes CAPRee5 (A) and 
CAPRee6 (B) 
59 
Figure 30 Kinetics of CAPRee4 60 
Figure 31 Quantification of enzyme activity by % cleavage 61 
Figure 32 Specificity of CAPRee4 towards CAPs over other proteases 62 
Figure 33 Specificity of CAPRee4 on CFBE41o- and M-1 cells with broad 
spectrum inhibitors 
63 
Figure 34 Localization and cleavage of CAPRee5 on M-1 cells 65 
Figure 35 Cleavage of CAPRee5 on M-1 cells and hNEC 66 
Figure 36 Localization of CAPRee6 in M-1 cells 67 
Figure 37 Localization and cleavage of CAPRee6 on M-1 cells at low 
temperature 
68 
Figure 38 Localization of CAPRee6 in M-1 cells at 30 °C 70 
Figure 39 Localization of donor and acceptor fragment of CAPRee6 at 37 °C 
(A) and 30 °C (B) 
71 
Figure 40 Soluble CAP activity of mTEC cells 72 
Figure 41 Surface-bound CAP activity on murine tracheal epithelial cells 
from wildtype and βENaC-transgenic animals 
74 
Figure 42 Quantification of CAP activity on CFBE41o- and CFBE with 
wildtype CFTR overexpression by CAPRee1 
75 
Figure 43 Quantification of CAP activity on CFBE41o- and CFBE with 
wildtype CFTR overexpression by CAPRee3 
 
76 
Figure 44 Cleavage of CAPRee3 on hNEC in absence and presence of serine 
protease inhibitor Pefabloc SC® 
77 
Figure 45 Quantification of CAP activity on healthy and CF hNEC 78 
List of Tables   
 
10 
III List of Tables 
 
Table 1 Modifications of CAPRee1 33 
Table 2 Modifications of CAPRee2 and maximal D/A ratio fold change 49 
   
   
   
   
  
  
 
 
Abstract 
 
11 
IV Abstract 
 
The epithelial sodium channel (ENaC) and the proteolytic processing of its alpha- and γ-subunits by 
channel-activating proteases (CAPs) play a crucial role in sodium transport across different epithelial 
membranes, including the airways, and in airway surface liquid (ASL) homeostasis.  The loss of ion 
transport homeostasis results in various diseases, including one of the most frequent lethal genetic 
disorders: Cystic fibrosis. The fundamental cause of the disease is a mutation of a chloride channel, 
resulting in loss or reduction of chloride secretion. Not only the chloride transport is affected, but 
also the sodium transport via ENaC which is increased in CF. It has been shown that CAP expression is 
elevated in primary bronchial epithelial cultures of Cystic Fibrosis (CF) patients compared to tissue 
from healthy subjects. However, the impact of CAPs on ENaC activity and ASL regulation in the CF 
lung disease is unknown.  
In order to study the role of CAPs in CF lung disease and their regulation in the disease context, 
substrate-based Förster Resonance Energy Transfer (FRET) probes were developed for measuring 
protease activity. In contrast to most commercial substrates, the probes presented in this work, are 
equipped with two fluorophores. Proteolytic cleavage of the probe resulted in a loss of FRET, giving a 
ratiometric readout reflecting enzyme activity. The attachment of a lipid anchor enabled the 
detection of membrane-associated enzyme activity in a spatially resolved manner. Different 
substrate sequences and fluorophore combinations were synthesized and tested towards their 
physical and biochemical properties. Not only extension or contraction in the amino acid sequence 
between both fluorophores affects the efficacy of FRET and maximal fold change of the ratio upon 
full cleavage of the probe, but also the identity of the flanking amino acids significantly contributes. 
For the lipidated probes, the combination of Coumarin 343 and TAMRA turned out to be the best 
working combination. 
Probes based on different substrate sequences have been evaluated with respect to selectivity for 
CAPs over other proteases. In vitro characterization using recombinant enzymes as well as cell-based 
characterization using broad-spectrum inhibitors identified the probe based on the CAP cleavage site 
in the human ENaC γ-subunit as the most selective one towards CAP activity. Probes based on the 
autoactivation cleavage site of CAP3, however, also have sufficient specificity and perform better 
with respect to localization and dynamic range compared lipidated versions. Furthermore, the 
fluorophore combination and potentially the insertion of the lipid anchor significantly affect the 
specificity. 
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As proof of concept, the probes were successfully tested in primary human nasal epithelial cells and 
primary murine tracheal epithelial cells. Application of the probes to a small cohort of CF patients 
and a healthy control showed that the novel FRET probes are able to detect increased CAP activity in 
nasal cells from CF patients compared to healthy control samples. Murine tracheal epithelial cells of 
βENaC-transgenic mice, a mouse model for CF lung disease, however, have significantly reduced CAP 
activity compared to cells isolated from wild type mice.  
Both experimental sets suggested that our FRET probes are a useful tool to measure CAP1 and CAP3 
as potential biomarkers in human specimens for different diseases as well as research tools for 
further investigation of CAP activity in chronic lung diseases, including CF, idiopathic pulmonary 
fibrosis and lung cancer.  
Zusammenfassung 
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V Zusammenfassung 
 
Epitheliale Natriumkanäle (ENaC) und die proteolytische Prozessierung der α- und γ-Untereinheiten 
durch Kanal aktiviernde Proteasen (CAPs) spielen eine wichtige Rolle beim Natriumtransport über 
verschiedene epitheliale Gewebe, einschließlich der atemwege, und der Homöstase des 
Atemwegsflüssigkeit. Der Verlust des Ionentransport-Gleichgewichts führt zu verschiedenen 
Erkrankungen, einschließlich einer der häufigsten, genetischen lethalen Erkrankungen: Zystische 
Fibrose (Mukoviszidose, CF). Die grundlegende Ursache der Erkrankung ist eine Mutation in einem 
Chloridkanal, die zu einem Verlust oder der Reduktion der Chloridsecretion führt. Es ist jedoch nicht 
nur der Chloridtransport betroffen, sondern auch der Natriumtransport über ENaC, der in CF erhöht 
ist. Es wurde gezeigt, dass die Expression von CAPs auf primären Bronchienepithel-Kulturen von CF –
Patienten gegenüber Gewebeprobe von gesunden Probanden erhöht ist. Die Bedeutung der CAPs auf 
die Aktivität von ENaC und die Regulation der Atemwegsflüssigkeit im Zusammenhang mit der CF-
Lungenerkrankung ist bisher unklar. 
Um die Rolle der CAPs bei der CF Lungenerkrankung und ihre Regulation in diesem Zusammenhang 
zu untersuchen, wurden Substrat-basierte Förster- Resonanzenergietransfer (FRET)-Sonden 
entwickelt, mit dem Ziel, die Enzymaktivität zu messen. Im Gegensatz zu den meisten kommerziell 
erhältlichen Substrasten wurden die Sonden, die in dieser Arbeit präsentiert werden, mit zwei 
Fluorophoren ausgestattet, so dass ein ratiometrisches Auslesen die Enzymaktivität wiederspiegelt. 
Das Anhängen eines Lipidankers ermöglicht die Detektion der Membran-assoziierten Enzymaktivität 
mit räumlicher Auflösung. Verschiedene Substratsequenzen und Fluorophorkombinationen wurden 
hergestellt und auf ihre phyikalischen und biochemischen Eigenbeschaften hin untersucht. Nicht nur 
die Verlängerung oder Verkürzung der Aminosäuresequenz zwischen den Fluorophoren beeinflussen 
die Effizienz des FRET und die maximale Änderung des Verhältnisses bei vollständiger Spaltung, 
sondern auch flankiernde Aminosäuren tragen signifikant dazu bei. Für die lipidierten Sonden zeigte 
sich die Kombination aus Coumarin 343 und TAMRA als beste Fluorophor-Kombination. 
Sonden, basierend auf verschiedenen Substratsequenzen, wurden hinsichtlich ihrer Spezifität für 
CAPs über andere Proteasen untersucht. Sowohl die Charakterisierung in vitro mit Hilfe 
rekombinanter Enzyme, als auch die Zell-basierte Untersuchung unter Verwendung von 
Breitspektrum-Inhibitoren identifizierten die Sonden, die auf der Schnittstelle der γ-Untereinheit von 
ENaC basieren, als die spezifischste für CAPs. Die Sonden, die auf der Schnittstelle für die 
Selbstaktvierung von CAP3 basieren, weisen eine ausreichende Spezifität auf und funktionieren als 
lipidierte Sonden besser hinsichtlich ihrer Lokalisierung und der dynamische Breite. Außerdem ist zu 
Zusammenfassung 
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bemerken, dass die Fluorophorkombination sowie möglicherweise das Anhängen des Lipidankers 
signifikant zur Spezifität beitragen. 
As Nachweis der Machbarkeit wurden die Sonden erfolgreich auf primären humanen Nasenepithel-
Zellen und murinen Luftröhren-Zellen getestet. Die Auswertung einer kleinen Kohorte von CF-
Patienten und gesunden Kontrollen konnte zeigen, dass die neuartigen FRET-Sonden in der Lage sind, 
die erhöhte CAP activity in Nasenzellen von CF-Patienten gegenüber gesunden Kontrollen zu messen. 
Murine Luftröhren-Zellen von βENaC-transgenen Mäusen, ein Mausmodell für die CF-
Lungenerkrankung, zeigen signifikant verringerte CAP activity im Vergleich zu Zellen, die aus Wildtyp-
Mäusen isoliert wurden. 
Beide Experimente schlagen unsere neuen FRET-Sonden sowohl als Messinstrument für CAP1 und 
CAP3 als mögliche Biomarker bei humane Proben  für verschiedene Krankheiten, als auch als 
Werkzeug für die Forschung vor, um die Regulation von CAPs in chronischen Lungenerkrankungen 
wie CF, idiopathische Lungenfibrose oder Lungenkrebs zu untersuchen. 
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1. Introduction 
1.1 Ion transport defects in cystic fibrosis 
 
Cystic fibrosis (CF) is among the most common lethal genetic disorders in the Caucasian population 
with 1 case per 2500 newborns in Germany. It is caused by mutations in the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene, resulting in dysfunctional chloride channels in of 
many epithelial tissues. This leads to reduced transport of chloride and hydrogen carbonate ions 
across the apical membrane into the airway surface liquid3. Although CF affects many organs, the 
major cause for morbidity and mortality is the severe lung disease4-5. The following discussion 
focusses on CF lung disease. 
Numerous mutations in the CFTR gene are known and they have various effects on CFTR function and 
consequently on the severity of the disease. In general, the lack of functional CFTR leads to reduced 
transport of chloride and hydrogen carbonate ions across the apical membrane into the airway 
surface liquid3.  
In healthy tissue, anion transport is coordinated with sodium absorption across epithelial sodium 
channels (ENaC).  As consequence of the sodium absorption, the transport of water across the apical 
membrane is regulated.  A balance of chloride secretion and sodium absorption control the level of 
hydration of the airway surface liquid (ASL) which is maintained at a physiological thickness of ~ 7 
µM. In response to drying, chloride is secreted to increase the water transport. Soluble factors such 
as extracellular adenosine are highly important for the coordinated ion transport3 (Figure 1). 
  
 
In CF, the coordination of chloride and sodium transport is lost due to the mutated CFTR. The 
absorption of sodium and water from the ASL is not stopped at the physiological level so that the ASL 
is continuously dehydrated, leading to the collapse of ciliary beating and mucus clearance3. In vivo, 
although there are compensatory mechanisms, the lack of mucus clearance results in increased 
 
Figure 1: Ion transport processes in healthy lung epithelium 
Chloride is secreted via CFTR and sodium is absorbed into the 
epithelial cells via ENaC across the apical membrane counteracting 
the release of sodium via tight junctions. Water is transported via a 
paracellular pathway from the apical to the basolateral side of the 
cells. The transport is further affected by soluble and membrane-
bound factors that modulate CFTR and ENaC activity. 
Figure from 
http://www.cfmedicine.com/htmldocs/cftext/basicproblem.htm 
on 01.06.2018, 13:00  
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bacterial load, chronic inflammation and finally in lung destruction by a number of proteases. The 
importance of sodium transport for the CF lung disease was also shown using a mouse model with 
overexpression of β-ENaC. The animals show a similar pulmonary phenotype compared to human CF 
lung disease6.  
1.2 The epithelial sodium channel and its proteolytic regulation by 
channel-activating proteases 
 
Epithelial sodium channels are rate-limiting in sodium transport across airway epithelial cells2. ENaC 
is a heterotrimer, consisting of an α-, β- and γ-subunit. After channel formation, the β-subunit is not 
further processed.  The α- and γ-subunits contain inhibitory fragments and are subjected to 
proteolytic processing. Upon proteolytic cleavage, the fragments are released to activate ENaC2,7 
(Figure 2). 
 
  
                    Figure from 
2
   
               
The α-subunit is processed in the trans-Golgi network by the serine protease furin during the 
biosynthetic pathway. The cleavage by furin releases an inhibitory tract which increases the activity 
from low to moderate level. The γ-subunit is partially cleaved by furin. The release of the inhibitory 
fragment however requires cleavage by a second protease and leads to highly active channels. 
Channels with the inhibitory tract of the γ-subunit still in place can be transported to the plasma 
membrane as silent channels with reduced opening probability compared to fully processed 
channels2,8.  
Depending on the tissue, different proteases are able to fully activate ENaC. In the following, several 
proteases are described in more detail. This is however not an exhaustive list and many serine 
proteases might be able to cleave and activate ENaC in a similar manner2. 
 
Figure 2: Proteolytic activation of ENaC 
Whereas the β-subunit of ENaC is not 
processed, the α-subunit is processed by furin 
in the finger domain of the large extracellular 
loop (ECL). The γ-subunit can be processed by 
various proteases including prostasin and 
channel-activating protease 2 (CAP2)  
N-terminal (Nt), C-terminal (Ct) tails, first (M1) 
transmembrane domain, second (M2) 
transmembrane domain, amino acid (aa) 
 
 
Figure from 
2
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1.2.1 Channel-activating protease 1: Prostasin 
 
One of the most relevant ENaC-activating proteases is serine protease prostasin, also called CAP1. It 
was first identified in seminal fluid and its active site is closely related to other trypsin-like serine 
proteases including trypsin itself, hepsin, kallikrein and coagulation factor XI9. Its expression is not 
limited to the prostate gland, but the enzyme is also found in significant abundance in other 
epithelial tissues in lung, kidney, colon, pancreas, salivary glands etc., and these tissues are also 
affected in CF. It is  glycosylphosphatidylinositol (GPI)-anchored in the plasma membrane. As a 
trypsin-like protease, CAP1 recognizes basic amino acids, especially arginine residues, in the position 
N-terminal  of the cleavage site and is inhibited by many serine protease inhibitors such as aprotonin, 
leupeptin or camostat mesilate9-11. 
Prostasin and its target ENaC are involved in many physiological and pathophysiological conditions, 
including regulation of blood pressure, sodium and potassium homeostasis in the colon or regulation 
of the airway surface liquid volume in the lung11-14. 
Murine knockout models revealed that prostasin is indispensable for survival. A constitutive, 
systemic knockout is embryonically lethal due to placenta defects. An epiblast-specific knockout 
enabled embryonic development but due to severe skin defects, the mice die within few days after 
birth15-16. Interestingly, the importance of prostasin for embryonic and postnatal survival is 
independent of its enzymatic function. Mice with a systemic catalytic knockout, where the serine of 
the catalytic triad had been mutated to non-functional alanine, developed a normal skin barrier and 
do not show impaired survival17.  
In 1997, it was reported that prostasin can cleave the inhibitory tract in the γ-subunit of epithelial 
sodium channels and significantly increases their activity in the Xenopus cell line A6. Further it was 
shown that ENaC is regulated by a protease expressed on the surface on the same cell. However, 
prostasin can also be released from the membrane18.  
Airway-specific knockout of prostasin revealed its role in the activation of ENaC in airway-epithelial 
cells under physiological conditions. In the absence of prostasin in the alveolar epithelial cells 
decreased ENaC-mediated sodium currents by 40%19. Furthermore, RNA and protein levels of 
prostasin have been found to be increased in cystic fibrosis cell lines as well as primary human airway 
epithelial cells of CF patients20-22. To summarize, prostasin (CAP1) seems to be one of the central 
mediators of increased ENaC activity and sodium transport in CF. 
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1.2.2 Channel-activating protease 2 
 
TMPRSS4 or CAP2 is a type II transmembrane serine protease that is very closely related to CAP1. 
Studies with murine enzymes expressed in Xenopus oocytes showed that CAP2 is able to activate 
ENaC in a similar manner as CAP123-25. The activation is dependent on its proteolytic activity26. A 
murine knockout model did not reveal any physiological role of CAP2 on the activation of ENaC. 
Furthermore, the mice were viable, fertile and without any obvious phenotype27. The lack of 
importance to sodium transport in the lung is likely due to its very low expression in healthy 
conditions, both in mouse and human28-29. The spectrum of its targets remains largely unknown and 
so does its physiological role27. Recently however, TMPRSS4 has come to forefront in cancer 
research, as it is suggested to be involved in different cancer types including lung, prostate, breast 
and many more. In disease state, TMPRSS4 (CAP2) seems to be strongly upregulated and involved in 
tumor signaling, proliferation and disease progression28, 30-33.   
1.2.3 Channel-activating protease 3: Matriptase 
 
Channel-activating protease 3 (CAP3), also called matriptase or suppressor of tumorigenicity-14 (ST-
14), was first identified in conditioned medium of breast cancer cells34 and in colorectal cancer 
tissue35. As described for prostasin, matriptase is expressed in many epithelial tissues, including lung, 
skin and kidney. In vitro co-expression with ENaC in Xenopus oocytes revealed the ability of 
matriptase to cleave the γ-subunit of the sodium channel and activate to similarly to CAP1 and 
CAP226.  
ENaC is the only well characterized substrate of CAP3. A constitutive knockout of CAP3 in mice is 
characterized by early postnatal death within 48 h after birth due to severe defects in epithelial 
barrier formation. This leads to fatal dehydration of the newborn mice36. The mice are born with an 
altered lipid composition and the loss of proteolytically processed filaggrin, one of the major 
epidermal proteins that is required for keratin aggregation and the formation of the cornified 
envelope, a protective barrier at the inner leaflet of the cell membrane in korneocytes. In the 
stratum corneum, filaggrin is completely decomposed to hygroscopic amino acids that maintain 
epidermal hydration in wildtype animals. The N-terminal S-100 filaggrin fragment is believed to be 
transcriptional regulator during late stratum corneum differention37.   
In order to further investigate targets and the physiological role of CAP3, hypomorphic mice have 
been created that show a 100-fold reduction in epidermal CAP3 mRNA levels and consequently 
reduced, but not fully depleted protease activity. Unlike the CAP3 knockout mice, the hypomorphic 
mice are viable, fertile and develop a skin disease mimicking autosomal recessive ichthyosis 
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described for humans with a mutation in the ST-14 gene. This mutation also results in reduced CAP3 
activity. The phenotype of CAP3 hypomorphic mice is most likely due to reduced amounts of 
processed profilaggrin38. However, not only the skin of these mice is affected by the reduction of 
proteolytic activity of CAP3, but they are also characterized by reduced barrier formation in the gut 
where only 1 % of the normal matriptase mRNA level was detected. The transepithelial electrical 
resistance is significantly reduced, suggesting impaired formation of tight junctions. In matriptase 
hypomorphic mice, the turnover of Claudin-2, a tight junction protein that has been associated with 
permeability, is reduced although matriptase does not directly process it39.  
Although most CAP3 research is focused on its major physiolocigal role in the skin, matriptase has 
also been associated with idiopathic pulmonary fibrosis (IPF) where it has been found to be 
upregulated, like CAP2, and described as a trigger of fibrosis29,40. Matriptase hypomorphic mice are 
not susceptible to IPF, indicating the central role of matriptase in the context of this disease40. In CF 
however, matriptase does not seem to be upregulated21.  
1.2.4 Other relevant or potential ENaC-activating proteases  
 
Apart from the channel-activating proteases CAP1-3 described above, many more proteases are 
involved in proteolytic processing of ENaC. 
As mentioned above, proteolytic cleavage of ENaC by furin is absolutely crucial for channel function. 
Furin is a subtilisin-like proprotein convertase that is ubiquitously expressed in many tissues. It is 
mostly located in the Golgi apparatus where it is involved in the proteolytic processing of many 
different proteins in the secretory pathway. Furin is a calcium-dependent serine protease that 
recognizes a very similar amino acid sequence to the CAPs: arginine residues in the P1 and P4 
position. Further, it prefers repeated basic amino acids in P1 and P241.  
Proteolytic cleavage by furin in the α-subunit of ENaC releases an inhibitory fragment so that ENaC is 
partially activated. Together with other CAPs, furin-mediated cleavage also leads to the release of an 
inhibitory fragment in the γ-subunit42. 
Until now, furin was believed to exclusively act intracellularly in the Golgi network where it processes 
most of its targets. Recent studies, however, suggest that in CF airway epithelial cells excessive furin 
activity might also be located at the plasma membrane43.  
In other tissues than the lung, ENaC is activated under physiological conditions by a number of other 
serine proteases that are closely related to CAP1-3. For example, in the kidney, the urinary tissue 
kallikrein has been shown to cleave ENaC in the same position as prostasin and thereby increase its 
Introduction 
 
20 
activity44-45. In pathophysiological circumstances like proteinuria, urinary plasminogen is converted to 
active plasmin, another ENaC activator in the kidney8,46. 
Human airway trypsin-like protease (HAT) is very closely related to CAP2 and CAP3. It is also a 
transmembrane trypsin-like serine protease that is expressed in airway epithelial cells, mostly in the 
trachea and lower airways47. In contrast to prostasin and matriptase, the mouse analog of HAT is 
dispensable in embryonic development, postnatal survival and skin integrity48. So far, the 
physiological role of HAT remains unclear but it might be related to some specific regulatory 
processes.  Based on the substrate specificity, HAT might be able to activate ENaC, but this has not 
been shown so far. The latest publications suggest that HAT is upregulated in pulmonary fibrosis, as 
CAP2 and CAP3, but it seems to have protective role rather than contributing to disease 
progression49. Up to now, HAT has not been linked to CF. 
In CF, a number of additional proteases have been described to be potential ENaC activators in the 
lung.  CF lung disease is characterized by a severe, chronic neutrophilic inflammation which finally 
leads to the destruction of lung tissue and emphysema50. Neutrophil elastase (NE), one of the 
neutrophil serine proteases, is found in high amounts in the CF lung and is correlated with the 
severity of the CF lung disease51. The enzyme has been found to be a potential activator of near-
silent ENaCs, cleaving the inhibitory tract of the γ-subunit close the physiological CAP cleavage site52-
53. Activation of ENaC by NE, however, requires prior processing of the channel by furin so that furin 
inhibition prevents the activation by NE. This observation is in contrast to the inhibition of CAPs 
which does not affect the activation by NE43. Other proteases that are released by macrophages like 
macrophage elastase (MMP-12), matrix-metallopreptidase (MMP-) 9 or by neutrophils like cathepsin 
G or proteinase 3 have never been linked to ENaC activation so far. 
Furthermore, increased amounts of the cysteine protease cathepsin S have been found in the 
bronchoalveolar lavage (BAL) fluid of CF patients, independent of Pseudonomas aeruginosa 
infection54 as well as in cultured airway epithelial cells of healthy and diseased origin55. In vitro data 
show that cathepsin S is able to proteolytically process and activate epithelial sodium channels. The 
putative cleavage sites in the γ-subunit are identical to the ones suggested for NE, in both cases distal 
to the CAP cleavage site56. The physiological role of cathepsin S in ENaC activation remains unclear so 
far.  
Similarly to cathepin S, the cysteine protease cathepsin B has been shown to be expressed in 
cultured airway epithelial cells55 and increase ENaC activity in the airway. So far, the precise cleavage 
site has not been identified, but the polybasic recognition motive that is also required for cleavage by 
CAPs and chymotrypsin also seems to be necessary for cathepsin B57-58.  
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Both cathepsins B and S favor acidic conditions for optimal enzyme activity, in contrast to CAPs which 
have been shown to have higher activity in basic conditions. In CF, due to reduced hydrogen 
carbonate transport via CFTR, the airway surface liquid is slightly acidified which might both increase 
the activity of cathepsins as well as decrease the activity of CAPs57.  
 1.3 Interplay between CAP1 and CAP3, models of altered protease-
antiprotease balance and increased ENaC-activity in CF airways  
 
CAPs 1 and 3 are most relevant for ENaC activation under physiological conditions. Interestingly, 
murine knockout models suggested that these enzymes are tightly coupled together in a highly 
complex system, including their natural inhibitors hepatocyte growth factor activator inhibitor (HAI)-
1 and -2. CAP1- and CAP3- deficient mice have an identical phenotype, apart from the embryonic 
lethality of the constitutive CAP1 knockout59. Both enzymes are synthesized as inactive zymogens 
that require proteolysis to get activated. At least in mice, they have been shown to be co-localized in 
the skin59 and in human airway samples, both enzymes are found to be expressed21. Matriptase-
deficient mice lack proteolytically processed CAP159 and in vitro studies revealed that CAP1 triggers 
CAP3 zymogen activation60. CAP3 activation does not require prostasin catalytic activity as 
matriptase undergoes auto-activation via proteolytic cleavage61. Catalytically inactive CAP3 cannot 
be activated by direct proteolysis of CAP160.  
In vivo, the activity of CAP1 and CAP3 is strongly regulated by their endogenous inhibitors HAI-1 and 
HAI-2. Similarly to constitutive knockouts of the proteases, complete deficiency of one of the 
inhibitors or haploinsufficiency of both are lethal in murine models62-63. Strikingly, the developmental 
deficits, due to HAI-1 and HAI-2- deficiency, were rescued by reduced CAP1 activity64.  
To summarize, a balance between CAP1 and CAP3 activity is required for crucial biological processes; 
deficiency in any of the factors is associated with severe defects and lethality.  
Many diseases are associated with an impaired protease- antiprotease balance42, including 
pulmonary fibrosis65-66 and cystic fibrosis. For the neutrophil serine proteases, the break of the 
antiprotease shield sets the stage for lung destruction in CF67. Limiting CAP activity is one the major 
regulators for epithelial sodium transport via ENaC which seems to contribute to the ion transport 
imbalance in the CF airways.  In the airways, the regulation of proteolytic cleavage of ENaC is coupled 
to the change in airway surface liquid volume which is dependent on the osmotic force created by 
sodium absorption and chloride secretion68.  
In normal airways, a fraction of ENaC is transported to the plasma membrane as “near-silent” 
channels that require proteolytic cleavage by CAPs for full activation. In the airway surface liquid, 
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soluble endogenous CAP inhibitors like HAI-169, HAI-221 and bikunin70 are present that are able to 
limit proteolytic activity. A model suggests that increasing ASL volume reduces the concentration of 
soluble inhibitor, resulting in increased protease activity. Consequently, ENaC activity is increased, 
leading to increased sodium and water absorption until the physiological volume and ASL height are 
reached. By restoring the protease-antiprotease balance, the secretion and absorption processes 
return to their physiological levels. In case of reduction in the ASL, the concentration of soluble 
inhibitors increases so that the proteolytic activity of CAPs is reduced. Therefore, absorption goes 
down and secretion of water from the epithelial cells overweighs the absorption – the ASL increases 
to its physiological volume21,68 (Figure 3 A-B). 
In CF however, this regulation process is disrupted (Figure 3 C-D). Interestingly, CF airway epithelial 
cultures do respond more strongly to the exogenous inhibitor aprotinin whereas they are less 
affected by the addition of exogenous trypsin. This suggests that CF airway epithelial cells have less 
endogenous inhibitor, more constitutively active sodium channels and less near-silent, inactive 
channels. Consequently, CF airway cultures have less possibility to limit sodium and water 
absorption21,68. Furthermore, data from CF airway cultures suggest that the expression of CAP1 is 
significantly increased compared to normal tissue21.  
A   B   C   D 
 
 
 
 
 
 
In the airways, ENaC activity is also regulated by its allosteric modulator short-palate lung and nasal 
epithelial clone 1 (SPLUNC-1). In contrast to HAI-1 and HAI-2, SPLUNC-1 does not affect protease 
activity but causes the internalization of α- and γ- subunits of ENaC, reducing the amount of active 
Figure 3: Regulation of ASL height by activation and inactivation of ENaC in normal and CF epithelium 
In normal epithelium, high airway surface liquid volume leads to the activation of ENaC by active CAPs (A). 
Consequently, the sodium transport increases and the ASL volume decreases. At low ASL volume, the soluble 
inhibitor SPLUNC1 prevents ENaC activation and extracellular ATP increases CFTR function so that the volume is 
restored (B). In CF, hyperactive CAPs as well as inflammatory proteases like NE are present in epithelial cells (C).  
Figure from 
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channel on the cell surface. Furthermore, it increases the ubiquitination of the α-subunit by Nedd-4-
2, an E3 ubiquitin-protein ligase71-72. Interestingly, SPLUNC-1 has been shown to be inactive under 
acidic conditions, such as CF airways, due to highly pH-sensitive salt bridges in the molecule. Reduced 
activity of SPLUNC-1 might also contribute significantly to increased ENaC activity in CF airways73.  
To summarize, it remains a question of debate which key factors contribute to the impaired ion 
transport balance in CF and more tools are required to obtain further insight on the 
pathophysiological mechanisms.   
1.4 Basic principles of fluorescence and fluorescence energy transfer 
 
Fluorescence is a type of luminescence in which the absorption of photons causes the transition of an 
electron from its ground electronic level to an excited singlet level. Within nanoseconds, the electron 
falls back to a lower excited state and subsequently to the ground state, emitting light with lower 
energy, corresponding to a longer wavelength compared to the excitation light. In contrast to 
phosphorescence, the spin electron remains paired with the ground state electron during the whole 
process. The loss of energy is caused by non-radiant, vibrational relaxation between the excited 
states. This process is essential for the existence of fluorescent properties of a molecule. The 
difference between excitation and emission wavelength is called Stokes shift74.  
Fluorescence microscopy is based on molecular fluorescence. In molecules with more complex 
electronic systems, the energy level of the ground and excited levels is not discrete but is spread to 
energy bands. This results in the typical absorption and emission spectra of fluorophores. All 
fluorophores share the property that they contain conjugated double bonds which allow the 
electrons to be displaced in a rigid and planar molecule. The larger is the conjugated electron system, 
the higher the emission and absorption wavelength 74. 
In the past decade, the variety and quality of fluorophores available for biological applications have 
increased enormously. Nowadays, there are fluorophores available throughout the whole spectrum 
of visible light as well as UV-excited and infrared dyes.  Improvements towards sharp excitation and 
emission spectra as well as high extinction coefficients and high quantum yields have been made by 
chemical modifications of older fluorophores like fluorescein and rhodamine or completely new 
designs75.  
In biological experiments, fluorophores are frequently used to monitor the location of specific 
labeled molecules or proteins. In more advanced settings, they are very useful tools to monitor 
dynamic processes, e.g. the activity of a protease. Most commercially available protease substrates 
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are designed as fluorogenic substrates that become fluorescent at a distinct wavelength upon 
cleavage of the fluorophore from the peptidic recognition motive.  
Foerster Resonance Energy Transfer (FRET) describes a process in which a donor fluorochrome 
transfers its energy to another fluorophore or quencher without emission of light. For the energy 
transfer, the two molecules, so called donor and acceptor, must be in a very close proximity (several 
nanometers), the Foerster radius75.  In case of protease substrates, donor (D) and acceptor (A) 
fluorophores are linked by a peptidic recognition sequence for the enzyme. As long as the molecule is 
still intact, the energy absorbed by the donor fluorophore is transferred to the acceptor, FRET occurs. 
The donor fluorophore is almost fully quenched whereas the acceptor fluorophore emits fluorescent 
light. Upon cleavage the donor fluorescence increases significantly whereas the acceptor 
fluorescence decreases and the change in D/A ratio is a measure of enzyme activity (Figure 4). 
 
 
 
Similar ratiometric probes have been successfully established for MMP-12 and NE76-77.   
1.5  Aims of the project 
 
The development and use of personalized drugs requires fundamental understanding of the 
pathophysiological processes combined with comprehensive characterization of the phenotype of 
each individual patient. In CF research, the strongest research focus is typically characterization and 
modulation of CFTR function. Nowadays, a number of CFTR modulators and correctors are on the 
market and more research is ongoing. ENaC and proteases as therapeutic targets have been 
neglected for a while even though there are promising studies showing improvements in the 
phenotype after inhibition of the ENaC/protease axis43, 78-79. One of the reasons might be the lack of 
tools to investigate protease activity to identify biological processes as well as protease activity levels 
in patients. Up to now, soluble fluorogenic peptides, RNA and protein quantification were the limited 
available tools to quantify enzyme activity in patient samples or mouse tissue. Therefore, I wanted to 
develop tools that facilitate enzyme activity quantification in murine and human samples. 
Figure 4: Principle of FRET probe design and readout 
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From experience in the Schultz and Mall research groups, it is known that ratiometric FRET probes 
which insert themselves into the plasma membrane because they bear lipid side chains, are useful 
tools to detect and quantify membrane-bound enzyme activity76-77. In the past, the focus was on 
inflammatory cell-derived proteases that are responsible for the destruction of lung tissue. In this 
project, we aimed to develop probes for the quantification of channel-activating protease activity in 
human and murine samples. As described, the proteases seem to be redundant because one can 
replace another in the task of ENaC activation. Therefore, we did not aim to develop a probe which is 
able to dissect the activity of several channel-activating proteases from each other but rather to 
measure the sum of them.  
A suitable CAP probe should thus fulfill the following criteria: 
1. Stable insertion of the lipidated probe into the plasma membrane with no or very low 
internalization in the time frame of our experiments, varying from 2 to 10 hours 
2. High dynamic range of the FRET signal to enable quantification of small differences in 
enzyme activity 
3. Applicability to murine and human samples 
4. Selectivity towards proteases that cleave ENaC in a similar manner 
 
After successful design and characterization, the probes undergo initial proof of concept experiments 
to determine whether they are useful tools and/or suitable biomarkers that can be used in ex vivo 
with CF patient samples. 
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2. Results 
 
2.1 Representative purification and identification of peptide-based 
probes after solid-phase synthesis 
 
All FRET probes were synthesized by partially automated, fluorenylmethoxycarbonyl (Fmoc)-based 
solid phase peptide synthesis (SPPS) as described in the methods section. After cleavage from the 
resin in acidic conditions, the probes were purified by HPLC. All chemical structures are shown in the 
Material and Methods section (6.2.2) and on the addendum. The detailed synthetic procedures are 
described in the Material and Methods section (6.2.2). 
 
 
 
 
In Figure 5, a representative preparative HPLC trace of the soluble probe CAPRee1 after cleavage 
from the resin is shown during purification. For the majority of soluble probes synthesized, the 
peptide sequence was fully synthesized, but the coupling of the fluorophores was achieved in lower 
Figure 5: Representative preparative HPLC trace of CAPRee1 during purification 
Part A shows the full spectrum of the wavelengths detected over time. At about 6 min, a molecule was detected 
absorbing at low wavelength (220 nm, peptidic part) and at 350 nm (MetOCou). This represents the byproduct 
containing only the donor fluorophore. At 8.5-9 min, the desired compound, absorbing at all three wavelengths 
220 nm (petidic part, Ch1), 350 (MetOCou, Ch2) and 450 nm (Cou343 Ch3), was eluted. Part B shows the 
chromatogram at selected wavelengths, the concentration of acetonitrile (right hand side). 
wavelength 
time [min] 
time [min] 
concentration acetonitril [%] 
Pressure of pumps [100 bar] 
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yield. Therefore, as byproducts during the synthesis, probes bearing only one of the fluorophores 
were obtained.  
Compounds absorbing at 220 nm, 350 nm (7-amino-4-methoxycoumarin (MetOCou)) and 450 
(Coumarin343 (Cou343)) nm were collected and submitted to analytical HPLC with coupled mass 
spectrometry to check purity and mass.  
In case of lipidated probes, the synthesis efficiency was affected by the lipid chain which had been 
coupled in the second step of synthesis. The detailed synthetic steps are described in Material and 
Methods (6.2.1 and 6.2.2). Therefore, more byproducts with aborted peptide chains were observed 
in some cases. Peaks with absorbance at 220 nm, 450 (Cou343) nm and 550 (TAMRA) nm were 
collected and checked by mass spectrometry. Keeping in mind that TAMRA had been used as a 
mixture of two isomers during synthesis, successfully synthesized compounds showed up double 
peaks in the analytical HPLC with identical mass. As control molecules for the expected localization of 
the fragments after cleavage, the fragments after peptide cleavage were also synthesized 
independently for selected probes. Apart from HPLC and mass spectrometry, these were further 
analyzed by NMR. All analytical data and chromatograms are shown in the appendix.  
After purification and removal of the solvents, the samples were dissolved to stock solutions in 
DMSO in millimolar concentration. We observed that Coumarin343 is not stable in dry conditions at -
20 °C, most likely due to remaining TFA from the solvents used in HPLC (Figure 4). Purification 
without acid or formic acid instead for TFA failed due to worse separation of the compounds. 
Compounds stored in DMSO or water were not prone to degradation and proved stable for at least 2 
years of storage at -20°C (Figure 6). The concentration was measured by absorbance of Cou343 in 
ethanol (ε=44100 L*mol.1*cm-.1)76.  
After purification and quality check, the samples were submitted to characterization by high 
resolution mass spectrometry at the Mass Spectrometry Facility @OCI, University of Heidelberg. 
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Figure 6: Stability of CAPRee1 as lyophylized powder and in DMSO solution 
Part A shows the purity of CAPRee1 after 7 months of storage as lyophilized powder. Part B is the mass 
corresponding to peak 1, C to peak 2. Most likely due to remaining traces of TFA in the powder, Cou343 was 
degraded significantly. The mass of the compound lacking Cou343 absorbance increased by 16 Da, which might 
suggest the addition of an oxygen atom somewhere on the ring system which destroys the conjugated system. The 
exact structure could not be solved as NMR is difficult for molecules of this size and requires comparably large 
amounts of probe which were not available. In contrast, storage in water or DMSO prevents degradation of the 
fluorophore (D). The large solvent peak is due to DMSO. Consequently, all probes were stored in DMSO solution 
after purification.  
1  
time [min] 
time [min] 
mass/charge mass/charge 
concentration acetonitril [%] 
Pressure of pumps [100 bar] concentration acetonitril [%] 
Pressure of pumps [100 bar] 
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2.2 Characterization of CAP probe based on autoactivation cleavage site 
of matriptase 
 
For CAPRee1-3, the amino acid (aa) sequence is identical to the sequence of the autoactivation 
cleavage site of CAP3 (R611 – G618) and related to the amino acid sequence of the commercial 
substrate sold by R&D systems (Cat# ES014) for CAPs 1 and 380. For the soluble probe, the donor 
fluorophore was added to the N-terminal part of the molecule, the acceptor on the side chain of a C-
terminal lysine residue. The lipidated probes were designed with the acceptor fluorophore at the N-
terminal, basic and hydrophilic part of the molecule and the donor fluorophore and the lipid anchor 
at the more hydrophobic, C-terminal part of the peptide sequence. The water soluble acceptor part 
diffuses away after cleavage while the hydrophobic donor part remains attached to the plasma 
membrane. Therefore, a dual read out of the cleavage is achieved: first, FRET is lost due to 
separation of the fluorophores to distances higher than the Foerster radius and second, we observe 
the loss of colocalization of the fragments. 
In Figure 7, the common chemical structure of the CAP3-based probes is shown. The detailed 
structures of all probes are shown in the Methods Section (6.2.2). For the different CAPRee probes, 
the fluorophores (R) and linkers (X) and their positions were modified as well as single point 
mutations in the amino acid sequence. 
 
  
 
 
 
 
 
 
 
Figure 7: Common structure of all CAP3-based CAPRee probes 
All CAP3 based CAPRee probes share the common recognition sequence which is derived from the autoactivation cleavage site 
of CAP3. One fluorophore, Cou343, is coupled to a C-terminal lysine. In position R, different fluorophores were used to optimize 
the performance of the probe. In position X, a lysine with palmitoic acid could be coupled to obtain lipidated probes. 
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2.2.1 Physical properties of soluble and lipidated probes CAPRee1-3 
 
From experience, it was known that having at least one polyethylenglycol (peg)-linker moiety 
adjacent to the aa sequence is crucial for solubility in water. All soluble probes are equipped with 7-
amino-methoxycoumarin (MetOCou, donor (D)) and Coumarin343 (Cou343, acceptor (A)) as the 
fluorophore pair as this has been established to give good FRET efficiency in solution76-77. 
For CAPRee1, the D/A ratio does not change in the absence of enzyme, indicating good solubility of 
the probe and no unspecific loss or gain of FRET (Figure 6 A and B). The initial D/A ratio calculated 
from the emission wavelength scan between the maximal donor (400 nm) and acceptor fluorescence 
(490 nm) is 0.56 ± 0.027 (average ± SEM, calculated by linear regression), independent of the 
concentration of the probe varying between 0.5 µM and 4 µM. Murine CAP3 cleaved CAPRee1 over 
time (C and D) as quantified by the ratio of MetOCou and Cou343. The normalized trace is calculated 
by division of the D/A ratio value by the average of the negative control, calculated from Fig. 6 B. 
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Figure 8: Behavior of CAPRee1 in absence or presence of enzyme 
A emission wavescan of CAPRee1 in absence of enzyme with excitation wavelength 350 nm 
B quantification of the ratio at 400 nm and 490 nm over time in absence of enzyme, n=5, plotted as mean ± SEM 
C emission wavescan CAPRee1 in presence of 5 nM mCAP3 with excitation wavelength 350 nm 
D quantification of the ratio at 400 nm and 490 nm over time in presence of 5 nM mCAP3. The normalized D/A ratio was 
calculated by division of each absolute D/A ratio value by the average D/A ratio value in absence of enzyme.  
 
The assay was performed in 50 nM Tris-HCl and 0.05 % Brij-35 in water at neutral pH. Each curve, except B, was shown 
as representative curve for n=1. A was measured in five replicates. Positive and negative controls were included in all 
experiments. 
 
A       B
      
 
 
 
 
C         D 
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In general, the normalized D/A ratio shows the dynamic range (maximal fold change) that is reached 
for a distinct probe which makes it very useful for the comparison of different probes. For the 
application on human or murine specimen later on, the calculation of the fold change is not always 
possible due to experimental requirements as described later. To be consistent throughout, all 
quantification was done without normalization unless indicated otherwise. Upon cleavage by mCAP3, 
the D/A ratio increases both by increase in donor fluorescence and decrease in acceptor 
fluorescence. When the assay was performed in basic conditions, as recommended by the supplier of 
the recombinant enzymes, the D/A ratio peaked and decreased afterwards, indicating that at least 
the donor fragment precipitated after cleavage. Consequently, all further experiments were 
performed at neutral pH, where the D/A ratio enters a plateau upon complete cleavage (Figure 9). 
The behavior of the probe in different pH was observed in more than 100 traces of each condition 
with different probe and enzyme concentrations as well as for different enzymes.  
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The lipidated probe was designed for the detection of enzyme activity on the surface of cells and 
inserts into the outer leaflet of the plasma membrane, as can be seen by confocal microscopy 
(include images to demonstrate the localization). For the characterization, the probes are tested in 
vitro. In previous studies, liposomes had been used to provide an artificial membrane into which the 
probe can insert76-77. Therefore, liposomes approximately 320 nm in size were generated in CAP 
assay buffer. In contrast to MMP12 and NE which had been tested before, the insertion into these 
small liposomes drastically impaired proteolytic cleavage by human and murine CAP3. Consequently, 
liposomes could not be used for the in vitro characterization of the lipidated probes (Fig. 10A). As 
alternatives, a neutrophil-like cell line, HL-60, which is handled in suspension, was tested as well as 
the use of pure buffer. Undifferentiated HL-60 cells do not express relevant serine proteases on their 
Figure 9: pH-sensitivity of donor fluorescence and  absolute D/A ratio change 
The assay was performed with 10 nM mCAP3 in 50 nM Tris-HCl and 0.05 % Brij-35 at the given pH, adjusted by addition 
of NaOH. The curves are plotted as representative traces with n=1.  
A                   B 
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surface. Comparison of pure buffer and usage of HL-60 cells as membrane supply did not show 
significant differences in cleavage rate,  and the cleavage was much faster compared to liposomes 
(Fig. 10 B). Because of the good solubility of the lipidated probes, the use of cells as support is not 
required. Therefore, the characterization was done in pure buffer; the composition was enzyme-
dependent as described in the methods section.  
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The lipidated CAPRee probes are equipped with a different set of fluorophores because the 
combination of MetOCou and Cou343 is not suitable for imaging on cells. First, standard microscopes 
do not have a laser or lamp which is able to excite MetOCou at 350 nm. Second, continuous 
excitation of the fluorophores with UV light is not compatible with live cell imaging over longer time 
periods. Therefore, the combination of fluorophores has to be shifted to higher excitation and 
emission wavelength. Previously, Cou343 and TAMRA had been chosen for lipidated probes. The 
performance of such a probe, CAPRee3, is presented in Fig. 11. As expected, the donor fluorescence 
is quenched by the acceptor fluorophore as long as the molecule is intact, but the initial FRET is lower 
compared to the soluble probe CAPRee1. In absence of enzyme, the D/A ratio is constant. 
Furthermore, the lipidated probes are cleaved much more slowly, which is not unexpected and has 
been observed before also for MMP12 and NE sensors76-77. For enzyme quantification, a comparison 
between recombinant enzymes, which are composed of the catalytic subunit and lack the 
membrane-anchoring and regulatory regions, and cell-bound endogenous enzymes is not possible so 
that absolute values for enzyme concentration cannot be concluded. Most likely, the activity of 
recombinant and endogenous enzymes will differ significantly.  
 
Figure 10: In vitro cleavage of CAPRee3 in buffer, on liposomes or HL-60 cells 
The assay was performed with 2 µM of CAPRee5, in A 10 nM mCAP3 and B 50 nM mCAP3. The HL-60 cells were 
handled in PBS, buffer and liposomes in 50 nM Tris, 0.05 % Brij-35. The traces are exemplary and were measured 
as single measurements over time. For B, the experiment was performed for eight different enzyme 
concentrations and three different probe concentrations (total n=24).  
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In order to optimize FRET, several modifications have been tested towards their effect on FRET 
efficiency and also specificity (described in 3.2.2). The detailed modifications are listed in Table 1 
together with the resulting initial D/A ratio of the intact molecule.  
 
 
# Modification Initial D/A ratio 
CAPRee1_a R in P1 -> K in P1 0.4 
CAPRee1_b 3 additional C-terminal aspartic acid residues  1.3 
CAPRee1_c additional peg linker in P5 1.9 
CAPRee1_d Additional C-terminal lysine residue 2.4 
 
The replacement of the arginine in position P1 of the peptide does improved the FRET efficiency and 
the initial D/A ratio. CAPRee1_a was further tested for its specificity as described later. CAPRee1_b 
was synthesized to check the effect of additional, negatively charged amino acids without modifying 
the two-dimensional distance between the fluorophores. Potentially, the lipidated probe might be 
internalized into the cell due to its overall positive charge. However, the mechanism of 
internalization of lipidated peptides is not known. The intial FRET ratio increased significantly, 
suggesting that the probe, despite its small size, occupies a 3-dimensional structure which is affected 
by the addition of negative charges. This might also be the case for the lipidated probe where the 
dynamic range is already dramatically reduced compared to CAPRee1. Therefore, the addition of 
negative charges is not favored. The insertion of a second peg-linker N-terminally of the arginine in 
Figure 11: In vitro cleavage of CAPRee3 in presence of 10 nM mCAP3 
 The experiment was performed in 50 mM Tris-HCl with 0.05 % Brij-35 at 2 µM probe concentration.  
A                 B 
Table 1: Modifications of CAPRee1  
CAPRee1: MetOCou- RQARVVGG peg K(Cou343) 
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P4 in CAPRee1_c increased the distance between the fluorophores by approximately 1 nm in the 2-
dimensional model, which resulted in a strong loss of FRET in the intact molecule. The effect was 
tested for 8 concentrations between 20 µM to 0.02 µM in absence and or presence of enzyme. For 
all, the dynamic range remained very poor, with a maximum of 3.5 for 1.25 µM probe concentration. 
Similarly, in CAPRee1_d where an additional lysine residue was inserted between the fluorophores, 
the initial FRET ratio is significantly increased (Fig. 12). 
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The maximal D/A ratio change for the lipidated probe CAPRee2 was poor compared to that of the 
soluble probe CAPRee1. Therefore, the combination of different fluorophores with Cou343 was 
tested. The choice of fluorophores was based on the overlap of the excitation spectrum with the 
emission spectrum of Cou343 and a large red shift for the emission of the acceptor fluorophore as 
well as high extinction coefficient and quantum yield. Furthermore, the fluorophore should have 
minimum absorbance at 405 nm, where Cou343 is usually excited in the microscope. In addition, the 
price of purchasing the fluorophores is not negligible because for the synthesis, large amounts are 
Figure 12: Modifications of CAPRee1 and their effect on initial D/A ratio 
The experiment was performed in 50 mM Tris-HCl with 0.05 % Brij-35 at 2 µM probe concentration in the absence of 
enzyme. Each trace was measured individually, replicates were renounced for A, B and D as the probes or the described 
modifications were not further used, except C. C was repeated once with an additional concentration series from 20 µM 
to 0.02 µM.  
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needed compared to labelling techniques. Therefore, advanced dyes like Alexa variants are not an 
option so far, especially not during the phase of establishment of a new probe. 
Initially, the lipidated probe (which one) was synthesized with a similar structure to that of the 
soluble probe CAPRee1, i.e. with one peg linker (state how long this is – two ethylene glycol units I 
think). For insertion into the plasma membrane, a lysine which was palmitoylated on the side chain 
was added between the C-terminal donor fluorophore and the peg-linker (Figure 7, position X). In the 
probes CAPRee2_a and CAPRee2_b, TAMRA was replaced by Cy3 and Dy485-XL (Figure 7, position R). 
These fluorophores were chosen because it was hoped that Cy3 would be a better quencher 
compared to TAMRA, because of its 3x higher extinction coefficient. The quantum yield, however, is 
much lower compared to TAMRA. Dy485-XL is coumarin-based, with a large Stokes shift and its 
absorbance spectrum has perfect overlay with the emission of Cou343. As the combination of two 
coumarins works very well for the soluble probe this was thought to offer good possibilities for the 
lipidated probe. The structures of the dyes are shown in Figure 13.  
 
     
 TAMRA          Cyanin-3              Dy485-XL 
 
 
 
CAPRee2 with TAMRA as second fluorophore had an initial D/A ratio of about 1.35, which is as 
expected for this combination of dyes76-77. Upon addition of 50 nM mCAP3, the probe was cleaved 
slowly over time and was not fully cleaved after 5 h (Figure 14). CAPRee2_c which contains Cy3 had a 
similar initial D/A ratio but was cleaved faster and reached a higher final D/A ratio. However, this 
variant was also not fully cleaved after 5h of incubation. For CAPRee2, the D/A ratio did not increase 
further even when acceptor fluorescence remained. Potential reasons will be discussed later. Dy485-
XL did not improve the initial D/A ratio, but decreased it significantly. The FRET in the intact molecule 
Figure 13: Structures of different acceptor fluorophores tested for lipidated CAPRee probe 
 TAMRA was incorporated in CAPRee2 CAPRee2_a and CAPRee3, Dy485_XL in CAPRee2_b  and Cy3 in CAPRee2_c.  
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is rather poor. This might be due to the low extinction coefficient of the dye or an unfavorable 
orientation of the dyes in the molecule. 
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The use of the sensor on primary cells requires the application of rather high concentrations due to 
the experimental setup. Therefore, a variant of CAPRee2 with an additional peg-linker between the 
aa sequence and the N-terminal fluorophore was synthesized to increase aqueous solubility 
(CAPRee3, detailed structure in appendix). In contrast to the soluble probe CAPRee1, where the 
addition of a second peg-linker with a total length of 4 ethylene glycol units did strongly affect the 
FRET in the intact molecule, the increase in the 2-D distance between the fluorophores in the 
lipidated probe CAPRee3 did not have a major impact on the D/A ratio. This behavior of the probe 
suggests that it indeed takes a certain shape so that the increase in the theoretical two-dimensional 
length between the fluorophores does not result in increased distance between the fluorophores. 
The results from the in vitro experiments might not directly translate to the behavior on the cell 
Figure 14: Effect of different acceptor fluorophores on lipidated CAPRee probes CAPRee2, CAPRee2_b, 
CAPRee2_c 
CAPRee2 is synthesized with TAMRA as acceptor fluorophore (A). Compared to CAPRee1, the acceptor of the 
lipidated probe is not as efficient in quenching the donor fluorophore. Therefore, the initial ratio is 1.35 for 
CAPRee2 (C). CAPRee2_c has a Cy3 derivative instead of TAMRA (B).  Spectrum of CAPRee2_b with Dy485-XL 
instead of TAMRA.  (D) The assay was performed in presence of 50 nM mCAP3 in assay buffer. The traces are 
shown as representative traces for n=1.  
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surface because the probe will be embedded in a dense network of surface proteins, and the close 
proximity to the hydrophobic plasma membrane might also affect the structure and FRET efficiency.  
2.2.2 Kinetic properties and specificity towards CAPs over other proteases 
 
For the development of useful tools for the quantification of protease activity, the specificity of the 
probe is fundamental. The specificity of the CAPRee probes was tested towards a number of 
proteases that have been published to be relevant in the context of CF lung disease54, 57, 81-82. In this 
context it is worth mentioning that there are no small molecule inhibitors available that enable the 
distinction between different CAPs so it is to be expected that the design of a substrate selective for 
one of them might not be possible. Due to redundancy of the CAPs in mediating ENaC activation, this 
was also not the focus of this work. 
The specificity of the synthesized probes was tested for human and murine enzymes. As previously 
described, the D/A ratio was affected by the pH of the assay buffer so it was set to neutral conditions 
irrespective of what was recommended for the enzyme. Furthermore, absolute quantification of 
selectivity was not possible because of the high variability of enzyme activity which is reported for 
specific substrates. Being natively membrane-bound enzymes, the reduction to the catalytic subunit 
will not be comparable to the native enzyme with respect to the activity. Furthermore, 
recombinantly expressed enzymes lack regulatory domains, which will also have significant effect on 
the activity of the enzyme.  
To normalize enzyme activity for semi-quantitative specificity data, the activity of each enzyme was 
determined for the substrate recommended by the manufacturer or the commercial CAP substrate 
of R&D systems with a similar recognition sequence.  
To prove that CAPRee1 was exclusively cleaved in the expected cleavage site, the peptide was 
redesigned with a D-arginine in the putative cleavage site (CAPRee1*). Enzymes do not recognize 
unnatural D-amino acids as substrates so that CAPRee1* should not be cleaved by mCAP3 or  hCAP3 
(Figure 15A). The expected cleavage site was further confirmed by mass spectrometry (mass 
expected for acceptor fragment 872.94 Da, mass found 871.9 Da). 
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Remarkably, this is not the case for neutrophil elastase (NE) which cleaves CAPRee1* with identical 
cleavage rate compared to CAPRee1 (Figure 15 B). NE does not recognize arginine in the cleavage site 
but small aa residues like valine77. It was confirmed by mass spectrometry that neutrophil elastase 
cleaved between the valine residues in P1’ and P2’ and therefore, a D-arginine in P1 did not prevent 
cleavage by NE (Figure 15 B). The cleavage by NE is of no major concern as long as the probe is 
applied to activity measurements in epithelial cells, which do not express NE. However, it has to be 
kept in mind for the application in samples such as sputum supernatants where high NE activity is to 
be expected. To determine CAP activity in such samples selective NE inhibitors like sivelestat83 can be 
used to block NE activity. Sivelestat is not expected to block CAP activity84. 
Enzymatic reactions can be described by the Michaelis-Menten model of enzyme kinetics. The 
Michaelis-Menten equation is as follows: 
𝑣0 =
𝑣𝑚𝑎𝑥[𝑆]
𝑘𝑀 + [𝑆]
 
with 𝑣0 being the initial reaction rate, 𝑣𝑚𝑎𝑥 the maximal reaction rate, [𝑆] the substrate 
concentration and 𝑘𝑀 the Michaelis constant. According to the model, the reaction rate is dependent 
on the substrate concentration85. For murine CAP3, the corresponding data is shown in Figure 13. 
Based on the donor fluorescence emission, the cleavage exactly followed Michaelis-Menten kinetics. 
The reaction rate was dependent on the substrate concentration until saturation was reached and 
the initial reaction rate could no longer increase. Remarkably, the D/A ratio did not follow this trend 
but, in a concentration range from 50 nM to ~ 3 µM, the increase was independent of the substrate 
Figure 15: Modification of CAPRee1 – D-arginine in P1 
The assay was performed with 2 µM of the given probe in presence or absence of mCAP3 or hCAP3 (A).  In B, 6.5 ng/ml hNE 
were added. Each trace was measured as single trace within a dilution series. The cleavage rate was enzyme concentration 
dependent for CAPRee1 in presence of NE, human or murine CAP3 and furthermore concentration dependent for 
CAPRee1* in presence of NE. The cleavage of CAPRee1* in presence of NE was done for 12 different NE concentrations, 
showing a concentration dependent cleavage rate.  
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concentration (Figure 16 D and F). This is highly advantageous for the application of our probe which 
is used in this concentration range. In contrast to commercial substrates, CAPRee probes cannot be 
used in the saturation range, i.e. [S]>> 𝑘𝑀, due to solubility problems. On the cell surface, the 
concentration cannot be measured exactly. Therefore, it is crucial that the increase in D/A ratio 
exclusively depends on the enzyme concentration and is not affected by the probe concentration, 
which might vary due to loading efficiency. For high concentrations, i.e. [S]> 3 µM, the increase in 
D/A ratio was not independent of the probe concentration.  The maximal D/A ratio as well as the rate 
of its increase decreased with increasing probe concentration (Figure 16 E). This might be due to 
intermolecular effects or product inhibition effects. For low concentrations, i.e. [S]< 50 nM, the 
increase in D/A ratio was also concentration-dependent and decreased with decreasing probe 
concentration. The range in which the increase in D /A ratio was concentration independent, was 
similar for all enzymes tested, i.e. CAP1 and CAP3 (human and murine). 𝐾𝑀 values were also 
comparable for the different enzymes in the low µM range.  
For CAPRee1, the maximal fluorescence intensity and maximal D/A ratio upon full cleavage were 
independent of the enzyme concentration. They are only dependent on the substrate concentration 
(Figure 17 A-B). This was expected as the maximal fluorescence intensity is dependent on the 
amount of fluorophore present in the sample. The amount of unquenched MetOCou determines the 
intensity detected at 400 nm. This should be independent of how fast the maximum is reached, i.e. 
independent of the enzyme concentration. 
Upon cleavage of CAPRee3 by hCAP3, the maximal fluorescence intensity (Figure 17 C) and dynamic 
range of the D/A ratio (Figure 17 D),  seem to be partially  be dependent of the enzyme 
concentration in the range between 3 nM and 50 nM hCAP3. For higher concentrations of enzyme, 
the maximum fluorescence intensity of the donor as well as the dynamic range were independent of 
enzyme concentration. For HAT, no concentration dependence of the D/A ratio increase was 
observed (Figure 17 E). For mCAP3, the concentration dependence of the maximal donor 
fluorescence intensity was most pronounced (Figure 17 F).  
All experiments were performed for four different substrate concentrations. The behavior was 
independent of the substrate concentration, so that precipitation at a certain concentration of the 
fragments is unlikely. Most likely, this effect is due to product inhibition which depends on the 
specific enzyme and might vary significantly. More experiments would be required to definitively 
answer this question.  
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For the lipidated probes, testing such a high concentration range was not possible due to low 
solubility and weak signals at low concentrations under in vitro conditions. Therefore, the 
concentration range was reduced to 0.5 µM to 4 µM. For hCAP3 and mCAP3, the Michaelis constant 
was somewhat lower at around ~ 700 nM.  
 
 
A 
 
 
 
B 
Figure 16: Determination of CAPRee1 kinetics with mCAP3 
The assay was performed with 10 nM mCAP3. The probe concentration varied between 33.3 µM and 2 nM.  
A: donor fluorescence for difference probe concentrations. B: donor fluorescence for very low probe concentrations. 
C: kinetic plot, initial slopes of A and B vs. probe concentration. D and E: D/A ratio or different probe concentrations. 
F: lope of D/A in the first 10 min vs. lg2 of the probe concentration [µM] 
Each trace was measured once, the traces are plotted for n=1. Identical experiments were performed for four different 
enzyme concentrations. 
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Due to this behavior, the analysis of kinetic curves had to be reconsidered. The quantification of 
donor fluorescence seems not to be ideal because it is heavily influenced by numerous factors. The 
quantification of enzyme activity based on D/A ratio changes is much more robust. Over a set of 100 
kinetic measurements, the D/A ratio curves were either fitted by linear regression in the first minutes 
or by non-linear regression fitting an inverse exponential function, calculating half-life and plateau 
height. Analysis revealed that the half-life did not significantly correlate to enzyme concentration, 
due to the behavior described that the maximal fluorescence and/or D/A ratio are not independent 
of enzyme concentration. Therefore, the plateau height was also an objective measure because this 
was not the case for all enzymes. The linear slope gave highly significant (p<0.001) correlation to the 
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Figure 17: Behavior of donor fluorescence and D/A ratio of CAPRee3 upon cleavage by hCAP3, mCAP3 and HAT 
The experiments were performed in identical buffer conditions (50 mM Tris-HCl, 0.05 % Brij-35). The traces are 
representative for CAPRee1 at 4 µM (A and B) and CAPRee3 in 1 µM concentration (C-F). The effects described are 
however independent of the substrate concentration which was varied between 0.5 µM and 4 µM (i.e. 0.5 µM, 1 µM, 
2 µM, 4 µM). The numerical values of donor fluorescence emission were probe concentration dependent. Each 
substrate concentration was tested once for all given enzymes and concentrations thereof as controls. A-E are 
performed with human enzymes, F with murine CAP3.   
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enzyme concentration in all cases and was therefore the measure for all following experiments. The 
normalization to 1 as initial ratio at timepoint 0 is only possible if a negative control is available. For 
primary cells this would increase the number of experiments significantly or is partially even 
impossible. In case of murine tracheal epithelical cells or human nasal epithelial cells, it is not 
possible to obtain negative control and kinetic data from one sample due to technical limitations.  
Based on in vitro data, this normalization is not required for the read out of enzyme activity. 
The cleavage of CAPRee1 was assessed for the following human proteases: CAP1, CAP3, HAT, furin, 
CTSS, CTSB, MMP12 and NE (Figure 18).  
 
  
0 50 100 150 200 250
0
5
10
15
12.5 nM hCAP3
1.56 nM HAT
100 nM hFurin
31.25 nM hCTSB
16 nM CTSS
50 nM MMP12
210 pM NE
time [min]
D
/A
 r
a
ti
o
 
CAPRee3
0 50 100 150 200 250
0
5
10
15
25 nM hCAP3
3.125 nM HAT
100 nM hFurin
31.25 nM hCTSB
time [min]
D
/A
 r
a
ti
o
 
0 50 100 150 200
0
5
10
15
50 nM mCAP1
12.5 nM hCAP1
time min]
D
/A
 r
a
ti
o
 
 
 
 
 
 
Murine and human CAP1 are not included in the common graph due to comparably low enzyme 
activity. An activity comparable to the other enzymes could not be achieved.  
To summarize, CAPRee1 was not only cleaved by CAPs, but also significantly by HAT, as expected, NE, 
cathepsin B and furin to some extent. The lysine in the cleavage site of CAPRee1_a prevented 
A      B 
 
 
 
C       
 
 
 
 
 
 
 
 
Figure 18: Cleavage of CAPRee1 and CAPRee3 by different recombinant enzymes 
 The assay was performed with the given enzyme concentration for CAPRee1 (A) and CAPRee3 (B). Probe concentration was 
2 µM. The buffer composition was adapted to the enzyme. Enzyme concentration was normalized to cleavage of the 
respective commercial substrate sold for the enzyme. CAP1 could not be normalized to the other enzymes due to very low 
cleavage of the commercial substrate. (C) shows the cleavage of CAPRee1. All enzymes were tested in 8 or 12 different 
enzyme concentrations and 4 different substrate concentrations. The graphs show representative traces. All enzymes 
cleaved their respective commercial substrate from R&D systems as positive controls. The reaction rate for CAPRee1 and 
CAPRee3 was enzyme concentration dependent. Each concentration was measured once (n=1), for a total n of 32-48 
combinations per enzyme and substrate.  
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cleavage by CTSB. CAPRee1 was not cleaved by cathepsin S and MMP12 at all. Interestingly however, 
the lipidated probe CAPRee3 was not cleaved by cathepsin B and furin at all. Cathepsin S and MMP12 
were not further tested. For murine enzymes, the situation was comparable, i.e. the soluble probe 
CAPRee1 was cleaved by furin and cathepsin B, but not the lipidated probe CAPRee3. So far, the 
lipidated probe had not been carefully characterized76-77. It is expected in the protease field that the 
amino acid sequence is crucial for recognition as a substrate, but adjacent fluorophores should not 
significantly affect the specificity. However, this data shows that the modification from the soluble to 
the lipidated probe was not without effects on specificity. Further investigation is required to 
understand whether the fluorophores or the lipid anchor affect the binding to certain enzymes. On 
the cell surface, the lipid anchor will most likely not affect the recognition because it is expected to 
be hidden in the membrane. However, cleavage might be affected by the distance of the cleavage 
site from the membrane as well as the distance and flexibility of the catalytic subunit of the enzyme 
from the membrane.  
2.2.3 Specificity of CAPRee1 on cell lines 
 
Because the soluble probe was shown to be rather unspecific in experiments with recombinant 
enzymes, two relevant cells lines, i.e. human bronchial epithelial cells (CFBE41o-) and murine kidney 
collecting duct cells (M-1), were tested with broad spectrum inhibitors that inhibit certain classes of 
enzymes. Serine proteases were blocked by Pefabloc SC, an irreversible, less toxic 
phenylmethylsulfonylfluorid (PMSF) derivate, metalloproteases by complexing agents like 
ethylenediaminetetraacetic acid (EDTA), cysteine proteases by E-64 and aspartic proteases by 
pepstatin A. The concentration was varied in the range recommended by the supplier of the inhibitor 
and incubated in DMEM + Hepes buffer to maintain neutral pH at atmospheric CO2 20 min before 
addition of the substrate. After preincubation with the inhibitors, CAPRee1 was added at 2 µM 
concentration in DMEM + Hepes and the given inhibitor concentration. Except for Pefabloc SC, the 
inhibitors did not affect the cleavage of CAPRee1, whereas the serine protease inhibitor completely 
abolished cleavage on M-1 cells (Figure 19 A). On CFBE cells, camostat and Pefabloc SC significantly 
reduced the cleavage of CAPRee1, but did not abolish it completely (Figure 19 B). Interestingly, 
incubation with EDTA increased the cleavage rate, which might be explained by the fact that divalent 
cations have been published to inhibit regulate CAP1 activity10. Therefore, CAP1 activity might 
increase upon incubation with EDTA. Cleavage by proteases other than serine protease is not 
relevant on the respective cell lines. From this data, epithelial cells do not express NE or cathepsin B 
on their surface. Therefore, CAPRee1 was specific enough to exclusively detect serine protease 
activity. It was however not possible to distinguish between HAT and CAPs as HAT is also blocked by 
camostat mesilate and Pefabloc SC. 
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2.2.4 Characterization of lipidated probes on murine and human cell lines 
 
Apart from physical and biochemical properties of the probe as described above, the behavior of the 
CAPRee2 and CAPRee3 probes on the surface of cells is crucial for an utilizable probe. Internalization 
of the intact probe is a disqualifier because the probes are aimed to detect surface-bound protease 
activity. Furthermore, the separation of the fluorophores after cleavage is indispensable, i.e. only the 
donor fragment may remain attached to the membrane and the acceptor fragment should diffuse 
away from the cell surface. Ideally, the donor fragment would be internalized after cleavage to 
obtain a memory effect. The mechanism however, how the MMP12-probe LaRee is internalized after 
cleavage, remains unknown. Therefore it is unclear, how probes need to be designed to achieve this 
behavior. In case that the behavior is sequence-dependent, it cannot be designed on purpose as the 
recognition motive of the target enzymes mostly determine the sequence. 
Figure 19: Specificity of CAPRee1 on M-1 and CFBE cells with broad spectrum inhibitors 
To exclude cleavage by other than serine proteases, M-1 (A) and CFBE41o
- 
(B) cells were seeded into 96-well multititer 
plates, incubated with the inhibitors for 20 min and afterwards incubated with CAPRee1. The cleavage was measured 
over time. A and B show representative traces, C and D show the linear increase in the first 30 min as mean ± SEM for 
an n=3. For M-1 cells, only incubation with Pefabloc SC is significantly different from the inhibitor control and all other 
inhibitors (p<0.001), but not different from zero.  For the CFBE cells, none of the curves was not significantly different 
from zero. Pefabloc SC, camostat and EDTA were significantly different from no inhibitor (p<0.0001). Statistics was 
calculated by One-way ANOVA and Bonferroni Post Test. 
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The experiments were performed on a Leica SP8 confocal microscope. For localization experiments in 
submerged conditions, the cells were seeded the day before the experiment into 8-well LabTek® 
dishes. Initially, the experiments were performed using the 405 nm- UV laser light for donor 
fluorophore excitation. After working out that the CAP activity is rather low which requires long 
imaging times in live cell imaging, the experimental conditions were changed and for later 
experiments, the 458 nm laser line of the Argon laser was used. The little red shift of the excitation 
light reduced energy-associated cell damage and improved survival of the cells. The signals of donor 
and acceptor fluorophores were collected in the Leica Hybrid Detectors. After initial adjustments for 
the experimental setup (i.e. submerged or air-liquid-interface), the gain was kept without further 
modifications. The intensity of the excitation light was adjusted according to signal intensity for every 
individual experiment. All experiments with human cells and cell lines were performed with a 40x or 
63 x oil objectives. For the imaging of murine tracheal epithelial cells, a 20x water objective was used. 
As proof of concept, HEK293 cells which do not have endogenous CAP activity were seeded into a 
LabTek® chamber and incubated with CAPRee2. Imaging was started immediately after addition 
without washing. The probe localizes exclusively to the plasma membrane. After 20 min of imaging, 
recombinant human trypsin, which cleaves CAPRee2 very efficiently, was added to the cells and 
imaged for another 20 min (Figure 20 A). Before the addition of exogenous enzyme, no change in the 
D/A ratio was observed. Similarly, murine CAP3 cleaves CAPRee2 on the surface of HEK cells (Figure 
20 B). After addition, the D/A ratio increased rapidly upon cleavage. CAPRee2 is not significantly 
internalized after cleavage (Figure 20 C). 
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To summarize, CAPRee2 could be cleaved on the surface of cells by exogenous enzymes. Next, 
endogenous enzymes expressed on the surface of cells have to be able to cleave the probe. As model 
systems for human enzymes, the human bronchoepithelial cell derived from a CF patient, CFBE41o-, 
was chosen. The cell line expresses all relevant CAPs and is homozygous for the most frequent CFTR 
mutation ΔF508. For murine systems, a lung cell line with CAP expression was not available. 
Therefore, the popular renal cortical collecting duct cell line M-1 was used for our experiments. The 
cell line expresses all relevant CAPs as well as ion channels including ENaC and CFTR and is heavily 
used in this field of research86-89.  
Similar to HEK cells, CAPRee2 localized to the plasma membrane of M-1 cells (Figure 21 A). In 
contrast to HEK cells, M-1 cells express proteases on their surface that cleave CAPRee2 over time. 
The cleavage could be blocked by the addition of 10 µM camostat mesilate (Figure 21 B). The D/A 
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0 
     t=0 min    t=60 min               LUT 
Figure 20: CAPRee2 on HEK293 cells  
HEK cells do not express serine proteases capable of cleavage of CAPRee2 on their cell surface. A Addition of 5 nM 
recombinant human trypsin after 20 min. B mCAP3 enzyme addition at t=0. Images were taken after 10, 30 and 60 min of 
incubation C localization of CAPRee2 and ratio change represented as colour change according to look up table (LUT).  
In A, 15 positions with each 11-40 cells were imaged (total n=366) and plotted as mean + SD over time. In B, each time point 
was measured individually. The plot represents mean ± standard deviation (SD). For t=0 min, n=131, for t= 10 min, n=883, 
for t=30 min, n=46, for t=60 min, n= 74. n equals number of cells quantified. 
A             B  
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ratio increased from about 3-4 up to a plateau around 6.5 (Figure 21 C). As shown for the soluble 
probe CAPRee1, the cleavage of CAPRee2 of the surface of M-1 cells could be fully blocked by the 
serine protease inhibitor camostat mesilate. 
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Figure 21: CAPRee2 on M-1 cells 
2 µM CAPRee2 is incubated on M-1 cells in phenol red-free and serum-free DMEM at 37 °C and 5 % CO2. A 
shows a representative image of the donor fluorescence signal after addition and after 18 min. B represents the 
quantification of the D/A ratio over time in absence of inhibitor, represented as mean ± SD (n=92 cells). The 
inhibitor, 10 µM camostat mesilate, was incubated for 20 min before addition of the probe (n=21 cells). C 
represents representative images of the mean D/A ratio after addition and after 18 min in absence of inhibitor.  
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To test CAPRee2 for the application in human systems, CFBE41o- cells were seeded into Lab-Tek 
chambers and cultured overnight. Typically, the cells grow in islets which impedes immediate 
homogenous staining and which is only achieved after several minutes of incubation. CAPRee2 
localizes to the plasma membrane and remains there for several hours. CFBE41o- cells express CAPs 
so that the probe is cleaved over time, shown as increased brightness of the donor channel (Figure 
22). 
                  
 t= 0 min    t=180 min    LUT 
 
 
 
 
Both in vitro and cell-based assays revealed that the maximal ratio change obtained from CAPRee2 is 
rather low. To test whether a modification does improve the maximal fold change, M-1 cells were 
stained with the probes in suspension and spinned on glass slides either directly after addition of the 
probe (“uncleaved”) or after incubation with 2 nM trypsin for 1 h (“cleaved”). This results in the 
maximal fold change that is to be obtained (Table 2). As the cells could be carefully washed, acceptor 
fragments that are non-covalently attached to the plasma membrane could be washed off (Figure 
23). First, the probe was modified so that the position of Cou343 and lipid were interchanged so that 
the theoretical distance between the fluorophores was reduced (CAPRee2_c). The modification 
however did not improve the performance but decreased the maximal fold change compared to the 
original probe CAPRee2 on fixed M-1 cells.  Therefore, the modification of the acceptor fluorophore 
was done on the original backbone of CAPRee2. 
 
 
100 
 
 
50 
 
 
0 
Figure 22: Localization of CAPRee2 on CFBE41o
-
  
The cells were seeded in LabTek
tM
 dishes over night and incubated with 2 µM CAPRee2. The images represent the 
Cou343 fluorescence directly after addition and after 3 h of incubation. The images show representative images from a 
dataset of 15 different positions. 
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Table 2: Modifications of CAPRee2 and maximal D/A ratio fold change 
# Acceptor fluorophore Modification compared to CAPRee2 fold change  
CAPRee2 TAMRA - 6.5 
CAPRee2_a TAMRA Position of Cou343 and lipid interchanged 5.9 
CAPRee2_b Dy485-XL - 2.5 
CAPRee2_c Cyanin-3 - 8.0 
CAPRee3 TAMRA Additional peg-linker between TAMRA 
and N-terminal Arg 
3.1 
 
Next, the acceptor fluorophore was modified. As described above, TAMRA was replaced by a Dy485-
XL- and a Cyanin-3 derivative. The structures are shown in Figure 10. If not indicated otherwise, the 
images shown are representative images from M-1 cells. However, there was no significant 
difference observed in the localization of the probe on the different cell lines. The cleavage of the 
probe was faster on M-1 cells so that they were chosen for the comparison experiments. 
First, the large stokes-shift dye Dy485-XL was tested for its performance as acceptor fluorophore. It is 
a coumarin-based dye which should be less sticky compared to cyanin-3 as well as less prone to form 
stacks compared to TAMRA. Additionally, the excitation spectrum of the dye has perfect overlap with 
the emission spectrum of Cou343 which might significantly improve the quenching of the donor. The 
extinction coefficient of Dy485-XL however is rather low and in the range of Cou343. Due to 
additional sulfonate groups on the dye, it should be very hydrophilic. In vitro testing however already 
revealed that the dye did not improve the performance of the probe. Potentially, either the 
orientation of the dyes towards each other is not ideal or the low extinction coefficient and quantum 
yield are not sufficient for a well performing acceptor fluorophore. The observation was confirmed 
by cell-based experiments. The D/A ratio in the intact molecule was very high compared to CAPRee2. 
The maximal ratio change obtained in ideal conditions with fixed cells is about 2.5 which was very 
poor compared to the previously described probes CAPRee2 and CAPRee2_a. (Figure 23).  Life cell 
imaging did not improve the D/A ratio change, but did show a second unfavorable feature of the 
probe. The acceptor fragment seems to localize to vesicles after cleavage (Figure 24). Consequently, 
CAPRee2_b was not further characterized because it did not show any improvements compared to 
CAPRee2. 
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Cyanin-3 has a higher extinction compared to TAMRA which might increase the quenching effect in 
the intact molecule. In vitro, the performance with respect to maximal D/A ratio change was 
improved, which was even further confirmed by experiments on fixed cells stained in suspension 
(Figure 20 A-B). Live cell experiments however revealed a critical feature of cyanin-3 as acceptor 
fluorophore: the dye was very sticky towards membranes so that the acceptor fragment did not 
diffuse away but remained attached to the cell in dot-shaped structures, potentially vesicles (Figure 
Figure 23: CAPRee2 and derivatives on fixed M-1 cells 
A absolute D/A ratio on fixed M-1 cells with 1 µM of the respective probe, fixed with 4 % paraformaldehyde in PBS.  
B maximal D/A ratio fold change normalized to D/A ratio of the uncleaved samples. Data as mean ± SD.  
n=17 positions for all expect, CAPRee2 cleaved (n=14) and CAPRee2_c cleaved (n=34). Within one position, the mean was 
averaged. Each position contained about 50 cells. 
 
A                                                         B 
Figure 24: Localization of CAPRee2_b on M-1 cells after 3 h 
The cells were incubated with 4 µM CAPRee2_b for 3 h and imaged. The donor localizes to the plasma 
membrane whereas the acceptor is localized to dot-shaped structures. The cells were imaged in phenol red-and 
serum-free DMEM at 37 °C and 5 % CO2. 10 different positions were chosen and imaged. The image is 
representative. 
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25 A). There was a very clear difference in localization of donor and acceptor signal which indicates 
that this happened to the cleaved probe and not the intact molecule. The donor remained attached 
to the plasma membrane whereas the acceptor was obviously localized to vesicles. This only happens 
in case of loading the intact molecule. When the donor and the acceptor are separated by cleavage 
of the probe before addition, only the donor fragment loads onto the cells whereas the acceptor 
does not efficiently bind to the cell membrane due to the lack of lipid anchor (Figure 25 C). This 
property is highly disadvantageous in case where the cells cannot be washed during imaging which is 
the case in all relevant applications of the CAPRee probes. This resulted in a strongly decreased 
maximal D/A ratio change of about 2 in live-cell imaging conditions (Figure 25B). However the 
difference to the inhibitor control was still highly significant (p< 0.0001). 
A second probe was synthesized with Cy3 as acceptor with an additional peg-linker to increase the 
solubility of the acceptor fragment, but it did not significantly change the behavior of the fragment 
compared to CAPRee2_c. To conclude, cyanin-3 is not an adequate acceptor fluorophore for the 
CAPRee probes.   
The modification of acceptor dyes did not improve the overall behavior of the lipidated probe 
compared to TAMRA. CAPRee2 might not be hydrophilic enough for some relevant applications. For 
cells that are grown in air-liquid-interface (ALI) conditions, the application of high volumes to the 
apical “air” side of the cells might be detrimental. On the other hand, the cell density is extremely 
high compared to submerged conditions. The cells were seeded with 5x higher density compared to 
LabTekTM dishes and cultured for several weeks instead of hours. Therefore, the amount of cell 
membrane to be stained is much higher compared to submerged conditions. Consequently, a probe 
with very good water solubility was required which can be loaded in high concentrations up to 20 µM 
in aqueous solution without precipitation. This enabled the application of low volumes with sufficient 
loading of the probe onto the cell membrane. Furthermore, the volume to which the acceptor 
fragment will diffuse after cleavage is extremely low in ALI condition, i.e. about 20 µl. Therefore, an 
additional peg-linker was inserted between the acceptor fluorophore and the arginine in P4 to obtain 
increases aqueous solubility (CAPRee3). As shown in the in vitro characterization, the insertion of the 
linker did not significantly affect the maximal ratio change for CAPRee3. On fixed cells, the difference 
seemed to be higher but in live cell imaging conditions, the probe did give a sufficiently high ratio 
change. The probe initially localized to the plasma membrane and did not internalize significantly. 
There was no membrane staining detectable for the acceptor after cleavage. The probe has similar 
localization compared to CAPRee2 on M-1 and CFBE cells as well as similar cleavage behavior (Figure 
26). The quantification of the D/A ratio change in live cell conditions will be presented later. 
 
Results 
 
52 
A 
                                              
                                               
B 
0 10 20 30 40 50
0
2
4
6
without inhibitor
10 µM camostat
time [min]
a
b
s
o
lu
te
  
D
/A
 r
a
ti
o
 
no inhibitor 10 µM camostat
0.00
0.02
0.04
0.06
0.08
0.10
in
c
re
a
s
e
 D
/A
 r
a
ti
o
 
        
  
 
 
 Cou343                               Cy3 
 λ=405 nm                λ=5 61 nm  
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t=180 min 
Figure 25: Localization and cleavage of CAPRee2_c on M-1 cells 
The cells were incubated with 4 µM CAPRee2_c for 10 min and imaged right after incubation and after 3 h in phenol red- and 
serum-free DMEM at 37 °C and 5 % CO2. For part A, the contrast and brightness was adjusted individually to show the 
localization. In B, the cells were preincubated with 10 µM camostat mesilate before the addition of the probe, data as mean ± 
SEM. 5 positions were imaged and averaged, with each 50-100 cells.  Although the ratio is higher in total, the increase in the 
D/A ratio is not significantly different from 0 for the inhibitor control. The given wavelengths are the respective excitation 
wavelength for the image.  
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Results 
 
53 
A 
 
                               
                             
                             
 
 
 
 
 
 
 Cou343                               TAMRA 
 λ=405 nm                λ=561 nm 
 
 
 
t= 10 min 
 
 
 
 
 
 
t=70 min 
 
 
 
 
 
t= 120 min 
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Figure 26 A: Localization of CAPRee3 on M-1 cells 
 
The cells were incubated with 2 µM of the probe and, where indicated with 50 nM mCAP3. The cells were 
imaged for 2 h, the images are representative for each time point. Cou343 is the donor fluorescence, TAMRA 
acceptor fluorescence. For each condition, 10 positions were imaged with similar cell density. 
Results 
 
54 
B 
 
                           
                         
                         
 
 
 
 
In FRET measurement setups, it is challenging to separate the signals from donor and acceptor dyes 
because of their spectral overlap. In our case, Cou343 has a comparably large tails which results in 
light emission in the range where usually acceptor fluorescence is detected. On the other hand, the 
 Cou343                               TAMRA 
 λ=405 nm                λ=561 nm 
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Figure 26 B: Localization of CAPRee3 on CFBE41o
-
  cells 
The cells were incubated with 2 µM of the probe and, where indicated with 50 nM mCAP3. The cells were 
imaged for 2 h, the images are representative for each time point. Cou343 is the donor fluorescence, TAMRA 
acceptor fluorescence. For each condition, 10 positions were imaged with similar cell density. 
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acceptor fluorophore is partially illuminated by the excitation light of the donor. As both 
fluorophores have to be imaged simultaneously, the overlap of the signals cannot be prevented. To 
calculate these effects and correct the signals mathematically, probes which have only one of the 
fluorophores were synthesized as donor- or acceptor-only probes. For these experiments, probes 
which only lack the respective fluorophores but were identical to CAPRee2 with respect to sequence. 
Therefore, the donor-only but also the acceptor-only probe did load on the cells similarly to the 
CAPRee2. The bleed through and direct excitation of the acceptor were imaged. The bleed through of 
Cou343 into the acceptor channel is around 10 to 15 %, thus limiting the theoretical maximal D/A 
ratio change. The direct excitation of TAMRA adds onto the energy transfer effect, lowering the initial 
D/A ratio artificially. In case of CAPRee2 and CAPRee3 for which the acceptor fragment diffused 
away, this phenomenon was advantageous because not only the signal due to energy transfer from 
the donor was lost upon cleavage but also the direct excitation from the 405 nm laser because of the 
spatial separation of the fragments. For the cyanin-3-based probes however, this was detrimental.  
The fragments resulting from the enzymatic cleavage of CAPRee3 had been synthesized and applied 
to cells. The fragments were synthesized and fully characterize by Madeleine Schultz. As expected, 
the donor fragment, which was identical for CAPRee2 and CAPRee3, localized to the plasma 
membrane whereas the acceptor fragment remained in solution and did not load onto the cells 
(Figure 27). The acceptor fragment could be easily washed off, so that no signal was remaining after 
wash. The lipidated fragment did not internalize. 
 
 
                           
 
 
 
Figure 27: Localization of cleavage products of CAPRee3 
The given wavelength represents the excitation wavelength for the respective image. The probe was applied 
at 2 µM concentration. The cells incubated with donor fragment were washed. The cells with acceptor 
fragment are shown unwashed. Washing removed the unbound acceptor fragment. 
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To summarize, CAPRee2 and especially CAPRee3 are suitable probes for the detection of enzyme 
activity on the surface of murine and human cells. The maximal D/A ratio change was sufficiently 
high to quantify changes. They localized exclusively to the plasma membrane upon addition and 
remained there for the time line of relevant experimental setups. Due to the higher solubility of the 
probe, CAPRee3 was used in the following application experiments. 
 
2.3  Characterization of ENaC-based CAP probes 
 
So far, the probes are based on the autoactivation cleavage site of CAP3. These probes are cleaved 
by CAPs as well as HAT but not by furin. Furin however has been published lately to play a crucial role 
in the regulation of ASL volume and other processes in the CF lung43. Therefore, a second class of 
CAPRee probes had been designed which has the CAP cleavage site in the γ-subunit of ENaC as 
substrate sequence (RKRK VGGS), CAPRee4 and CAPRee5. The repeat of basic residues might turn it 
into a furin substrate which recognizes tandem basic amino acids. The furin cleavage site in γ-ENaC 
however is RKRR82 and furin prefers R in P1 in general, so that it remains to be tested whether the 
new probe is a target for furin. 
CAPRee4 and CAPRee5 were synthesized and purified by Jonas Wilhelm and Frank Stein. CAPRee5 
and modifications of it could not be synthesized efficiently for unknown reasons. When TAMRA was 
coupled as the first step of synthesis, no amino acids did efficiently couple to the unprotected N-
terminus. The attachment of TAMRA as final step of synthesis on one hand enabled successful 
synthesis of the peptide, but TAMRA did not couple anymore. Therefore, the synthesis strategy was 
changed for CAPRee6: instead coupling TAMRA via amide coupling, TAMRA was coupled together 
with a second peg-linker moiety via copper-catalyzed click chemistry onto a glycine residue bearing 
an alkyne. TAMRA was linked to an azide functionality. In a one-pot-reaction, NHS-activated TAMRA 
was coupled to a peg-linker bearing an amino group on one end and an azide group on the other 
end. Without interim purification, by addition of copper (I) and Tris[(1-benzyl-1H-1,2,3-triazol-4-
yl)methyl]amin (TBTA), the TAMRA derivate was coupled to the alkyne group on the C-terminal 
glycine. Furthermore due to the low performance of CAPRee5, the part which was tested to be less 
relevant for CAP recognition (P1’-P4’) was changed back to the sequence used in CAPRee1-3 VVGG 
instead of VGGS. 
The detailed structures are shown in the addendum and the methods section. The synthesis is 
described in section 6.2.2. Analytical data is presented in the appendix. 
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2.3.1 Physical properties of soluble and lipidated probes  
 
The soluble CAPRee4 probe has been equipped with the same combination of dyes as CAPRee1. 
Furthermore, the two-dimensional distance between the fluorophores is also identical. The positions 
of Cou343 and MetOCou however were interchanged so that Cou343 was attached to the basic 
motive in all ENaC-based probes.  
Unlike CAPRee1, the D/A ratio in the intact molecule was dependent on the probe concentration 
(Figure 28 A). Without the addition of enzyme, the D/A ratio remained mostly unchanged over time, 
but for concentrations lower than 3.33 µM, the D/A ratio increased with decreasing probe 
concentration (Figure 28 B). For concentrations higher than 3.33 µM, the D/A ratio did not change 
with increasing concentration, suggesting that intermolecular effects did not play a significant role 
(Figure 28 B). The maximal donor fluorescence emission was dependent on the probe concentration 
(Figure 28 C), i.e. higher concentrations give rise to higher final donor fluorescence intensity. The 
donor fluorescence intensity was also enzyme- concentration dependent to some extent (Figure 28 
D), i.e. for example 2.5 and 5 nM hCAP3 gave rise to different final plateaus. 
Similarly to CAPRee1, the maximal D/A ratio change was independent of the substrate in a 
concentration range up to about 3.33 µM. For higher concentrations, the D/A ratio change decreased 
significantly (Figure 28 E, F). Consequently, for CAPRee4, there was no concentration range in which 
the D/A ratio was completely independent of the probe concentration. This represents a strong 
disadvantage over CAPRee1 which is more robust to minor variability in the concentration compared 
to CAPRee4. 
The maximal D/A ratio change at a given probe concentration (2 µM in G and 3.3 µM in H), was 
independent of the enzyme-concentration, both for human (Figure 28 G) and murine (Figure H) 
CAP3. In the direct comparison, murine CAP3 cleave the probe much faster compared to the human 
orthologue.  
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Figure 28: In vitro behaviour of CAPRee4 
A absolute D/A ratio in absence of enzyme in dependence of probe concentration. B initial D/A ratio is substrate 
concentration dependent. C MetOCou fluorescence emission for different probe concentrations. D MetOCou 
fluorescence emission with different concentrations of hCAP3. E dependence of the maximal D/A ratio from 
probe concentration. E quantification of the maximal D/A ratio. F absolute D/A ratio over time upon cleavage 
with different concentrations of hCAP3. G absolute D/A ratio over time upon cleavage with different 
concentrations of mCAP3. 
Each trace was measured in a single well. The data was obtained for 8 different substrate concentration from 
two independent dilution series and 12 different enzyme concentrations for each enzyme, pipetted from two 
independent dilution series. 
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The lipidated probe CAPRee5 had a very poor performance compared to CAPRee2 and CAPRee3. 
Although the two-dimensional distance is similar to CAPRee2 and lower compared to CAPRee3, the 
sequence of four basic residues seemed to be detrimental for FRET in the lipidated probe. The initial 
D/A was about twice as high, resulting in a FRET ratio change of about 2. Furthermore, the donor 
fluorescence decreased continuously for CAPRee5 in vitro. This was different in cell-based 
experiments. On liposomes, basically no cleavage could be observed. The properties were not 
significantly changed for CAPRee6, which is more hydrophilic, but has an even further 
twodimensional distance between the fluorophores. For CAPRee6, the donor fluorescence increased 
for about 1 hour in these settings, but afterwards decreased rapidly. Therefore, the ratio change was 
very poor and thus was expected to not allow quantification of enzyme activity on the cell surface. 
2.3.2 Kinetic properties and specificity towards CAPs over other proteases 
 
Due to the poor performance of the lipidated probes with respect to FRET and maximal D/A ratio 
change and the undesirable behavior on the surface of cells (see section 2.3.3), the lipidated ENaC-
based probes CAPRee5 and CAPRee6 require major redesign. Therefore, only the soluble probe 
CAPRee4 was analyzed regarding kinetics and specificity to estimate whether redesign is worth the 
effort. From the probes CAPRee1-3, it became clear that modifications of the dyes might have 
influence on the specificity and kinetic parameters so that the lipidated probes were not fully 
characterized.  
Similarly to CAPRee1, CAPRee4 in a concentration range from 0.33 µM to 30 µM was tested for 
cleavage by hCAP3 and mCAP3 in 12 different concentrations. Compared to CAPRee1, the cleavage 
was much faster, so that the enzyme concentrations had to be dramatically reduced compared to 
previous experiments. For CAPRee4 and CAPRee5, the comparison is very difficult because the 
quantification of the cleavage was hardly possible. The maximum in donor fluorescence was reached 
Figure 29: Emission wavescans of the lipidated probes CAPRee5 (A) and CAPRee6 (B) 
The probes are cleaved by 5 nM mCAP3. The experiment was performed twice with different enzyme 
concentrations. 
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after 1 h compared to approximately 5 h or more for CAPRee2 and CAPRee3. It remained unclear 
however if full cleavage was already reached or if this was due to the poor performance of the probe. 
For murine CAP3, the cleavage rate was even further increased.  
For the calculation of the Michaelis-constant, the linear increase of the donor fluorescence was 
considered. Up to 10 µM, the behavior of the probe was in line with regular Michaelis-Menten 
kinetics, for 30 µM, the initial reaction rate decreased by about 30 to 50 %. Most likely, this is due to 
product inhibition. Quantification of the Michaelis constant 𝑘𝑀 revealed that is also in the low 
micromolar range, slightly lower than for CAPRee1 (Figure 30).  For 1.25 nM enzyme, the calculated 
𝑘𝑀 is 1.4 µM for hCAP3 and 1.6 µM for mCAP3. The cleavage rate however was still much higher 
compared to CAPRee1, suggesting a high difference in the turnover number. Quantification and 
quantitative comparison however was not possible and would require deeper investigation. As the 
experiments had to be performed with recombinant enzymes, the comparison of the in vitro data 
with patient- or model system-derived numbers is anyway not possible, nor is the use of in vitro data 
for the absolute quantification of enzyme concentration on the cell surface.  
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Similarly to CAPRee1, the initial reaction rate based on the D/A ratio increase in the linear range was 
only in a certain range probe-concentration independent (Figure 16 F, Figure 31 A). For CAPRee4, it 
did not decrease with concentrations lower than 50 nM. The initial increase in D/A ratio was 
dependent of the probe concentration for CAPRee4 (Figure 31 A). 
 
 
 
Figure 30: Kinetics of CAPRee4 
A human CAP3, B murine CAP3; As an example shown are the results which was performed with 1.25 nM enzyme. The 
curves were fitted by non-linear regression to calculate 𝑣𝑚𝑎𝑥  and 𝑘𝑀. Similar traces were obtained for 12 different 
enzyme concentrations for each enzyme from two independent dilution series. Each concentration was measured 
once. 
A            B 
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As the increase as well as the maximal D/A ratio are substrate-concentration dependent, the 
quantification became more robust and less susceptible to pipetting errors when the read out as 
both normalized to positive and negative control. The cleavage % was calculated the following:  
% 𝑐𝑙𝑒𝑎𝑣𝑎𝑔𝑒 =
(𝐷 𝐴⁄ /
𝐷𝑛𝑜 𝑒𝑛𝑧𝑦𝑚𝑒
𝐴𝑛𝑜 𝑒𝑛𝑧𝑦𝑚𝑒
⁄ )
max (𝐷 𝐴⁄ )
 
Figure 31: Quantification of enzyme activity by % cleavage 
A: dependence of the initial increase in D/A ratio from the substrate concentration. B: cleavage in % calculated by 
normalization to negative and positive control. C: slopes of B in the first 10 min for different substrate concentrations with 
1.25 nM hCAP3. D: comparable to C for 1.25 mCAP3. E: slope of % cleavage with 2 µM CAPRee4 and different 
concentrations of hCAP3. F: slope of % cleavage for 3.33 µM CAPRee4 and different concentrations of mCAP3.  
Each concentration was measured once. Error bars indicate the error of the slope calculated by linear regression for each 
trace. In total 8 different probe concentrations and 12 different enzyme concentrations were tested. 
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with D representing the donor fluorescence emission and A the acceptor fluorescence. Max stands 
for the maximal value measured for the respective enzyme and substrate concentration. 
Consequently, the values range between 0 and 1. It was observed that for a similar concentration 
range compared to CAPRee1, the increase in cleavage % was independent of the substrate 
concentration, i.e. for concentrations lower than 3.33 µM (Figure 31 C). The slopes were not 
significantly different (p>0.05). For concentrations higher than 3.33 µM, the slope was significantly 
different (p < 0.001, for 6 µM vs. 2µM and 1 µM, p<0.01). Significance levels were calculated by One-
way ANOVA with Bonferroni correction90. Similarly, for mCAP3, the increase of cleavage % was 
independent of the substrate concentration, i.e. all p-values are > 0.05, expect the comparison of 10 
µM and 6 µM to 1 µM (Figure 31 D). The initial increase in cleavage % was significantly depending on 
the enzyme concentration. For hCAP3, all slopes are significantly different with p<0.001 exept the 
comparisons of 0.3125 nM with 0.625 nM and 0.156 nM (Figure 31 E). For mCAP3, there is no 
significant different between 5 nM and 2.5 nM, but the for lower concentrations, with the exception 
of 0.3125 nM compared to 0.625 nM and 0.156 nM, the slopes are significantly different. To 
summarize, for probes like CAPRee4, for which the D/A ratio increase and maximum are 
concentration-dependent, the quantification of enzyme activity by calculation of cleavage % might be 
an appropriate option. 
CAPRee4 was also tested with respect to cleavage by other human proteases similarly to CAPRee1. 
Unexpectedly, the probe was not cleaved by furin at all. Furthermore, CAPRee4 was hardly cleaved 
by cathepsin B and human airway trypsin. Therefore, CAPRee4 had a much higher specificity towards 
CAPs as CAPRee1. Similarly to CAPRee1, CAPRee4 was not a substrate for cathepsin S (Figure 32). The 
probe was cleaved by mCAP1 and hCAP1. Murine enzymes have not been tested, expect mCAP1 and 
mCAP3. 
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Additionally, CAPRee4 was tested on M-1 and CFBe41o- cells with broad spectrum inhibitors (Figure 
33). As previously shown for CAPRee1, only the serine protease inhibitors camostat mesilate and 
Figure 32: Specificity of CAPRee4 towards 
CAPs over other proteases 
rmCAP3 625 pM 
rhCAP3 5 nM 
rhHAT 300 pM 
rhFurin 100 nM 
rhCTSB 20 nM 
rhCTSS 100 nM 
 
Each concentration was measured with n=1. 
For each enzyme, 8 different concentrations 
were measured. All enzymes cleaved their 
respective commercial substrates. 
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Pefabloc SC had significant effects on the cleavage of CAPRee4.  After the measurement, all cells had 
been checked under the microscope for viability to exclude artefacts. For the human cell line, 
similarly to CAPRee1, EDTA rather increased the cleavage rate, suggesting that the probe was 
significantly cleaved by CAP1 which is partially inhibited by divalent cations. After incubation with 
Pefabloc SC, the cells died after about 3 h of incubation with the inhibitor. As the probe cannot pass 
the plasma membrane, the activity detected is measured as sum of surface-bound enzyme activity 
and activity released from the membrane during the time of the experiment.  
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To summarize, the sequence of CAPRee4 seems to be very promising with respect to a highly specific 
a rapidly cleaved probe. As long as the fluorophores and attachment of the lipid anchor do not 
significantly affect the recognition, the lipidated probes might be worth further improvements. 
 
 
 
 
Figure 33: Specificity of CAPRee4 on CFBE41o
- 
 and M-1 cells with broad spectrum inhibitors 
The cells were incubated for 20 min with the respective inhibitors. Afterwards, 2 µM CAPRee4 was added to the cells 
and the cleavage was measured in submerged conditions in the plate reader. The probe was dissolved in phenol red- 
and serum-free DMEM with 25 nM HEPES to maintain neutral buffer at atmospheric CO2. The assay was performed 
at 37°C.  A and B are representative traces, C and D are shown as mean ± SD, n=3 per condition. A and C: CFBE cells, 
B and D M-1 cells. 
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2.3.3 Characterization of lipidated probes on murine and human cell lines 
 
In vitro, the lipidated probes CAPRee5 and CAPRee6 were shown to have very low ratio change upon 
cleavage. This observation was to be confirmed in cell-based experiments and they were tested 
regarding the behavior on the cell surface. It should be tested how molecules behave that have one 
highly positively charged half of the molecule and one rather hydrophobic one. From the results, 
conclusions about the general design of this kind of FRET probes might be drawn. 
M-1 cells were incubated with 2 µM of CAPRee5 in presence of the serine protease inhibitor 
camostat mesilate which should block all endogenous enzymatic activity and in presence of 7.4 nM 
mCAP3 to obtain full cleavage. From this data, the maximal fold change to be obtained in live cell 
imaging conditions was measured (Figure 34).  
As expected, the fold change was very poor. Furthermore, the localization was not as desired. When 
incubated with camostat mesilate, a significant amount of the intact probe was internalized into 
vesicles and stored intracellularly. The cleaved probe however seemed to remain in the membrane. 
Interestingly, the probe did not seem to be cleaved by endogenous enzymes neither on M-1 cells nor 
on primary human nasal epithelial cells (hNEC) (Figure 35). Compared to CAPree3, the distance of the 
cleavage site to the lipid anchor was shorter which might impair the binding of membrane-bound 
enzyme activity. 
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Figure 34: Localization and cleavage of CAPree5 on M-1 cells 
The cells were incubated with 2 µM CAPRee5 in presence of 10 µM camostat mesilate or 7.4 nM mCAP3. A represents the 
absolute D/A ratio, B the maximal fold change. C represents representative images of donor and acceptor fluorophore as 
well as the ratio in presence of inhibitor, D in presence of mCAP3. The brightness of Cou343 and TAMRA is adjusted to the 
signal to show localization. The ratio is represented with the same LUT in C and D. E: LUT for D/A ratio. In A, n=15 (+ 
inhibitor) and n=16 (+7.4 nM mCAP3) positions. In each position was averaged from 50-100 cells each. 
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As consequence of these results, the lipidated probe was modified and two additional peg-linkers 
were inserted. This increased the distance of the cleavage site in the two-dimensional structure to 
the same distance as CAPRee2 and CAPRee3. Furthermore, TAMRA was not coupled via amide 
coupling to a lysine residue, but it was clicked onto a glycine bearing an alkyne moiety. HPLC data 
revealed that the probe in total was indeed more hydrophilic. The sequence of the positions P1’ to 
P4’ was changed to the VVGG which had been used for CAPRee1-3. 
On the cell surface however, the behavior remained unchanged. Both on M-1 cells, the probe was 
still internalized as intact molecule (Figures 36). On CFBE cells, the probe had a comparable 
localization.  
As CAPRee2 and CAPRee3 did not show significant internalization after hours on the cell surface, the 
attachment of the two fluorophores and the lipid anchor are unlikely to cause the internalization. 
Potentially, the sequence itself triggers uptake into vesicular structures. Furthermore, the position of 
donor and acceptor on the molecule had been interchanged so that the combination of a highly 
positively charged series of amino acids close to the lipid anchor might trigger internalization.  
 
 
 
 
 
 
 
           
Figure 35: Cleavage of CAPRee5 on M-1 cells and hNEC 
M-1 cells were incubated with 4 µM CAPRee5 and imaged 
without washing. 
hNEC cells were incubated with 16 µM CAPRee5 for 15 min 
and washed with PBS prior to imaging.  
For hNEC, 20 positions were imaged and averaged with 
each about 50-100 cells. For M-1 cells, three positions were 
imaged and averaged with each  
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Figure 36: Localization of CAPRee6 in M-1 cells 
The cells were incubated with phenol red-free and serum-free DMEM and 2 µM of CAPRee6 at 37 °C. The images are 
representative images from two datasets with each 20 positions. The experiments were performed on different days and 
different passage number of the cells.  
To improve and make probe design more efficient in the future, further experiments were performed 
to get information about the mechanism of internalization. Therefore, the cells were kept on ice 
during incubation times and imaged for short periods at room temperature. Incubation at low 
temperature should reduce active cellular processes. In case that the cells do actively import the 
probe into vesicles, the internalization should be significantly reduced by temperature reduction. 
Incubation of the cells with Pefabloc SC completely blocked the internalization at low temperatures 
(Figure 37 A), suggesting that the intact molecule was not internalized in previous experiments. The 
probe was slowly cleaved on the cell surface and the donor fragment was accumulating inside the 
cell whereas the acceptor fragment does not enter the cell (Figure 37 B). Quantification revealed that 
the D/A ratio marginally increased, and the ratio plasma membrane/intracellular decreased over 
time (Figure 37 C). 
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Figure 37: Localization and cleavage of CAPRee6 on M-1 cells at low temperature 
The cells were incubated with 4 mM Pefabloc SC for 20 min before addition of 2 µM CAPRee6 (A) and kept on ice during 
incubation. In B, the cells were incubated in phenol red- and serum-free medium with 2 µM CAPRee6 on ice. The cells were 
imaged after 2 h (A) or at the given time points at room temperature. Change in D/A ratio (C) and change of ratio of plasma 
membrane and intracellular signal for Cou343 (D) was quantified. C: mean ± SD,D: mean ± SEM n=139 (t=2.5 min), n=60 
(t=10.5 min), n=84 (t=17.5 min), n= 104 (t=38 min) n= 119 (t=44.5 min), n= 97 (t=76 min), n= 74 (t=131 min), n=97 (t=335 
min). n is the number of cells quantified. 
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To find out whether the probe might be used at lower temperatures than 37 °C which are tolerated 
by the cells, a third series of experiments was performed at 30 °C. This is the temperature which can 
be maintained inside the environment box of the microscope used without cooling the system at 
ambient temperature. Furthermore, from experience, also primary cells tolerate 30 °C during culture 
and experiments.  
 
                                   
                                   
                                    
Figure 38: Localization of CAPRee6 on M-1 cells at 30 °C 
The cells were incubated with 2 µM CAPRee6 for the given time points at 30 °C in 5 % CO2. The given wavelenghs represent 
the excitation wavelength for the image. The images shown are representative from a dataset of 10 positions per condition. 
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Figure 39: Localization of CAPRee6 on CFBE41o
-
 cells at 30 °C 
The cells were incubated with 2 µM CAPRee6 for the given time points at 30 °C in 5 % CO2. The given wavelengths 
represent the excitation wavelengths for the series of image below. The images are representative for 10 different 
positions. 
Figure 38 and 39 shows the results at 30 °C for M-1 cells and CFBE41o- cells. The internalization rate 
is much lower and more comparable to the experiment with incubation on ice for M-1 cells. For CFBE 
cells, the probe is still significantly internalized into vesicles. The change in localization would be ideal 
for a probe. The dynamic range however remains very poor in live cell imaging conditions.  
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Although a very small ratio change had been expected from in vitro data, the ratio change on the cell 
surface was quantified and revealed that it is indeed very low and could not be optimized 
significantly by modifying imaging settings. 
Furthermore, in all experiments, we observed no reduction in the acceptor channel. Even with 
loading of the cleaved probe, we observed significant membrane staining in the acceptor channel. 
Finally, for further information about the behavior of the probe, the expected fragments of CAPRee6 
were synthesized and subjected to similar experimental conditions. The fragments were synthesized 
and fully characterize by Madeleine Schultz. Analytical data is shown in the appendix. The donor 
fragment was strongly internalized at 37 °C, but not at 30 °C. Interestingly, even in the absence of a 
lipid anchor, the acceptor fragment did efficiently load onto cells. Further investigation would be 
required to identify the subcellular localization. Therefore, a second factor for the poor ratio change 
was the fact that the acceptor fragment did not diffuse away but remained attached to the cell 
(Figure 40). 
A 
                                  
B 
                           
Figure 40: Localization of donor and acceptor fragment of CAPRee6 at 37 °C (A) and 30 °C (B) 
The cells were loaded with 2 µM of the fragments for 15 min and washed afterwards. Imaging was performed after 30 min. 
The images are representative. In total, 10 positiones were images per condition.  
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To summarize, the lipidated CAPRee5 and CAPRee6 probes require major changes in the design. For 
various reasons, the current design is not useful for the purpose of design. Both the poor initial FRET 
as well as the internalization early on is detrimental for the use of the probes. 
2.4 Application of CAP probes to murine models systems: tracheal 
epithelial cells isolated from βENaC-transgenic show significantly 
decreased CAP activity compared to wildtype C57BL/6 mice 
 
βENaC-transgenic mice were established as a model for cystic fibrosis lung disease. By 
overexpression of the β-subunit in airway epithelial cells, constitutively active αβ-channels are 
formed that to not require proteolytic activation. Consequently, the sodium transport across the 
airway epithelial cells is significantly increased which leads to airway surface dehydration and mucus 
plugging6, 91. So far, it is unclear whether CAP activity is up or down regulated or unchanged in 
βENaC-transgenic mice.  
Murine tracheal epithelial cells were isolated from 10 mice and pooled. The cells were seeded into 
Transwell® inserts and cultured for 2 days under submerged conditions and 8-10 days in air-liquid-
interface before imaging. The cells were washed with PBS apically every second medium change and 
before application of CAPRee3. The supernatant was collected and incubated with CAPRee1.  
Each well was washed with 100 µl PBS. The soluble CAP activity was quantified by CAPRee1 and 
revealed no significant difference between wild type and βENaC-transgenic animals (Figure 41 A -B). 
For easier handling of the samples and higher comparability, freezing is required to collect samples 
from several days or weeks. For the experiment, one sample was divided, one half used for enzyme 
quantification immediately after washing the cells, the other half was frozen for 24 h, thawed and 
submitted to CAP activity quantification. Freezing significantly reduced the initial increase in D/A 
ratio both in wild type and βENaC-transgenic samples (Figure 41 C-D).  The mean difference however 
was not different between the groups so that freezing reduced enzyme activity in total, but did not 
change the difference between the samples.  
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To conclude, freezing samples is valid and enables the collection of higher sample numbers which 
can be analyzed in one experiment.  
Furthermore, CAP activity was quantified on the surface of mTEC cells by CAPRee3. After washing the 
cells with PBS, the cells were incubated with 8 µM CAPRee3 in PBS for 15 min and washed. During 
imaging, the cells had full culture medium supply from the basolateral side and 20 µl PBS on the 
apical side. The cells were imaged with a 20x water objective. The Transwell® inserts was placed onto 
a cover slip which was surrounded by a special humidity chamber to maintain the humididy on the 
cell surface and reduced evaporation on the ASL.  
Whereas wild type mTEC cleaved CAPRee3 in less than two hours on their surface, βENaC-transgenic 
mice had hardly any CAP activity (Figure 42 A). The initial increase was significantly different between 
the genotypes (Figure 42 B), the slope of the initial increase in D/A ratio was not significantly 
different from zero for βENaC-transgenic mTECs. Representative images of different time points are 
shown in Figure 42 C. 
Figure 41: Soluble CAP activity of mTEC cells 
A cleavage of CAPRee1 over time. B quantification of the initial increase in the first 30 min in wildtype and βENaC-
transgenic samples. C comparison of fresh and frozen samples of wildtype supernatant, D comparison of fresh and 
frozen samples of transgenic supernatants. In A each trace is measured once. In B, the replicates per genotype 
(n=4) were grouped. Data is mean ± SD, n=4. In C and D, each sample was measured once. Error bars represent the 
error of the linear regression analysis. 
Results 
 
75 
 
A 
0 50 100 150 200 250
0
2
4
6
8
wildtype
betaENaC-transgenic
wildtype + inhibitor
time [min]
a
b
s
o
lu
te
 D
/A
 r
a
ti
o
  
B 
C
w
id
lty
pe
be
ta
E
N
aC
-tr
an
sg
en
ic
w
ild
ty
pe
 +
 in
hi
bi
to
r
0.00
0.02
0.04
0.06
0.08
0.10
in
it
ia
l 
D
/A
 r
a
ti
o
 i
n
c
re
a
s
e
 
               
 
 
 
To conclude, surface-bound CAP activity is much higher in wild type mTECs compared to βENaC- 
12 
 
6 
 
0 
             t= 0 min     t=150 min 
Figure 42: Surface-bound CAP activity on murine tracheal epithelial cells from wild type and βENaC-transgenic animals 
The surface-bound CAP activity of mTECs was quantified with CAPRee3, comparing wild type and βENaC-transgenic 
animals. Furthermore, the wild type cells were incubated with 4 mM Pefabloc SC for 30 min before the experiment. All 
experiments were performed after 15 min preincubation with 8 µM CAPRee3. In A, two wells per condition were imaged 
with each 5-10 positions. Each position was considered as one measurement (n=10 wild type, n=20 for transgenic, n=15 
for inhibitor). B is the slope calculated by linear regression. Error bars represent error of the fit.  C shows representative 
image for wild type mTEC in absence of inhibitor. 
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transgenic. Consequently, βENaC-transgenic are no useful model to investigate CAP activity and 
regulation in CF lung disease because the mice behave differently compared to what is expected in 
human pathology. However from a biological point of view, the downregulation or inhibition of CAPs 
to decrease the overshooting ENaC-activity is fully plausible. The mechanism however remains to be 
identified.  
2.5 Application of CAP probes to human samples: Increased CAP activity 
of CF cell lines and cultured human nasal epithelial cells isolated from CF 
patients compared to healthy controls 
 
Additionally to the primary murine cells, the applicability of the CAPRee probes was tested on human 
cell lines. CFBE41o-  cells are derived from a CF patient being homozygous for ΔF508 CFTR mutation, 
the most frequent mutations in the CFTR gene92. This cell line was used as a CF model. As healthy 
control cell line, a cell line derived from CFBE41o- but with stable overexpression of wild type CFTR 
gene was used (CFBE wt CFTR). Except CFTR, the cell lines share their genetic background which 
would not be the case for other bronchoepithelial cell lines like HBE, NuLi etc. 
Both CFBE cell lines were seeded into a 96-well multititer plate and incubated overnight. The cells 
were washed with PBS to remove dead cells and soluble enzyme activity. Afterwards, 2 µM CAPRee1 
in phenol red- and serum-free DMEM with 25 mM HEPES buffer was added. The assay was 
performed at 37 °C and atmospheric CO2  in the plate reader.  
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Washing of the cells removes soluble enzyme activity which had been accumulated during the time 
of culture in the 96-well-plate. CAPRee1 was able to detect membrane-associated CAP activity 
together with enzyme activity that had been released to the liquid during the time of the 
Figure 43: Quantification of CAP activity on CFBE41o
- 
and CFBE with wild type CFTR overexpression by CAPRee1 
Similarly to experiments with soluble commercial substrates, CAPRee1 can be used for the quantification of CAP activity 
on the cell surface and enzyme released from the cells during the experiment (A). Quantification of the initial increase in 
D/A ratio revealed a significantly higher enzyme activity (p<0.0001) (B).  Data is represented as mean ± SD for n=2 for 
each condition (A). In B, the errors bare represent the deviation of the linear regression of the first 30 min. 
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experiment. Quantification revealed that the CAP activity on the CF model cell line is more than 2-
fold increased compared to the healthy model cell line (Figure 43). 
Additionally, the lipidated probe CAPRee3 was tested in submerged conditions on both cell lines. 
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The cells were seeded into LabTekTM dishes and incubated over night. The imaging was performed 
under submerged conditions in phenol red-free and serum-free DMEM at 5 % CO2 and 37 °C. 
Whereas the CF model cell line CFBE41o- cleaved the probe within about 2 h, the control cell line 
with overexpression of wild type CFTR only showed little CAP activity (Figure 44). So far, it remains 
unclear whether the CAP expression levels or higher expression of inhibitors are responsible for the 
reduced activity and requires further investigation. 
Figure 44: Quantification of CAP activity on CFBE41o- and CFBE with wilddtype CFTR overexpression by CAPRee3 
CFBE cells were seeded into Lab-Tek
TM
 dishes and cultured over night in submerged conditions. In the next day, the 
cells were imaged after pre-incubation with CAPRee3 for 15 min and similarly to quantification by CAPRee1, the CF 
model cell line has significantly increased (p<0.0001) CAP activity compared to the healthy control cell line. C shows a 
representative ratio change on CFBE41o
- 
cells. A is shown as mean ± SD. The experiment was performed in triplicate 
on different days with different passage number. In each experiment, 10 positions per cell line were imaged. In each 
position, 10-20 cells were quantified automatically. B shows the slope calculated by linear regression, the error bars 
represent the error thereof. C: representative images of D/A ratio of CFBE41o
- 
cells at the given time points. 
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Additionally to the human cell lines, the CAP activity was investigated on human nasal epithelial cells. 
The cells were obtained by nasal surgery both from healthy controls and CF patients. In principle, the 
cells can also be collected by nasal brushing, a non-invasive and easy method. Therefore, nasal 
epithelial cells are an ideal system for the characterization of individual disease states. In the 
experiments, the question was addressed whether these cells can be used for the CAP activity 
quantification and whether on nasal cells, one can also observe the difference in CAP activity 
between CF and Non-CF samples.  
After isolation, the cells were expanded in culture flasks following the protocol established and 
performed in our lab by Heike Scheuermann. The detailed procedure is described in the methods. 
Independent of the genotype, some samples were used after 2 passages without freezing. Other 
samples had been frozen after the first passage and after thawing, they were directly seeded into 24-
well Transwell® filter inserts. Paired experiments revealed no significant difference between passage 
1 and passage 2 so that passage 2 was used for all following experiments because of easier handling 
and higher cell numbers. 
Similarly to mTEC cells, hNEC were imaged on the Transwell® filter inserts in the humidity chamber at 
37 °C with full culture medium supply from the basolateral side. The imaging was performed with a 
40x oil objective which is able to do adaptive focus control despite the large distance of the cells to 
the objective. Due to the high signal of the membrane in the DRAQ5 channel, focusing on the nuclei 
was not possible.  
Representative images of localization of the probe in x-y and x-z direction of donor and acceptor are 
shown in Figure 45. The probe localizes homogenously to the plasma membrane without significant 
internalization into vesicles or inner membranes. Consequently, it is not required to focus on the 
apical membrane. This would be highly disadvantageous due to inhomogeneity of cell height and loss 
of focus due to minor drifts in the focal plane. This however cannot be avoided during 10 h of 
imaging time and movement of the stage to different imaging positions. Inhibition of cleavage 
revealed that CAP activity could be completely blocked by addition of 4 mM Pefabloc SC® both to the 
apical and basolateral baths (Figure 45 B). The difference in the slope of the initial increase in D/A 
ratio was highly significant (p<0.0001). 
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For the comparison, four healthy controls and four CF samples were tested. All samples were 
measured in duplicate; however one had to be excluded due to technical issues. Because of the low 
CAP activity on nasal cells in general, the imaging time was extended to 10 h for the latest 
experiments. 20 positions were sequentially imaged every 15 min. All data sets were corrected for 
exact timing, i.e. the correction of the time due to the shift in imaging and the different times before 
starting the imaging process. 
Figure 45: Cleavage of CAPRee3 on hNEC in absence and presence of serine protease inhibitor Pefabloc SC® 
The cells were preincubated basolaterally and apically for 30 min with 4 mM of Pefabloc SC®. Afterwards, CAPRee3 was 
incubated in presence of inhibitor for 15 min. Then, the cells were washed apically, fresh PBS with inhibitor was added 
and the cells were imaged. Both wells were derived from batch of cells and imaged on the same day. The activity is 
strongly reduced, however the slope for cells incubated with inhibitor is still significantly different from zero (p=0.043. 
The difference between the slopes is highly significant (p<0.0001).  C shows a representative image of the donor 
fluorescence in x-y an x-z direction. For A, in each well, 20 positions were imaged with each about 50 cells. The D/A 
ratio calculated per ROI was averaged per position.  B represents the slope calculated for the first 60 min in both 
conditions. The error bar represents the error of the slope. C shows a representative image with 40 x magnification. 
Scale bar represents 50 µM. 
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After imaging, the initial increase in D/A ratio was quantified for each well by choosing the linear 
time individually for each sample. A minimum of 60 min of imaging, i.e. 4 time points measured, was 
set as minimum requirement. Figure 46 A shows the overview of the mean D/A ratio traces per 
patient. Quantification revealed that the initial increase in Non-CF control samples was very low and 
without strong variability. The CF group however was more heterogeneous and had a higher mean 
CAP activity. Considering each well as individual sample (n=15), the difference between the CF and 
Non-CF samples was statistically significant (p=0.02) (Figure 46 B). Averaging the initial D/A ratio 
Figure 46: Quantification of CAP activity on healthy and CF hNEC 
The cells were cultured on Transwell® filter inserts in ALI for at least 8 days. Two wells per patient were imaged. 
The cells were incubated with 16 µM CAPRee3 for 15 min and washed. During imaging, the cells had basolateral 
full medium supply and 20 µl PBS on the apical side. 
A shows the interpolated traces of two wells for each individual. Each well was imaged in 20 positions with 
approximately 50 cells per position. B represents the quantification of the initial increase of the D/A ratio in the 
first 60 min shown as Whiskers Plot from minimum to maximum values. Each well was considered as individual 
sample. The difference between Non-CF and CF is significant (p=0.02). C represents the averaged D/A ratio 
increase of two wells for each individual.  
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increase for each patient weakened the statistics, due to the lower sample number. The strong trend 
towards increased CAP activity remains (p=0.08) (Figure 46 C). 
To conclude, CAPRee3 was able to detect increased CAP activity in nasal epithelial cells derived from 
CF patients compared to healthy controls. So far, no conclusion could be drawn whether a specific 
mutation or a combination of those are responsible for increased CAP activity or whether this is due 
to inflammatory stimuli from the diseased CF lung. In my cohort, all patients bear one allele ΔF508 
mutated CFTR and one other mutation, partially unknown. The regulation of CAP activity will require 
further investigation. 
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3. Discussion 
 
In cystic fibrosis, the ion transport balance is disrupted by the lack of a functional CFTR chloride 
channel. Although the mechanism remains under discussion, not only chloride secretion across the 
epithelium, but also sodium transport across lung epithelial cells is altered. Due to increased sodium 
absorption, the water homeostasis is disrupted and consequently the viscosity of the airway surface 
liquid is dramatically increased, resulting in mucus plugging and reduced ciliary beating. As a 
consequence, chronic infection and inflammation manifest in the CF lung4.  
 
The mechanism of how the activity of epithelial sodium channels is increased is not understood so 
far. Similarly to the βENaC mouse model, mutations in human αENaC-subunit lead to a cystic fibrosis-
like lung disease93.  These mutations might also play a role in CF caused by mutations in the CFTR 
gene. Furthermore, the inhibition of ENaC by CFTR itself is under discussion. In Xenopus oocytes, it 
has been described that normal CFTR, in contrast to CFTR with ΔF508 mutation, is able to associate 
with ENaC and prevent the α- and γ-subunit from cleavage by proteases94. The proteolytic activation 
of ENaC might be one of the most relevant processes in increasing ENaC activity in various tissues, 
including the lung. Recent studies with inhibitors show that either by protecting ENaC from cleavage 
or by blocking protease activity, ASL dehydration and ciliary beating can be significantly improved 43, 
78. Clearly, channel-activating proteases play a major role in the pathophysiology but their regulation 
in different diseases remains unclear. Therefore, a novel FRET probe was developed that enables the 
quantification of enzyme activity on the surface of cells cultured in submerged or air-liquid-interface 
conditions. Additionally, the probes should be usable both in murine and human samples. 
3.1 Physical and biochemical properties of FRET probes  
 
For the quantification of CAP activity, two sets of CAP activity probes have been synthesized and 
tested for the physical behavior in vitro and on cells. The first set was based on the autoactivation 
cleavage site of human CAP3, the second set was based on the CAP cleavage site in the γ-subunit of 
human ENaC. To improve the performance of the probe, but also to increase knowledge about 
general design of such FRET probes, several small modifications on the soluble probe CAPRee1 were 
synthesized and compared to CAPRee1. Minor changes like the replacement of arginine by lysine do 
not significantly affect the FRET in the intact molecule (Figure 11). However not only the increase in 
distance between the fluorophores affect the D/A ratio but also extension of the peptide backbone 
outside the core structure between the fluorophores has significant effect on the D/A ratio in the 
intact molecule. Notably, the effects of modifications are not always comparable between the 
 Conclusion 
 
83 
soluble and lipidated probe. Whereas the insertion of additional four ethylene glycol units was 
detrimental for FRET in the soluble probe CAPRee1, this was not the case for the lipidated probes 
CAPRee2 and CAPRee3 (Figure 10 and Figure 11). The sequence of four basic amino acids in the 
ENaC-based probes CAPRee4-6 removed the initial FRET in the lipidated probes CAPRee5 and 6 but 
not in the soluble CAPRee4 (Figures 26 and 27).  So far, little is known about the three-dimensional 
structure of these short peptides which are equipped with two fluorophores. The amino acid 
sequence of CAPRee1-3 is derived from the autoactivation cleavage site of human CAP3 but there is 
not structural information available for this region. The murine enzyme with a very similar sequence 
has never been crystallized and this is true for the structure of ENaC, the basis for the CAP probes 4-
6. Structure prediction for peptides by OMICS_28421 suggest a linear model which is very unlikely as 
described before95. Furthermore, the comparison of lipidated and soluble probes, CAPRee4 and 
CAPRee5/6 point to a significant influence of the fluorophores on the secondary structure of the 
FRET probe. Our data suggest that a lot of positive charges significantly affect the FRET efficiency of 
Cou343 and TAMRA, but not of MetOCou and Cou343. It is well known that the environment, e.g. the 
amino acid sequence in proximity, and also positive charges have an impact on the fluorescence of 
small molecules96-97. Nevertheless, predictions of the ideal combination cannot be drawn from our 
data so that it remains to be tested for the design of FRET reporters for other enzymes. Highly 
positively charged molecules however should be avoided.   
The choice of fluorophores as FRET pair has been further tested (Figures 11, 20, 21, 22). Interestingly, 
the tested cyanin-3 derivative behaved well as acceptor fluorophore for FRET efficiency and gave the 
highest dynamic range on fixed cells, but performed poorly in cell- based assays. For unknown 
reasons, the acceptor fragment is localized to dot-shaped structures, suggesting the internalization 
into vesicles or endosomes. Preliminary experiments with a further red-shifted FRET reporter which 
was equipped with TAMRA and a mono-sulfonated cyanine-5 derivative suggest that this is an 
inherent problem of the cyanine dyes which are very sticky to membrane structures. Unpublished 
data by M. Schultz in the Schultz group point into a similar direction. Consequently, this class of 
fluorophores seems not to be suitable for FRET probes which are localized to the plasma membrane 
and require diffusion of the cyanine-bearing cleavage fragment. As the localization of the acceptor 
fragment with TAMRA does not show this behavior at all, this is clearly not related to the sequence. 
Further, it also does not seem to be related to hydrophilicity of the dye in general, because the 
acceptor fragment with Dy485-XL which is even sulfonated and according to HPLC less lipophilic, 
behaves similarly (Figure 21). 
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3.2 Specificity of soluble and lipidated probes 
 
In general, the specificity should be determined by the amino acid sequence, i.e. mediated by the 
binding of amino acid side chains into the catalytic center of the enzyme. Flanking moieties like 
linkers, fluorophores and the lipid anchor should not significantly affect the specificity, at least not in 
theory. 
The specificity is affected by at least two important factors: the affinity of the substrate to the 
enzyme (𝑘𝑀) and the catalytic turn over (𝑘𝑐𝑎𝑡). For human and murine CAP3, partially also CAP1, the 
𝑘𝑀 was calculated and was in the high nanomolar to low micromolar range for CAPRee1, CAPRee3 
and CAPRee4. Due to the experimental setup, 𝑘𝑐𝑎𝑡 was not easily accessible. It was observed 
however that CAPRee4 was faster processed by human and murine CAP3 more than 100 fold faster 
compared to CAPRee1. The lipidated analogs of CAPRee1 are even slower processed. This suggests a 
huge difference in 𝑘𝑐𝑎𝑡.  
With respect to specificity, this leads to the conclusion that CAPRee4 was much more specific 
towards CAPs over other proteases, as the cleavage rate of other proteases is not comparably 
increased (Figure 15, 29). For the lipidated probe CAPRee3, enzymes that efficiently bind the aa 
sequence in CAPRee1, are apparently hindered to cleave CAPRee3, either because of the lipid or the 
fluorophores in their respective position and orientation. Further experiments with minor 
modifications of the FRET probe are required to identify the reasons, first, why the lipidated probe is 
cleaved much slower in general and, second, why it is not recognized by some enzymes anymore.  
Considering the structure of our probes, it is not entirely unexpected that the fluorophores do 
matter. Especially for the lipidated probe, the mass of fluorophores and lipid anchor reach about 50 
% of the total molecule mass. Nevertheless, this effect has been ignored and was never carefully 
tested before10, 76-77. The current data clearly show that the modification of the fluorophores without 
modification of the amino acid sequence increases specificity towards CAPs over the other tested 
enzymes. However, this might not be the case for other enzymes that were not tested.  
Published recognition sequences e.g. for CAP1 did not improve the cleavage of the probe by CAP1 
which might actually be due to the fact that the fluorophore composition was different. 
Consequently, all probes have to be characterized in all variants to determine which should be used 
for a specific enzyme. So far, the effect of additional linkers or the addition of small amino acid 
residues has not been tested but this will also be necessary because they might change the distance 
of the fluorophore from the cleavage site in the FRET probe or enable or disable the binding of the 
fluorophores into hydrophobic pockets of the active center.  
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On one hand, this observation strongly increases the complexity of the design of FRET probes 
offering chances to create probes that are selective for the target enzymes over other enzymes that 
recognize similar sequences or are highly promiscuous like CTSB. Although for CTSB, the amino acid 
sequence can be highly variable, it nonetheless did not recognize CAPRee3 at all. No cleavage is 
observed, not even for very high enzyme concentrations. 
On the other hand, it also questions the concept of substrate sequence optimization. In principle, 
fluorophores significantly contribute to substrate specificity. Therefore, it is questionable whether 
small modifications in the amino acid sequence can improve or diminish specificity, if the binding is 
mostly mediated by the fluorophore or the lipid anchor. To answer these open questions, structural 
analysis of a complex of the target enzyme with a soluble and a lipidated version of our FRET probes 
would be highly interesting. Regarding the contribution of the fluorophores to specificity as a chance 
for the design of FRET probes which avoids cleavage by promiscuous protein-degrading proteases, 
the structural insights contribute to more efficient and more specific design. 
Studies with broad spectrum inhibitors however revealed that for studies on airway epithelial cells 
independent of their origin, the specificity of the FRET probes described in this work is high enough, 
also for CAPRee1 and CAPRee3 (Figure 16). For application in sputum supernatants of CF patients in 
which the NE activity is very high, the readout of CAP activity was only possible with addition of NE 
inhibitor. Interestingly, in contrast to purified NE from human blood, CF sputum supernatants were 
not able to cleave the modified CAPRee1*. The reasons for that remain to be investigated.  
3.3 Effects of amino acid sequence on localization  
 
For the desired application, the lipidated FRET probe has to anchor into the outer leaflet of the 
plasma membrane and has to remain there for the time frame of the experiment which has been 
shown to be at least 2-3 h. For primary human cells, experiments were performed up to 10 h. The 
design of a probe which fulfills this criterion is challenging, especially due the circumstance that there 
is very little knowledge about the mechanism that triggers internalization of these peptidic, lipidated 
structures. So far, it seems to be clear that it can be dependent on the fluorophore composition. For 
the previously established probes LaRee and Nemo, it was affected by the amino acid sequence76-77.  
In contrast to CAPRee2 and 3, CAPRee5 and 6 are internalized into dot-shaped structures, most likely 
vesicles. Whereas CAPRee2 and 3 are stable on the plasma membrane for hours and the donor 
fragment remains there without significant internalization, CAPRee5 and 6 are rapidly taken up by 
the cell. Reduction of the incubation temperature reduced the internalization significantly, 
suggesting active cellular machinery that triggers internalization. Nevertheless, it remains to be 
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answered how the amino acid sequence and fluorophore position determines the fate of the 
reporter both before and after cleavage. Although CAPRee3 and 6 share one part of the sequence, 
the localization is entirely different. Consequently, most likely the basic motive in CAPRee6 is crucial 
for cell entry. Peptides that are able to penetrate into cells, so called cell-permeable peptides (CPP) 
or protein transduction peptides have a common feature: they are amphiphilic, i.e. they have a 
hydrophobic and a hydrophilic part. All of our reporters, but especially CAPRee5/6, fulfill this 
criterion. Naturally occurring CPP are often highly positively charged molecules, also a central feature 
of CAPree4-698-99. However, they are longer compared to our probes and require α-helical 
structures99. All lipidated CAPREee probes are amphiphilic and have a number of positive charges, 
with the highest charges in the probes 5 and 6. The donor fragment of CAPRee2 and 3 however is 
overall uncharged which might prevent internalization. It remains unclear however, how CAPRee2 
and CAPRee3 as intact molecules as well as their lipidated donor fragments can actually escape from 
regular membrane turnover. They remain in the plasma membrane for several hours without 
significant internalization. 
 Addition of only the lipidated donor fragment of CAPRee6 however led to instantaneous 
internalization into the cytoplasm of the cell at 37 °C. This fragment is highly positively charged and 
hydrophilic on one end (C-terminal), due to the lipid anchor and donor fluorophore very hydrophobic 
on the other end which was sufficient to enable cell entry. Observation of entry of the donor 
fragment after probe cleavage might be masked by the high amount of uncleaved probe inside the 
cell which is no longer accessible to enzymatic cleavage. In the intact molecule, these properties 
might be sufficient to trigger endocytosis into vesicles. Redesign of the probe is required to 
overcome the internalization of the intact molecule as well as the poor FRET efficiency. So far, it 
cannot be conclusively said, how negative charges affect the internalization of our probes. The 
addition of negative charges by including several aspartic acid residues however had detrimental 
effects on the FRET ratio of CAPRee1_d, so that it has not been tested for the lipidated probe so far. 
The addition of negative charges by sulfonic acid moieties has been shown to be very efficient in 
keeping molecules at the plasma membrane so that sulfonated dyes or unnatural amino acids in the 
sequence might help to prevent internalization which is triggered by the sequence100. 
3.4 Analysis of kinetic properties of the CAPRee probes and consequences 
for assay design 
 
Commercially available protease substrates are usually designed as fluorogenic substrates, consisting 
of a fluorophore and a quencher which are linked by a small number of amino acids for specific 
recognition. Cleavage results in a strong increase in fluorescence. The fluorescence however is 
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affected by various factors like the microenvironment of the molecule, the pH, the probe 
concentration etc. 101 The CAPRee probes are designed with two fluorophores instead to obtain a 
ratiometric readout which should control for some of these factors. In case of the lipidated probes, 
the spatial separation of the two fluorophores gives an additional readout. Ideally, ratiometric FRET 
probes give a concentration independent readout. Figures 13 and 26 show that this is only partially 
the case.  
Commercial substrates have to be used in high concentrations to overcome the substrate 
concentration dependent increase in the reaction rate which occurs for concentrations around the 
Michaelis constant. Therefore, they are ideally used in concentrations of 10x 𝑘𝑀 in order to work in 
the concentration range of saturation of the enzyme. This is not possible with our FRET probes due to 
a lack of aqueous solubility. Calculations for 𝑘𝑀 for the soluble probe CAPRee1 show that it is in the 
low micromolar range for all CAPs. For the lipidated probes, it seems to be lower but the calculation 
is only by approximation because concentrations in the saturation range, i.e. higher than 4 µM 
cannot be tested due to solubility and precipitation artefacts.  
Interestingly, the D/A ratio does not follow Michaelis Menten kinetics. For CAPRee1, the increase in 
D/A ratio was mostly independent of the substrate concentration. For very low and high 
concentrations, the D/A ratio increase was decreased compared to the plateau (Figure 13). 
Therefore, the D/A ratio increase was ideal because it was very robust to small experimental 
inaccuracies. 
In contrast, this was not the case for CAPRee4 (Figure 26 and 27) for which both the initial D/A ratio 
in the intact molecule as well as the maximal D/A ratio upon cleavage depended on the probe 
concentration. Therefore, the D/A ratio increase was not exclusively dependent on the enzyme 
concentration anymore, but is also dependent on the probe concentration. This could be overcome 
by normalization of the D/A ratio to both negative and positive control (Figure 28), e.g. by calculation 
of the cleavage in %. By normalization to both initial D/A ratio and maximal D/A ratio, the slope of 
the % cleavage was exclusively dependent on enzyme concentration. Therefore, it also represents an 
adequate measure for enzyme activity. For the lipidated probes however, this requirement would be 
highly disadvantageous. Because of longer incubation times before the start of imaging and different 
background due to different origin of samples, the minimum for each sample was not easily 
experimentally accessible. Extrapolation from the slope might be an adequate way. Furthermore, the 
design of a caged version of our probes might be another option. The addition of a photolabile 
protecting group for example on the arginine residue in P1 of CAPRee3 might disable the recognition 
and cleavage by CAPs. Therefore, the cells could be incubated and washed without cleavage of the 
probe. Only upon illumination, the cleavable probe is released and can be tackled by the enzymes. 
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The protection of an arginine residue however requires elaborate chemistry102. Preliminary data 
obtained from CAPRee1_a which has a lysine in P1 suggests that the replacement of R by K might be 
an option that keeps both dynamic range and specificity of the probe. A lysine residue would be 
comparably easy to photocage and is even commercially available as Fmoc - Lys(4,5 - dimethoxy - 2 - 
nitro - benzyloxycarbonyl) – OH. The insertion of an amino acid that is photocaged requires a red 
shifted fluorophore combination that has very little absorbance in the UV-range. Such a combination 
has not been successfully established so far in our lab. Initial tests with TAMRA and a mono-
sulfonated Cyanin-5 derivate failed.  
Apart from difficulties to determine the initial FRET ratio on the specimen, the determination of the 
maximal D/A ratio in live cell imaging experiments was also not easy to achieve because of an 
inherent problem of the target enzymes: high concentrations or long incubation with CAPs will have 
a similar effect as incubation with trypsin – rounding up of the cells and detachment from the solid 
surface. Therefore, for samples with low enzyme activity like primary nasal cells of healthy control 
subjects, determination of kinetics of cleavage is highly time- consuming and difficult to obtain 
accurate data.   
In addition to the problem, that the D/A ratio increase might not be probe concentration-
independent, for the lipidated probe CAPRee3, the maximal donor fluorescence which was reached 
in the plateau was not only dependent on the probe concentration. For mCAP3, the fluorescence 
intensity in the plateau depended on the enzyme concentration (Figure 14) so that apparently, the 
probe was never fully cleaved. Therefore, no plateau was reached for this particular enzyme. For 
hCAP3 and HAT however, the final D/A ratio was independent of the enzyme concentration. This 
suggests that mCAP3 but not hCAP3 and HAT are subjected to product inhibition. As the enzyme 
tested are only recombinantly expressed catalytic subunits, the results might not be directly 
transferable to endogenous enzymes. Artefacts due to precipitation seem to be unlikely because the 
behavior is independent of the probe concentration and happens similarly with low probe 
concentrations but only depends on the ratio between enzyme und substrate concentrations. 
Further investigation is required to understand the mechanism.  
To summarize, several factors can influence the D/A ratio. Analysis of a large data set with known 
enzyme and probe concentrations showed that the quantification of the initial increase of the D/A 
ratio is a very robust measure for enzyme concentration and is always highly significantly correlated 
(p < 0.0001). The slope was always calculated by linear regression of at least 4 time points and over 
at least 30 min, for primary cells 60 min. The results are highly robust and are not significantly 
affected by the absolute D/A ratio values at the beginning of the experiment or the final plateau if it 
is reached during imaging. Absolute quantification of the enzyme concentration however is not easily 
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possible due to significant differences between the recombinantly expressed catalytic subunit or the 
full molecule which is endogenously expressed in the tested cell lines and airway epithelial cells. 
 3.5 Increased CAP activity in CF – cell lines and human nasal epithelial cells 
 
To test whether the CAPRee probes are useful research tools, they were applied in systems where 
one could speculate about the biological answer. As proof-of-concept, CAPRee1 and CAPRee3 were 
tested on primary murine tracheal epithelial cells and human nasal epithelial cells. Both cell systems 
are easily accessible so that they could also be the basis for future applications. As a first validation of 
the CAPRee probes, they were used in CF context, where CAP activity is abnormally regulated.  
So far, it was not clear how CAPs are regulated in the murine CF model which has been established 
by Mall et al 6. Mice that overexpress β-subunit of ENaC show a lung phenotype that is comparable to 
the human disease. MTECs from transgenic animals and littermate control wildtype mice were 
isolated and cultured for 14 days in ALI. It could be clearly shown that mTECs from βENaC- transgenic 
mice have significantly reduced CAP activity compared to wildtype littermate controls which had not 
been observed previously. It is known that the mice still have protease-sensitive αβγ-channels so it 
seems consistent that the protease activity is reduced to minimum to limit ENaC activity as far as 
possible. This would be in line with what is expected in a system where the regulation of protease 
activity is not disrupted. Therefore, it would be interesting to study CAP regulation comparing wild 
type and βENaC-transgenic. One challenge for this research is the lack of suitable CAP-knockout 
models. As described in the introduction, CAPs are crucial for survival and development of the 
animals so that a systemic knockout of the proteases is not possible. So far, in the existing CAP1 –
knockout model with conditional deletion in the lung, alveolar cells lack CAP1 whereas the βENaC-
transgene is expressed in Club cells6, 19. It is completely unclear how a double mutant mouse might 
behave.  
None of the CFTR mutant mouse strains show a lung phenotype comparable to human CF lung 
disease. Murine nasal tissue is comparable to human bronchial airways with respect to tissue 
composition and electric properties103. Therefore, potentially nasal cells of CFTR-knockout mice could 
also be used to study CAP activity. 
Several studies have shown that CAP activity is abnormally regulated in CF21-22,104. Therefore, the 
CAPRee probes were tested to see whether they are able to detect the increased CAP activity in the 
CF cell line CFBE41o- and the corresponding healthy control which expressed wildtype CFTR. Both 
CAPRee1 and CAPRee3 were able to detect the significantly increased enzyme activity in CF cells. The 
difference, however, was only about 2.5 fold, due to the fact that the healthy control also has 
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enzyme activity. This is in contrast to FRET probes for inflammatory proteases which are absent or 
inactive in healthy controls51,105.  
Human nasal epithelial cells are emerging in CF research on the way to personalized treatment of the 
disease. They are very easily accessible by nasal brushing or nasal surgery. Culturing protocols have 
been established in many labs so that their use is becoming more and more popular. So far, the cells 
were used as ex vivo, patient-derived testing system for CFTR modulator and corrector drugs. 
Protocols for the detection of electrophysiological properties have been established and the cells are 
nowadays well characterized so that personalized treatments can be tested106. Due to the low 
invasiveness of the procedure to obtain hNECs, both healthy controls and diseased people can be 
subjected to the procedure, repeatedly without significant side-effects. This allows higher sample 
numbers and can improve statistics.  
So far, human nasal epithelial cells have not been used in studies that investigate CAP activity. We 
cultured the cells in ALI conditions mimicking the in vivo situation. The quantification of CAP activity 
by CAPRee3 revealed that on cells derived from CF patients, CAP activity is increased. Whereas the 
healthy control samples show very little variability, CAP activity was very variable among the CF 
samples. When treating each well as individual sample, the increase in the CF samples was 
statistically significant. However, only four patients each with two wells were tested and included 
into the statistics. Averaging both samples per patient resulted in loss of significance, due to the low 
sample number and high variability of the patients.  
The proof-of-concept experiments that CAP activity can be quantified on hNEC cells despite long 
imaging times and challenging microcopy set ups set the stage for studying CAP activity and CAP 
regulation in human systems. Data obtained from model systems, either cell lines or murine tissue, 
can be validated ex vivo in a human system.  
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4. Conclusion 
 
In this work, the design, characterization and early application of fluorescent reporters for the 
quantification of CAP activity were described. Two different approaches for the design of the 
substrate sequence and optimization were tested as well as the modification of acceptor 
fluorophores to improve performance.  
Whereas the probes which were based on one of the most relevant physiological targets, ENaC, were 
shown to have comparably performance, the approach taking the autoactivation cleavage site of 
CAP3 as substrate sequence resulted in useful FRET probes. These probes were shown to be a 
suitable tool for CAP quantification in human and murine samples. Among the different lipidated 
probes tested, CAPRee3 is the best performing probe with respect specificity, localization and 
dynamic range upon cleavage. The probe is highly stable in the plasma membrane which enables 
quantification of even very low concentrations by imaging over several hours. Whereas the donor 
fragment remains to be bound in the plasma membrane, the acceptor fragment diffuses into the 
fluid on top of the cells, resulting in spatial separation of the dyes and loss of FRET. Due to very good 
aqueous solubility, the probe can be loaded onto cells in higher concentrations compared to 
CAPRee2. Therefore, staining of cells cultured in ALI is efficient and homogenous. The specificity is 
even better compared to the soluble analog CAPRee1 which has the same amino acid sequence.  
For CAPRee1 and CAPRee3, the change in D/A ratio is very robust towards little aberrations that 
result from pipetting errors or efficiency in loading of the probe onto the cell membrane. Over a 
large concentration range, the increase in D/A ratio is only probe concentration dependent. This is 
very advantageous compared to commercial protease substrates which have to be used in high 
concentrations which however reduces the sensitivity. CAPRee1 and CAPRee3 can be used in the low 
micromolar to nanomolar range without being susceptible concentration variability.  Furthermore, 
the quantification of enzyme activity by the lipidated CAPRee3 is independent of the cell number. 
Especially for cells that are cultured for several days up to weeks, the number of cells in the final 
experiment can vary significantly between different specimens. CAPRee3 is the first tool which 
enables the detection of CAP activity in a spatially resolved manner and on a single cell level. The 
activity of individual cells can be quantified which has not been possible so far. Therefore, the 
number of cells per specimen does not affect the quantification of enzyme activity which has been a 
critical drawback so far. 
To date, FRET sensors were applied in fixed samples and only very preliminary live cell imaging 
experiments were performed. From a technical perspective, live cell imaging is more challenging but 
also gives rise to new opportunities. Elaborate protocols for imaging of primary cells for several hours 
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without significant impact on the cells have been established to enable the spatially resolved 
quantification of CAP activity on primary cells for the first time. The detection of enzyme activity 
measured over time gives a more robust signal compared to the quantification of individual time 
points. Single time points might be excluded without severe loss of information. Especially for 
precious clinical samples, this is beneficial. 
In addition to the use of lipidated FRET probes in microscopy, the soluble probes have been 
successfully used in fluorescence plate reader assays which could in principle be done on cells that 
had been grown in Transwell® or Snapwell® inserts. The latter might enable the quantification of CAP 
activity and the detection of electric currents in the Ussing chamber from the same sample. This 
combination is not possible on inverted microscopes because Snapwell®-inserts are not transparent 
to the imaging light.  
The ability to detect CAP activity on cells that are grown on Transwell® filter inserts will also enable 
the simultaneous detection of the ASL height. This has not been possible so far with fluorogenic 
substrates that are commercially available. The combined measurement of CAP activity and ASL 
height might reveal new insights about how these processes are coupled in health and disease. 
To conclude, the FRET reporters developed in this work are novel research tools that will open 
various opportunities in the field of CAP activity and regulation research that have been impossible 
so far due to major technical limitations. Furthermore, the question whether CAPs might be relevant 
biomarkers for the stage and progression of chronic lung diseases, including CF, COPD or pulmonary 
fibrosis, can be further investigated.  
The applicabilty of the same probes to human und murine samples will facilitate the transfer from 
murine to human. In CF, but not limited to that disease, the characterization of CAP activity in ex vivo 
might also be an interesting tool on the way to personalized medicine. Quantification of CAP activity 
on patient speciment ex vivo, such as nasal epithelial cells, might discrimate patients that profit from 
serine protease inhibitor treatment from those who do not benefit from the drug. So far, CAP activity 
has not been measured on nasal epithelial cells so far. 
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5. Outlook 
 
So far, little is known about the regulation of CAP activity in CF and COPD. As previously described, 
CAP activity is increased in CF but the mechanism remains unclear. For COPD, the importance of 
CAPs is unknown und remains to be investigated. The combination of quantifiying RNA, protein and 
enzyme activity levels of CAPs as well as their cognate inhibitors might reveal at which level the 
protease activity is regulated in health and disease. 
From different areas of research, including gastrointestinal diseases or skin development, several 
factors have been suggested that might influence CAP activity. Inflammatory cytokines have been 
published to down-regulate CAP1 activity in the gut107. The application of our CAPRee probes might 
reveal how these stimuli affect CAP activity in the lung. In CF, CAP activity is potentially increased in 
presence of inflammatory cytokines108. Another report which used the murine M-1 cell line describes 
that interleukin (IL)-6 increases ENaC activity and CAP1 expression levels109.  IL-6 has been reported 
to be increased in CF110. CAPRee probes can be an important research tool in disecting the stages 
from RNA expression, translation and activation of the proteases. This might results additional 
knowlegde about the pathophysiological processes in CF and potentially reveal new therapeutic 
strategies. So far, it remains unclear, whether CAPs could be an interesting therapeutic target. As 
previously described, so far selective inhibtiors have not been designed which might be one of the 
greatest obstacles for CAPs as target. Therefore, an upsteam regulator of CAPs might lead to reduced 
side effects compared to the direct targeting of the proteases. For their identification, the use of our 
CAPRee probes might be an adequate tool. 
Clinical studies including different parameters of the CF or COPD lung disease which are established 
biomarkers such as FEV1% predicted,  or the identification of the CFTR mutation of the respective 
patient could be performed to investigate whether the CAPRee probes might be useful biomarkers. 
 
Additionally, the application of the FRET probes is not limited to CF. As described in the introduction, 
CAPs have been published to assiociated with pulmonary fibrosis, developmental defects in the skin 
as well as cancer development and progression28,40, 111. In COPD, the role of CAPs has not been 
assessed so far. 
Especially in the context of cancer, the lipdiated CAP probes could give great insights because of their 
spatial resolution. Potentially not only the amount of enzyme, but also the activity and localization of 
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activity are useful biomarkers for the progression of the disease. Such an investigation has not been 
possible so far. 
 
To summarize, CAPRee probes might be useful tools in different fields of research. They offer the 
unique chance to quantify CAP activity in a spatially and temperally resolved manner and will be 
helpful on the way to personalized treatment in different disease context. 
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6. Material and Methods 
 
6.1 Material 
 
Standard solvents for peptide synthesis were purchased from Fluka, Sigma-Aldrich (Steinheim, 
Germany) and Novabiochem (Darmstadt, Germany). Anhydrous 1-Hydroxybenzotriazole (HOBt), 2-
(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), Fmoc-Lys(Mtt) 
Wang resin and Fmoc-amino acids were from Novabiochem. [2-[2-(Fmoc-amino)ethoxy]ethoxy]acetic 
acid (Fmoc-OcO2-OH; peg-linker), Fmoc-Lys(Palm)-OH and Fmoc-Lys-Wang resin were from Iris 
Biotech (Marktredwitz, Germany). Coumarin 343 was purchased from Acros Organics (Geel, 
Belgium). 7-methoxycoumarin-3-carboxylic acid, palmitoic acid and COMU were from Sigma-Aldrich. 
5,6-Carboxytetramethylrhodamine-N-succimidyl ester (TAMRA-NHS) was from Primetech LLC (Minsk, 
Belarus) or Anaspec. Cyanin-3 was purchased from Lumiprobe (Hannover, Germany), Dy485-XL from 
Dyomics (Jena, Germany). 
Cell culture media and supplements for the CFBE cell lines, HL-60, mTECs and PBS were ordered from 
Gibco/Thermo Fisher Scientific, for the hNEC cells from PromoCell and for M-1 cells from ATCC. 
Equipment for cell culture and microtiter plates were from Corning.  
Recombinant enzymes and commercial protease substrates were purchased from R&D systems; NE 
was purchased from Merck Millipore (Darmstadt, Germany).   
6.2 Methods 
 
6.2.1 Chemical synthesis and purification of individual probes 
 
All probes were synthesized by Fmoc-based solid phase peptide synthesis on a Wang resin, pre-
loaded with an α-Fmoc–ε-unprotected lysine residue (CAPRee1-5), α-Fmoc-Asp(OtBu) residue 
(CAPRee1_b), α -Fmoc-Arg (Pbf) residue (acceptor fragment CAPRee3), α-Fmoc–ε-Mtt protected 
lysine residue (donor fragment CAPree6)  or α -Fmoc-propargyl-Gly residue (CAPree6). Before the 
start of the synthesis, the resin was swollen for 30 min in Dimethylformamide (DMF) or 
DMF/Dichloromethane (DCM) mixture. Fmoc deprotection was performed in 40 % piperidine in DMF 
for 3 min, followed by 12 min 20 % piperidine in DMF. The step was repeated once. Between all 
coupling and deprotection steps, the resin was washed with 1 ml DMF for 1 min with continuous 
shaking. This step was repeated four times. All amino acids of the CAPRee1-3 probes were coupled 
using 5 equivalents of the respective amino acid, 5 equi. HBTU, 5 equi. HOBt and 10 equi. 
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diisopropylethylamin (DIPEA) in DMF twice for 40 min at room temperature on a Syro peptide 
synthesizer. CAPRee4 and 5 were synthesized using an identical protocol manually. CAPRee6 was 
partially synthesized on the automated synthesizer, i.e. the Val and Gly residues were coupled 
automatically, the Arg and Lys residues were coupled manually to increase the yield. The detailed 
coupling protocol is given below for each probe. 
After complete synthesis, the probe was cleaved from the resin and fully deprotected with 95 % 
trifluoroacetic acid (TFA), 2.5 % tri-isopropyl-silane and 2.5 % water and precipitated from ice-cold 
diethyl ether. After centrifugation, it was once washed in ice cold either and dried over night or 
under argon flow. 
Purification was performed by HPLC, using an acetonitrile (ACN) gradient in water. Analytical HPLC 
was performed on a NUCLEODUR C18 ec 5 μm, 4 mm x 250 mm, Macherey Nagel, Düren, Germany) 
column, semipreparative HPLC was performed on 
cm x 21.2 mm, SUPELCO, Sigma-Aldrich) The detailed information for the gradient is given below. To 
improve performance, 0.5% TFA was added to both solvents. Characterization was achieved by ESI 
mass spectrometry, including high resolution mass spectrometry for the most important probes. The 
fragments were additionally characterized by NRM.   
Due to the sensitivity of the Coumarin343 towards remaining TFA after freeze-drying, all probes were 
immediately dissolved in DMSO and kept at -20°C for storage. Quality checks were performed 
regularly to confirm the integrity of the samples.  
The concentration of the DMSO stocks was measured using the absorbance of Coumarin343 
(extinction coefficient ε=44140 L*mol-1*cm-1) in ethanol. 
6.2.2 Detailed structures and procedures: 
 
CAPRee1: 
Expected mass: 1584.73 Da 
[M+1]+ exp. 1585.75, 1585.79 [M+2]2+ exp. 793.38, found 793.30/792.90, [M+3]3+ exp. 529.25, found 
529.25 
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Synthesis: 
1. Coupling of Cou3432: equiv. of dye, 3 equi. of (1-Cyano-2-ethoxy-2-
oxoethylidenaminooxy)dimethylamino-morpholino-carbenium-hexafluorophosphat 
(COMU) and 6 equi. of DIPEA in DMF/DCM 1:3 ratio for 2 h. The step was repeated once. 
2. Synthesis of the aa sequence and peg-linker 
3. Coupling of MetOCou: 2 equiv. of dye, 3 equi. of COMU and 6 equi. of DIPEA in DMF for 2 
h. The step was repeated once 
Purification: 
30-70 % ACN in water 
CAPRee1_a: 
Expected mass: 1557.72 Da 
[M+1]+ exp. 1558.72, not found [M+2]2+ exp. 779.36 , found 779.35 [M+3]3+ exp. 519.90, found 
519.95 [M+4]4+ exp. 390.18, found 390.05 
 
Synthesis and Purification identical to CAPree1 
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CAPRee1_b: 
Expected mass: 1913.99 Da 
[M+1]+ exp. 1913.99, not found; [M+2]2+ exp. 958.00, found 965.70, [M+3]3+ exp. 639.00, found 
644.40  
 
              
Synthesis: 
- Use of α-Fmoc-Asp(OtBu) Wang resin 
- Automatic coupling of 2 additional Asp residues 
- Coupling of α-Fmoc-ε-Mtt- protected lysine manually 
- Cleavage of ε-Mtt protecting group by 1 % TFA and 5 % TIS in DCM, change of cleavage 
cocktail every 15 min 6 times 
-  Coupling of Cou343: equiv. of dye, 3 equi. of COMU and 6 equi. of DIPEA in DMF/DCM 
1:3 ratio for 2 h. The step was repeated once. 
- Automatic coupling of the aa sequence and peg-linker 
- Coupling of MetOCou: 2 equiv. of dye, 3 equi. of COMU and 6 equi. of DIPEA in DMF for 2 
h. The step was repeated once. 
Purification: 
30-70 % ACN in water 
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CAPRee1_c: 
Expected mass: 1729.88 Da 
[M+1]+ exp. 1730.88, not found; [M+2]2+ exp. 865.94, found 865.85 [M+3]3+ exp. 577.62, found 
577.55[M+4]4+ exp. 43.47, found 433.45 
 
  
Synthesis and purification identical to CAPRee1 
CAPRee1_d: 
Expected mass: 1686.73 Da 
[M+1]+ exp. 1687.73, not found; [M+2]2+ exp. 844.16, found 843.1, [M+3]3+ exp. 563.10, found 
562.64, [M+4]4+ exp. 422.75, found 422.15 
  
Synthesis and purification identical to CAPRee1, the additional lysine had already been coupled on 
the resin 
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CAPRee2: 
Expected mass: 2161.58 Da 
[M+1]+ exp. 2162.78, not found; [M+2]2+ exp. 1081.79, found 1081.86 /1081.62, [M+3]3+ exp. 721.53, 
found 721.41/721.42 [M+4]4+ exp. 541.36, found 541.39 
 
Synthesis: 
- Coupling of Cou343: 2 equiv. of dye, 3 equi. of COMU and 6 equi. of DIPEA in DMF/DCM 
1:3 ratio for 2 h. The step is repeated once 
- Capping of unreacted amino groups by 10 % acetic anhydride in pyridine for 10 min 
- Couling of palmitoylated lysine, using 3 equi. of the amino acid, 3 equi. of COMU and 6 
equi. of DIPEA in DMF/DCM in 1:3 ratio for 2 h 
- Coupling of the amino acids and peg linkers 
- Coupling of TAMRA as NHS derivative with 1.1 equi. dye and 2 equi. DIPEA in DMF 
Purification: 
50-100 % ACN in water 
 
 
 
 
 
 Material and Methods 
 
101 
CAPRee2_a: 
Expected mass: 2161.58 Da 
[M+1]+ exp. 2162.78, not found; [M+2]2+ exp. 1081.79, found 1081.86 /1081.62, [M+3]3+ exp. 721.53, 
found 721.41/721.42 [M+4]4+ exp. 541.36, found 541.39 
  
Synthesis: 
- Coupling of palmitic acid onto the free ε-amino group with 5 equi. palmitic acid, 5 equi. 
HBTU, 5 equi. HOBt and 10 equi. DIPEA in DMF/DMC 1:3 for 2 h. The step was repeated 
once 
- Coupling of α-Fmoc-ε-Mtt- protected lysine manually 
- Cleavage of ε-Mtt protecting group by 1 % TFA and 5 % TIS in DCM, change of cleavage 
cocktail every 15 min 6 times 
-  Coupling of Cou343: equiv. of dye, 3 equi. of COMU and 6 equi. of DIPEA in DMF/DCM 
1:3 ratio for 2 h. The step was repeated once. 
- Automatic coupling of the aa sequence and peg-linker 
- Coupling of TAMRA as NHS derivative with 1.1 equi. dye and 2 equi. DIPEA in DMF 
Purification: 
50-100 % ACN in water 
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CAPRee2_b: 
Expected mass: 2237.74 Da 
[M+1]+ exp. 2238.74, not found; [M+2]2+ exp. 1119.87, found 1117.63  
 
  
Synthesis: 
- Coupling of Cou343: 2 equiv. of dye, 3 equi. of COMU and 6 equi. of DIPEA in DMF/DCM 
1:3 ratio for 2 h. The step is repeated once 
- Capping of unreacted amino groups by 10 % acetic anhydride in pyridine for 10 min 
- Couling of palmitoylated lysine, using 3 equi. of the amino acid, 3 equi. of COMU and 6 
equi. of DIPEA in DMF/DCM in 1:3 ratio for 2 h 
- Coupling of the amino acids and peg linkers 
- Coupling of Dy485-XL as NHS derivative with 1 equi. dye and 2 equi. DIPEA in DMF 
Purification: 
50-100 % ACN in water 
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CAPRee2_c: 
Expected mass: 2190.78 Da 
[M+1]+ exp. 2191.78, not found; [M+2]2+ exp. 1095.39, found 1095.50 /1094.68, [M+3]3+ exp. 730.26, 
found 730.10/730.122 [M+4]4+ exp. 547.70, found 547.95 
  
Synthesis:  
- Coupling of Cou343: 2 equiv. of dye, 3 equi. of COMU and 6 equi. of DIPEA in DMF/DCM 
1:3 ratio for 2 h. The step is repeated once. 
- Capping of unreacted amino groups by 10 % acetic anhydride in pyridine for 10 min 
- Couling of palmitoylated lysine, using 3 equi. of the amino acid, 3 equi. of COMU and 6 
equi. of DIPEA in DMF/DCM in 1:3 ratio for 2 h 
- Coupling of the amino acids and peg linkers 
- Coupling of Cyanin-3 as NHS derivative with 1.5 equi. dye and 2 equi. DIPEA in DMF 
Purification: 
50-100 % ACN in water 
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CAPRee3: 
Expected mass: 2306.74 Da 
[M+1]+ exp. 2307.74, not found; [M+2]2+ exp. 1154.37, found 1154.24/1154.16, [M+3]3+ exp. 769.91, 
found 769.75/769.77 [M+4]4+ exp. 577.69, found 577.61 
 
 
Synthesis and purification identical to CAPRee2 
 
CAPRee4:  
The probe was designed by Verena Rickert-Zacharias and synthesized by Jonas Wilhelm and Frank 
Stein. 
Expected mass: 1629.81 Da 
[M+1]+ exp. 1630.81, not found; [M+2]2+ exp. 815.91, found 815.55, [M+3]3+ exp. 544.27, found 
544.05  
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Synthesis:  
- Cleavage of ε-Mtt protecting group by 1 % TFA and 5 % TIS in DCM, change of cleavage 
cocktail every 15 min 6 times 
- Coupling of MetOCou: equiv. of dye, 3 equi. of COMU and 6 equi. of DIPEA in DMF/DCM 
1:3 ratio for 2 h. The step was repeated once. 
- Manual synthesis of the peptide backbone 
- Coupling of Cou343: 2 equiv. of dye, 3 equi. of COMU and 6 equi. of DIPEA in DMF/DCM 
1:3 ratio for 2 h. The step is repeated once. 
Purification: 30-70 % ACN in water 
CAPRee5: 
The probe was designed by Verena Rickert-Zacharias and synthesized by Jonas Wilhelm and Frank 
Stein. 
Expected mass: 2206.76 Da 
[M+1]+ exp. 2207.76, not found; [M+2]2+ exp. 1104.38, found 1104.20, [M+3]3+ exp. 736.59, found 
736.70, [M+4]4+ exp. 552.49, found 552.65 
 
 
Synthesis: 
- Coupling of TAMRA as NHS derivative with 1.1 equi. dye and 2 equi. DIPEA in DMF 
- Manual synthesis of the aa sequence  
- Couling of palmitoylated lysine, using 3 equi. of the amino acid, 3 equi. of COMU and 6 
equi. of DIPEA in DMF/DCM in 1:3 ratio for 2 h 
- Coupling of Cou343: 2 equiv. of dye, 3 equi. of COMU and 6 equi. of DIPEA in DMF/DCM 
1:3 ratio for 2 h. The step is repeated once 
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Purification: 50-100% ACN in water 
CAPRee6: 
Expected mass: 2504.0 Da 
[M+1]+ exp. 2505, not found; [M+2]2+ exp. 1253, found 1254.00, [M+3]3+ exp. 835.67, found 836.25 
 
Synthesis:  
- Coupling of the aa sequence and peg-linkers on the Fmoc-propargyl-glycine Wang resin, 
Val and Gly automatically, Arg and Lys manually 
- Couling of palmitoylated lysine, using 3 equi. of the amino acid, 3 equi. of COMU and 6 
equi. of DIPEA in DMF/DCM in 1:3 ratio for 2 h 
- Coupling of Cou343: 2 equiv. of dye, 3 equi. of COMU and 6 equi. of DIPEA in DMF/DCM 
1:3 ratio for 2 h. The step is repeated once 
- Coupling of 1-Amino-11-azido-3,6,9-trioxaundecane (1.2 equi. of peptide) and 5,6-
TAMRA-NHS (1.3 equi. of peptide) with 2 equi. DIPEA in DMF   
- Click of peptide with TAMRA-peg-azide with 1/3 equi. of azide and 0.5 equi. of Tris[(1-
benzyl-1H-1,2,3-triazol-4-yl)methyl]amin)  
Purification: 30-70 % ACN in water 
Fragments of the probes CAPRee3 and CAPree6 
All fragments were designed by Verena Rickert-Zacharias, synthesized and fully characterized by 
Madeleine Schultz. TAMRA-peg-azide was designed by Victoria Halls and synthesized by Madeleine 
Schultz. High resolution mass spectrometry was done as service in the OCI, University of Heidelberg, 
Germany. 
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Acceptor fragment CAPRee3: 
Expected mass: 1086.53 Da 
[M+H]+ exp. 1087.53, found  1087.53 [M+2]+ exp. 544.76, found 544.27 
 
 Synthesis: 
- Coupling of the amino acids manually on an α-Fmoc-Arg(Pbf) Wang resin 
- Coupling of TAMRA-NHS with 1.1 equi. and 2 equi. DIPEA 
 
Donor fragment CAPRee3: 
Expected mass: 1237.77 Da 
[M+1]+ exp. 1238.77, found 1238.79   
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Synthesis and Purification: 
 Identical to CAPRee3, amino acids coupled manually 
 
Detailed structure of with TAMRA-peg-azide: 
Expected mass: 700.3095, found: 700.3102 
 
  
Acceptor fragment CAPRee6: 
Expected mass: 1156.56 Da 
[M+1]+ exp. 1157.56, found 1157.56, [M+2]2+ exp. 579.78, found 579.28 
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 Synthesis and Purification similar to CAPRee6 up to Val in P1’, amino acids coupled manually 
Donor fragment CAPRee6: 
Expected mass: 1364.898 Da 
[M+1]+ exp. 1365.898, found 1365.901, [M+2]2+ exp. 683.449, found 682.45 
 
Synthesis: 
- Use of α-Fmoc-ε-Mtt lysine Wang resin 
- Manual coupling of the amino acids 
- Couling of palmitoylated lysine, using 3 equi. of the amino acid, 3 equi. of COMU and 6 
equi. of DIPEA in DMF/DCM in 1:3 ratio for 2 h 
- Coupling of Cou343: 2 equiv. of dye, 3 equi. of COMU and 6 equi. of DIPEA in DMF/DCM 
1:3 ratio for 2 h. The step is repeated once 
-  
 
 Material and Methods 
 
110 
6.2.3 In vitro characterization 
 
6.2.3.1 Characterization with recombinant enzymes 
 
The in vitro characterization of the probes was performed with recombinant human and murine 
enzymes. All experiments were performed in a Perkin Elmer EnSpire® multimode plate reader at 37°C 
and atmospheric CO2. We performed emission wavescans with a fixed excitation wavelength of 354 
nm for the soluble and 440 nm for the lipidated probes. The detected emission wavelength range 
was from 380 nm to 600 nm for the soluble and from 470 nm to 700 nm. In order to obtain 
ratiometric measurements, the step size was increased to 90 nm, resulting in measurements at 400 
nm and 490 nm for the soluble, and 490 nm and 580 nm for the lipidated probes.  
The FRET probes were diluted from DMSO stock solutions with final DMSO concentration up to 0.1 % 
in assay buffer. As long as not indicated otherwise, the final probe concentration was 2 µM. The 
enzyme concentrations varied depending on the given and measured enzyme activity, so that the 
latter one was comparable between different enzymes. The assay was performed in the 
recommended buffer composition, however regardless the pH unless stated otherwise, because we 
observed an unexpected decrease of the donor-to-acceptor ratio after cleavage in basic conditions. 
As this effect was exclusively pH-dependent, the pH was kept in neutral conditions (6.7-7.4) for all 
enzymes.  
The assay was started by addition of enzyme or substrate just before the microtiter plate was put 
into the plate reader.  
6.2.3.2 Characterization with broad spectrum inhibitors on M-1 and CFBE41o-  cells 
 
For cell-based experiments, the cells were trypsinized, washed with PBS and counted. Per well, 30 
000 cells were seeded and incubated over night to reach 90-100% confluency. Before the 
experiment, the cells were once washed with DMEM without addition of FCS, 
antibiotics/antimycotics and phenol red, but with the addition of 25 mM HEPES buffer to maintain 
the pH at atmospheric CO2. The inhibitors were dissolved from water or DMSO stocks, according to 
the manufacturer’s recommendations, in DMEM and incubated for 20 min on the cells at room 
temperature. The probe was added at 2 µM concentration in DMEM with 25 mM HEPES buffer.  
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6.2.3.3 Liposome preparation 
 
Liposomes were prepared by extrusion with an Avanti Mini Extruder. The extruder was cleaned and 
assembled according to the supplier’s protocol. The liposomes were formed to a final concentration 
of 3.8 mM liposome in assay buffer (50 nM Tris-HCl, 0.05% Brij-35 in water) with 90% 1,2-Dioleoyl-sn-
glycero-3-phosphocholine (DOPC) and 10 % 1,2-dioleoyl-sn-glycero-3-phospho-L-serine. The lipids 
were dissolved in chloroform which was removed under slow argon flow and. Afterwards, the dried 
lipids were rehydrated in buffer, preheated to 62°C, and shaked in a horizontal shaker for 1 h at 62°C. 
Whatman filter papers and the Whatman 400 nm filter membrane were equilibrated in buffer and 
after assembly, the extruder was heated to 62 °C. To avoid bubbles, the filter papers and filter 
membrane were again equilibrated with buffer. Afterwards, the liposomes were extruded by pushing 
the liquid 41 times through the filter membrane. The quality and size of the liposomes was checked 
by dynamic light scattering. The liposomes were smaller than expected with an average size of 320 
nm. 
Buffers: 
mCAP1, mCAP3, hCAP1, hCAP3, HAT, trypsin: 50 mM Tris, 0.05% (w/v) Brij 35 
CTSB: Activation Buffer: 25 mM MES, 5 mM DTT; Assay Buffer: 25 mM MES; dilution to 10 µg/mL in 
Activation Buffer, incubation at room temperature for 15 minutes, dilution to the desired 
concentrations 
CTSS: Assay Buffer, 50 mM NaOAc, 5 mM DTT, 250 mM NaCl; dilution to 10 µg/mL in Assay Buffer , 
incubation at room temperature for 2 hours, dilution to the desired concentrations 
Furin: 1 mM CaCl2, 50 mM Tris, 0.05% (w/v) Brij 35 
NE: 100 mM Tris-HCl, pH 7.5, 500 mM NaCl 
MMP12: 50 mM Tris, 10 mM CaCl2, 150 mM NaCl, 0.05% (w/v) Brij-35, pH 7.5 (TCNB); activation by 
adding APMA to a final concentration of 1 mM and incubating at 37 °C for 24 hours 
Commercial substrates: Cat.# refers to R&D systems 
mCAP1, mCAP3, hCAP1, hCAP3, HAT, trypsin: Boc-QAR-AMC Fluorogenic Peptide Substrate (Cat. # 
ES014) 
CTSB: Z-LR-AMC Fluorogenic Peptide Substrate (Cat.# ES008) 
CTSS: MCA-Arg-Pro-Lys-Pro-Val-Glu-NVAL-Trp-Arg-Lys(DNP)-NH2 (Cat.# ES002) 
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Furin: p-Glu-Arg-Thr-Lys-Arg-AMC (Cat. # ES013) 
NE: MeOSuc-AAPV-AMC (Cat. # 324740, Calbiochem) 
MMP-12: MCA-Lys-Pro-Leu-Gly-Leu-DPA-Ala-Arg-NH2 (Cat.# ES012) 
6.2.4 Cell culture 
 
6.2.4.1 Cell lines 
 
CFBE41o- and the corresponding cell line stably overexpressing wild type CTFR were kindly provided 
by Dr. D.C. Gruenert, Cal. Pacific Med. Cent. Res. Inst. The cells were cultured in 15 ml of  Minimum 
Essential Medium supplemented with 10 % Fetal Bovine Serine (FBS), 1 % L-Glutamine and 1 % 
penicillin/streptomycin in T-75 culture flask. The cells were subcultured with a ratio of 1:5 every five 
days with interim medium chance after 2 days of culture.  
The murine cell line M-1 has been purchased from ATCC as well as all culture media and 
supplements. The cell line was cultured in 15 ml of DMEM: F-12 Medium (ATCC® 30-2006), 
supplemented with 5 % FBS (ATCC® 30-2020) and 0.005 mM dexamethasone. The subculturing was 
performed according to the supplier’s protocol every 2 to 3 days in a ratio of 1:3. 
HL60 cells were cultured by Dario Frey according to the supplier’s protocols in Iscove's Modified 
Dulbecco's Medium with 20 % FBS in T-75 culture flasks. Cell density was maintained between 1 x 
105 and 1 x 106 viable cells/mL. The medium was renewed every 2-3 days by addition of 2/3 fresh 
medium to 1/3 of the cell suspension. 
HEK cells were cultured by Jan-Erik Hoffmann in high glucose Dulbecco's modified Eagle’s Medium 
containing 10% FBS and 1 % penicillin/streptomycin in 10 cm dishes. The cells were subcultered by 
addition of trypsin in a ratio of 1:10 every 2-3 days.  
6.2.4.2 Primary cells 
6.2.4.2.1 Murine tracheal epithelial cells  
 
The cells were prepared and cultured by Ayca Seyhan Agircan. 
The killing of wild type C57BL/6 mice and the breeding and killing of βENaC-transgenic animals was 
approved by the local animal welfare authorities (Regierungspräsidium, Karlsruhe, Germany). Mice 
were housed in a specific pathogen-free animal facility with free access to food and water. The mice 
were killed by the application of an overdose of ketamine/xylacin. The trachea was freed from 
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surrounding vessels, muscle and connective tissue in situ and put into collection medium (DMEM:F-
12 1:1, 1x Pen/Strep). After isolation 10 tracheas were pooled and washed in PBS.  
The tissue was transferred to dissociation medium (PBS Ca2+/Mg2+ free, 43 mM NaHCO3, 6.25 nM 
FeN3O9, 1 µM sodium pyruvate, 0.6x Pen/Strep, 1.4 mg/ml Protease E, 0.1 mg/ml DNAse I) and 
incubated over night at 4 °C. The temperature was increased to 37 °C for 1 hour before the 
dissociation reaction was stopped by addition of 1 % heat-inactivated FBS. The sample was filtered 
through a 100 µm cell strainer, rinsed with 10 ml culture medium and the fractions were pooled. 
After centrifugation at 1300 rpm for 10 min, the cell pellet was resuspended in 5 ml culture medium 
and seeded onto a 10 cm petri dish. To remove contaminating fibroblasts, the cell suspension was 
incubated for 2 h at 37 °C. The medium with airway epithelial cells was carefully removed. The cells 
were counted, centrifuged and resuspended to a density of 600 000 cells/500 µl. In each 12-well 
Transwell® culture insert, 500 µl of cell suspension were added apically, 2 ml of culture medium 
basolaterally. After 48 h, the medium was changed basolaterally, the apical medium was removed to 
start the air-liquid-interface culture. The medium was changed every other day, the cells were 
washed with PBS every second medium change. The cells were used in experiments after 14 to 21 
days after start of ALI culture.  
6.2.4.2.2 Human nasal epithelial cells 
 
The cells were obtained by medical personal in the Kopfklinik, University Hospital, Heidelberg. The 
isolation and culture was done by Heike Scheuermann. 
Human nasal cells were obtained from CF patients or Non-CF controls during nasal surgery. The 
tissue sample was washed in PBS to remove remaining blood. Afterwards, the tissue was cut into 
small pieces (~ 3 mm) in fresh PBS and transferred to 20 ml dissociation medium, supplemented with 
1.4 mg/ml protease E and 0.1 mg/ml DNAse I. After overnight incubation at 4°C, the dissociation was 
stopped by the addition of 5 ml heat-inactivated FBS.  The cells were filtered through a 100 µm cell 
strainer. For maximum cell recovery, the samples is washed with 10 ml culture medium, filtered 
through the same cell trainer again and pooled. Afterwards, the cells were centrifuged at 1300 rpm 
for 10 min. In case of remaining red blood cells, the cells were resuspended in red-blood-cell lysis 
buffer, incubated for 5 min and centrifuged at 1300 rpm for 5 min again. 
After discarding the supernatant, the cells were suspended in 5 ml of culture medium and seeded 
into a 10 cm tissue culture dish. To separate fibroblasts from airway epithelial cells, the cells were 
incubated for 2 h at 37°C. Under these conditions, fibroblasts adhere. The medium with the 
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remaining airway epithelial cells was transferred to a fresh falcon tube and the cells were counted. 
After 10 min centrifugation at 1300 rpm, the cells were resuspended in culture medium. 
The cells were expanded in a T-75 culture flask seeding 100 000 – 200 000 cells per flask in presence 
of Rho-Associated Protein Kinase inhibitor. 
The cells were seeded at a density of 100 000 cells/50 µl into 24-well Transwell® culture inserts. In 
the basolateral medium reservoir, 600 µl of culture medium were added. Every two days, the culture 
medium was changed, the day in-between, 15 µl of supplement mix was added to the culture 
medium. 48 h after seeding, the apical medium was removed and air-liquid-interface culture started.  
The experiments were performed after 14 to 21 days of culture. 
6.2.5 Microscopy 
 
All experiments were conducted on a Leica TCS SP8 confocal microscope. The microscope was 
equipped with an environment chamber (EMBL, Heidelberg) that enables the performance of 
experiments at 37°C and 5 % CO2. Furthermore, the use of a special humidity chamber for Transwell® 
culture inserts prevented the evaporation of low liquid volumes on the apical side of cells cultured in 
air-liquid-interface conditions.  
For the excitation of the donor fluorophore Coumarin343 of the lipidated probes, we used the 405 
nm UV laser in earlier experiments (CAPRee2, CAPRee2_a, CAPRee2_b, CAPRee2_c) and later 458 nm 
laser line of an Argon laser (CAPRee3, CAPRee5, CAPRee6). Direct excitation of the acceptor 
fluorophore TAMRA was performed with an diode pumped solid state (DPSS) laser at 561 nm, the 
nuclear stain DRAQ5 was excited with an helium-neon-laser line at 633 nm. For the detection of 
donor and acceptor fluorophores, we used the hybrid detectors with gates from 470 nm to 510 nm at 
a gain of 150 and 570 nm to 630 nm with a gain of 200. The nuclear stain was detected with a 
photomultiplier tube (PMT) between 650 nm and 715 nm with a gain of 650. The laser power was 
adjusted to staining efficiency and brightness of the signal. 
For imaging in submerged conditions, the cells were trypsinized, washed, counted and seeded in 8-
well LabTek® dishes with a density of 30 000 cells per well. After over night incubation, the cells were 
washed in DMEM without serum, antibiotics/antimycotics or phenol red. The cells were incubated 
with 2 µM probe and 10 µM DRAQ5 in DMEM for 5 min, then washed and fresh DMEM was added. 
The cells were imaged with a HC PL APO CS2 63x/1.40 OIL objective. 
For fixed cells, the cells were stained in suspension with 1 µM of the probe, as stated in the results 
section, in presence or absence of the given concentration of enzyme or inhibitors. After incubation, 
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the cells were spinned down onto a glass slide using a Cytospin centrifuge (Thermo Fisher Scientific) 
with 1000 rpm for 5 min. The cells were washed once with PBS and stained in 4 % formaldehyde in 
PBS. The cells were embedded with Fluoromount (Sigma Aldrich, Germany). 
Cultured murine tracheal epithelial cells and human nasal epithelial cells were imaged after air-
liquid-interface culture on Transwell® inserts. For loading, the probe was added apically in 100 µl PBS 
at a concentration of 16 µM for 15 min at room temperature. After incubation, the PBS was 
removed; the cells were washed twice in 100 µl PBS and 20 µl PBS were added for the imaging 
procedure. The Transwell® inserts was placed onto a glass cover slip which was part of a special 
humidity chamber which prevented evaporation of low, apical liquid volumes. Basolaterally, the cells 
were incubated in 500 µl full culture medium. Every position was imaged every 15 min, reducing the 
amount of light on the cells to minimum. As our probes do not show significant toxicity to the cells, 
the cells do survive several hours of imaging.   
Human cells were imaged with a HC PL APO CS2 40x/1.30 OIL objective, murine tracheal epithelial 
cells with a HC PL APO CS2 20x/0.75 IMM water objective.  
6.2.6 Image and data analysis 
 
The image analysis was performed in Fiji using FluoQ (published by Frank Stein et al.). The cells were 
segmented by a semi-automated process using DRAQ5 nuclear stain and a voronoi algorithm. The 
threshold for the signal was set semi-automated. The Macro automatically calculates the mean 
intensities for donor and acceptor signals as well as the ratio between them. The calculated mean 
was taken for quantification of enzyme activity112.   
Data handling and calculation of slopes was performed in R (Version 3.3.3). Graphics and statistical 
analysis was done in GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA, USA). 
6.2.7 Statistical analysis 
 
Statistical analysis was done in GraphPad. Unless indicated otherwise, bar charts are displayed as 
mean ± SEM. The initial increase in fluorescence or D/A ratio was done by linear regression analysis. 
Statistical analysis was performed with one-way ANOVA and Bonferroni multiple comparison test. 
For the comparison of two groups, we used an unpaired t-test. p < 0.05 was accepted to indicate 
statistical significance for the human nasal cell data. 
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8. Appendix 
 
CAPRee1: 
Expected mass: 1584.73 Da 
[M+1]+ exp. 1585.75, 1585.79 [M+2]2+ exp. 793.38, found 793.30/792.90, [M+3]3+ exp. 529.25, found 
529.25 
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CAPRee1_a: 
Expected mass: 1557.72 Da 
[M+1]+ exp. 1558.72, not found [M+2]2+ exp. 779.36 , found 779.35 [M+3]3+ exp. 519.90, found 
519.95 [M+4]4+ exp. 390.18, found 390.05 
 
 
 
CAPRee1_b: 
Expected mass: 1913.99 Da 
[M+1]+ exp. 1913.99, not found; [M+2]2+ exp. 958.00, found 965.70, [M+3]3+ exp. 639.00, found 
644.40  
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CAPRee1_c: 
Expected mass: 1729.88 Da 
[M+1]+ exp. 1730.88, not found; [M+2]2+ exp. 865.94, found 865.85 [M+3]3+ exp. 577.62, found 
577.55[M+4]4+ exp. 43.47, found 433.45 
 
 
 
 
 
 
 
Appendix 
 
130 
CAPRee1_d: 
Expected mass: 1686.73 Da 
[M+1]+ exp. 1687.73, not found; [M+2]2+ exp. 844.16, found 843.1, [M+3]3+ exp. 563.10, found 
562.64, [M+4]4+ exp. 422.75, found 422.15 
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CAPRee2: 
Expected mass: 2161.58 Da 
[M+1]+ exp. 2162.78, not found; [M+2]2+ exp. 1081.79, found 1081.86 /1081.62, [M+3]3+ exp. 721.53, 
found 721.41/721.42 [M+4]4+ exp. 541.36, found 541.39 
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CAPRee2_a: 
Expected mass: 2161.58 Da 
[M+1]+ exp. 2162.78, not found; [M+2]2+ exp. 1081.79, not found, [M+3]3+ exp. 721.53, found 
721.41/721.42, [M+4]4+ exp. 541.36, found 541.55 
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CAPRee2_b: 
Expected mass: 2237.74 Da 
[M+1]+ exp. 2238.74, not found; [M+2]2+ exp. 1119.87, found 1117.63  
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CAPRee2_c: 
Expected mass: 2190.78 Da 
[M+1]+ exp. 2191.78, not found; [M+2]2+ exp. 1095.39, found 1095.50 /1094.68, [M+3]3+ exp. 730.26, 
found 730.10/730.122 [M+4]4+ exp. 547.70, found 547.95 
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CAPRee3: 
Expected mass: 2306.74 Da 
[M+1]+ exp. 2307.74, not found; [M+2]2+ exp. 1154.37, found 1154.24/1154.16, [M+3]3+ exp. 769.91, 
found 769.75/769.77 [M+4]4+ exp. 577.69, found 577.61 
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CAPRee4: 
Expected mass: 1629.81 Da 
[M+1]+ exp. 1630.81, not found; [M+2]2+ exp. 815.91, found 815.55, [M+3]3+ exp. 544.27, found 
544.05  
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CAPRee5: 
Expected mass: 2206.76 Da 
[M+1]+ exp. 2207.76, not found; [M+2]2+ exp. 1104.38, found 1104.20, [M+3]3+ exp. 736.59, found 
736.70, [M+4]4+ exp. 552.49, found 552.65 
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CAPRee6:  
Expected mass: 2504.0 Da 
[M+1]+ exp. 2505, not found; [M+2]2+ exp. 1253, found 1254.00, [M+3]3+ exp. 835.67, found 836.25 
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Acceptor fragment CAPRee3: 
 
Expected mass: 1086.53 Da 
[M+H]+ exp. 1087.53, found  1087.53 [M+2]+ exp. 544.76, found 544.27 
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1H NMR spectrum (MeOD, 400 MHz):  8.79 (d, 4JHH = 1.6 Hz, 0.3H, TAMRA-5'), 8.41 (d, 
3JHH = 8.2 Hz, 
0.7H, TAMRA-6'), 8.29 (dd, 3JHH = 8.0 Hz, 
4JHH = 1.8 Hz, 0.3H, TAMRA-5'), 8.22 (dd, 
3JHH = 8.2 Hz, 
4JHH = 
1.7 Hz, 0.7H, TAMRA-6'), 7.86 (d, 4JHH = 1.4 Hz, 0.7H, TAMRA-6'), 7.54 (d, 
3JHH = 8.0 Hz, 0.3H, TAMRA-
5'), 7.17-6.96 (m, 6H, TAMRA-5' and TAMRA-6'), 4.5-4.2 (m, 4H, -CH of Arg, Gln, Ala), 3.98 (s, 2H, 
OCH2CON), 3.80-3.60 (m, 8H, peg), 3.4 (12 NMe2 protons of TAMRA obscured by proteomethanol in 
NMR solvent), 3.25-3.15 (m, 4H, NCH2 of Arg), 2.32 (t, 
3JHH = 7.5 Hz, 2H, CH2CO of Gln), 2.14 - 1.57 (m, 
10H, CH2 of Arg, Gln), 1.35 (d, 
3JHH = 7.2 Hz, 3H, CH3 of Ala). 
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Donor fragment CAPRee2 und 3: 
Expected mass: 1237.77 Da 
[M+1]+ exp. 1238.77, found 1238.79   
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1H NMR spectrum (MeOD, 400 MHz):  8.52 (s, 1H, C4H of Cou), 7.15 (s, 1H, C5H of Cou), 4.53 (br t, 
3JHH = 8 Hz, 1H, -CH of Lys), 4.38 (dd, 
3JHH = 9 Hz, 
3JHH = 5 Hz, 1H, -CH of Lys), 4.14 (d, 
3JHH = 7 Hz, 1H, 
-CH of Val), 4.05 - 3.3 (m, 15H, CH2 of Gly, peg, OCH2CON; -CH of Val; obscured by solvent), 3.4 (m, 
4H, NCH2 of Cou; obscured by solvent), 3.15 (partially obscured m, 4H, NCH2 of Lys), 2.85 (t, 
3JHH = 6 
Hz, 2H, CH2 of Cou), 2.7 (t, 
3JHH = 6 Hz, 2H, CH2 of Cou), 2.2 (m, 1H, CH of Val), 2.15 (t, 
3JHH = 7 Hz, 2H, 
CH2CO of Palm), 2.1 (m, 1H, CH of Val), 1.95 (m, 4H, CH2 of Cou), 1.9 - 1.4 (m, 14H, CH2 of Lys, Palm), 
1.27 (br, 24H, CH2 of Palm), 1.1 - 1.0 (m, 12H, CH3 of Val), 0.89 (t, 
3JHH = 7 Hz, 3H, CH3 of Palm). 
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TAMRA-peg-azide: 
Expected mass: 700.3095, found: 700.3102 
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1H NMR spectrum (MeOD, 400 MHz): 8.77 (d, 4JHH = 2 Hz, 0.5H, TAMRA isomer), 8.41 (d, 
3JHH = 8 Hz, 
0.5H, TAMRA isomer), 8.26 (dd, 3JHH = 8 Hz, 
4JHH = 2 Hz, 0.5H, TAMRA isomer), 8.21 (dd, 
3JHH = 8 Hz, 
4JHH = 2 Hz, 0.5H, TAMRA isomer), 7.94 (s, 0.5H, ring N3CCH isomer), 7.89 (s, 0.5H, ring N3CCH isomer), 
7.84 (d, 4JHH = 2 Hz, 0.5H, TAMRA isomer), 7.53 (d, 
3JHH = 8 Hz, 0.5H, TAMRA isomer), 7.15 (m, 2H, 
TAMRA both isomers), 7.06 (m, 2H, TAMRA both isomers), 6.99 (pseudo t, 2H, TAMRA both isomers), 
4.57 (t, 3JHH = 5 Hz, 1H, N3CH2 isomer), 4.48 (t, 
3JHH = 5 Hz, 1H, N3CH2 isomer), 4.30 - 4.36 (m, 1H, Prg-
αCH both isomers), 3.92 (t, 1H, 3JHH = 5 Hz, N3CH2CH2 isomer), 3.84 (t, 
3JHH = 5 Hz, 1H, N3CH2CH2 
isomer), 3.75 - 3.5 (m, 8H, remaining pegCH2), 3.44 - 3.3 (partially obscured by methanol, m, 2H, Prg-
CH2 both isomers), 2.7 (s, 12H, TAMRA-Me both isomers). 
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Acceptor fragment CAPRee6: 
Expected mass: 1156.56 Da 
[M+1]+ exp. 1157.56, found 1157.56, [M+2]2+ exp. 579.78, found 579.28 
 
 
Appendix 
 
159 
 
1H NMR spectrum (MeOD, 400 MHz):  8.78 (m, 0.6H, TAMRA isomer), 8.40 (d, 3JHH = 8 Hz, 0.4H, 
TAMRA isomer), 8.26 (m, 1H, TAMRA both isomers), 7.85 (s, 1H, ring N3CCH), 7.78 (s, 0.4H, TAMRA 
isomer), 7.53 (m, 0.6H, TAMRA isomer), 7.2 - 6.9 (m, 6H, TAMRA both isomers), 4.75 (m, 1H, -CH of 
Prg, both isomers), 4.53 (t, 3JHH = 5 Hz, 1H, N3CH2 isomers), 4.42 (t, 
3JHH = 5 Hz, 0.6H, N3CH2 isomer), 
4.30 (t, 3JHH = 5 Hz, 0.4H, N3CH2 isomer), 4.14 (d, 
3JHH = 8 Hz, 1H, -CH of Val), 4.0 - 3.5 (m, 25H, CH2 of 
Gly, peg, OCH2CON; -CH of Val), 3.3-3.0 (m, 14H, Prg-CH2 both isomers and NMe2 protons of TAMRA 
obscured by solvent), 2.19 (heptet, 3JHH = 6.5 Hz, 1H, Val-CH), 2.08 (heptet, 
3JHH = 7 Hz, 1H, Val-CH), 
1.05 - 0.95 (m, 12H, Val-CH3). 
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Donor fragment CAPRee6: 
Expected mass: 1364.898 Da 
[M+1]+ exp. 1365.898, found 1365.901, [M+2]2+ exp. 683.449, found 682.45 
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1H NMR spectrum (MeOD, 400 MHz):  8.64 (s, 1H, C4H of Cou), 7.17 (s, 1H, C5H of Cou), 4.72 (dd, 
3JHH 
= 8 Hz, 3JHH = 6 Hz, 1H, -CH), 4.61 (dd, 
3JHH = 8 Hz, 
3JHH = 5 Hz, 1H, -CH), 4.52 (dd, 
3JHH = 9 Hz, 
3JHH = 5 
Hz, 1H, -CH), 4.40 (unresolved dd, 3JHH = 8 Hz, 1H, -CH), 4.35 (dd, 
3JHH = 9 Hz, 
3JHH = 5 Hz, 1H, -CH), 
4.05 (d, 2JHH = 16 Hz, 1H, OCH2CON), 3.97 (d, 
2JHH = 16 Hz, 1H, OCH2CON), 3.8 - 3.3 (m, 12H, peg; NCH2 
of Cou), 3.3 - 3.1 (m, 6H, NCH2 of Arg and (Palm)Lys), 2.96 (t, 
3JHH = 7 Hz, 2H, NCH2 of Lys), 2.92 (t, 
3JHH 
= 7 Hz, 2H, NCH2 of Lys), 2.86 (t, 
3JHH = 6 Hz, 2H, CH2 of Cou), 2.80 (t, 
3JHH = 6 Hz, 2H, CH2 of Cou), 2.12 
(t, 3JHH = 7 Hz, 2H, CH2CO of Palm), 2.0 - 1.7 (m, 32H, CH2 of Cou, Arg, Lys, Palm), 1.3 - 1.2 (m, 24H, 
Palm), 0.9 (t, 3JHH = 7 Hz, 3H, CH3 of Palm). 
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Addendum: Overview of all structures 
 
CAPRee1:      CAPree1_a: 
            
CAPRee1_b:      CAPRee1_c: 
 
 
CAPRee1_d:      CAPRee2: 
         
       
CAPRee2_a:      CAPRee2_b 
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CAPRee2_c:      CAPRee3: 
 
 
CAPRee4:       
 
 
 
CAPRee5:  
 
 
CAPRee6: 
 
